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2. SYNPOSIS 
Title of clinical trial  A  pilot study of Concerta XL in adult offenders with 
ADHD 
Protocol Short Title/Acronym 
 
 CIAO project  
Study Phase if not mentioned in title 
 
 Phase IV study 
Sponsor name 
 
 Co-sponsors: King’s College London, and South London 
and Maudsley NHS Foundation Trust 
 
Chief Investigator 
 
 Prof Philip Asherson 
EudraCT number  2012-000517-37 
 
REC number  12/LO/0787 
 
Medical condition or disease under 
investigation 
 Attention Deficit Hyperactivity Disorder (ADHD) 
Purpose of clinical trial 
 
 To evaluate the effectiveness of Concerta XL in reducing 
levels of aggression, increasing engagement with 
educational activities and reducing symptoms of ADHD, 
in young male offenders with ADHD   
 
Primary objective 
 
 Primary outcome will be the effectiveness of treatment 
with Concerta XL to reduce levels of aggression, 
measured as the number of recorded critical incidents 
(records of disruptive behaviour) in the prison records.  
  
Secondary objective (s) 
 
 Secondary objectives will be to estimate the 
effectiveness of treatment with Concerta XL to increase 
engagement with educational activities; and decrease 
symptoms of ADHD and emotional dysregulation.  
 
Further analyses will test the mediation hypothesis that 
changes to symptoms of ADHD and emotional 
dysregulation mediate reduction in aggressive behaviour 
and engagement in educational activities. 
 
Trial Design  
 
 A 12-week open label pilot study of Concerta XL with 
dose-escalation to a maximum of 90 mg. Following the 
initial 12-week trial there will be an open label extension 
with further titration to an optimal dose for each individual 
participant, for a period of 6-months.   
 
Endpoints 
 
 The primary endpoint will be the number of recorded 
critical incidents (records of disruptive behaviour) in the 
prison records in the 3-months prior to the  
12-week assessment.  
Secondary endpoints will be recorded at the  
12-week assessment:  
- Ratings of aggressive behaviour by prison and 
education staffs (Modified Overt Aggression 
Scale – MOAS). 
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- Engagement with education activities over 
previous 3-months (Number of sessions attended, 
number of reports of disruptive behaviour in 
educational sessions). 
- Symptoms of ADHD (CAARS) and emotional 
dysregulation (WRAADS).   
 
Sample Size 
 
 A total of 100 participants will be recruited into the study. 
 
Summary of eligibility criteria 
 
 Males aged between 18 and 30 years who provide fully 
informed consent and have a clinical and research 
diagnosis of ADHD following assessment with the DIVA 
clinical interview for DSM-IV ADHD. 
 
IMP, dosage and route of 
administration 
 
 Concerta XL capsules, taken orally, at doses of 18, 36, 
54, 72 and 90 mg. 
Active comparator product(s) 
 
 None. 
Maximum duration of treatment of a 
 Subject 
 
 
 The initial treatment trial (and primary endpoint) is for 12-
weeks. 
 
The follow up open label extension will add an additional 
6-month period. 
 
Version and date of final protocol 
 
 Version 1.6 4th June 2013  
Version and date of protocol 
amendments  
 Version 1.00 12th January 2012, amended 16th July 2012 
Version 1.1 16th July 2012 
Version 1.2 20th July 2012 
Version 1.3 19th October 2012 
Version 1.4 26th March 2013 
Version 1.5 20th May 2013 
Date of first enrolment  1st March 2012 
Date of last completed  2nd December 2014 
Number of patients planned and 
analysed 
 100 participants planned 
121 participants completed baseline assessments 
72 participants completed 12-week endpoint 
assessments 
Statistical methods   Per protocol and intention to treat analyses were 
conducted using last observation carried forwards 
(LOCF). Pre-post changes in primary and secondary 
outcomes were evaluated using paired t-scores and 
effect size calculated using Cohen’s d 
Summary  Overall this study demonstrated the feasibility of 
conducting clinical trials of ADHD in young adult 
prisoners. Clinical effects were observed supporting the 
need for a definitive clinical trial. 
 
The primary outcome was the total number of 
adjudications reported by prison officers in the electronic 
prison records. The effects were d=0.53 using the per 
protocol analysis but only d=0.29 using the ITT analysis. 
Here the confidence that such change are accounted for 
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by the study medication is uncertain. Adjudication rates 
are relatively low and it may be that the prison regime is 
good at responding to adjudications events once they 
occur. Taking part in the clinical trial with weekly visits 
form research staff may further impact in a beneficial way 
on aggressive or antisocial behaviour. However we did 
not select on the primary outcome, so adjudications rates 
could have gone up as well as down. Taking into account 
the small effect on the primary outcome for the ITT 
analysis, and the moderate effect in the pp analysis it is 
clear that no conclusions can be drawn from the analysis 
here. A larger, placebo controlled trial is required to 
address this question. 
 
With regard to secondary behavioural outcomes reported 
by prison and education staff, the same arguments apply 
as for adjudications. No conclusion can be drawn. 
Overall thee positive effects on behavioural outcomes 
(aggression, antisocial behaviour and engagement with 
education) indicate the need for a larger definitive trial 
powered and designed to address these questions.    
 
In contrast, the effects on symptoms, particular core 
ADHD symptoms, but also other domains were 
substantial, being in the range of d=.5 to 2.  For example 
if we consider the effect in core ADHD symptoms 
measured using the investigator rated Conners ADHD 
rating scale. The results of the single arm open label pilot 
study show a mean decrease of 25.0 points with a 
standard deviation of 9.1. This suggested a standardised 
effect size of d=2.75. It could then reasonably be 
assumed that at least 20% of this effect might be 
attributed to the effects of MPH since previous meta-
analyses show an average effect around d=0.5.  
 
The trial procedures and medication were found to be 
safe. Titration was to lower doses with no evidence of 
drug seeking behaviour. Adverse effects were those 
commonly seen when treating ADHD with 
methylphenidate. No serious adverse events occurred.  
 
Overall this study demonstrated the feasibility of 
conducting clinical trials of ADHD in young adult 
prisoners. Clinical effects were observed supporting the 
need for a definitive clinical trial. The data presented here 
was successfully used in an application to the National 
Institute of health Research (NIHR) for a randomised 
placebo controlled trial of 200 adult offenders with ADHD, 
following similar procedures to those used here. The 
study following on from this starts in June 2016.  
 
 
  
Date of trial report  28th February 2016 
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4. ETHICS 
4.1. Independent ethics committee (IEC): The study and all amendments were reviewed 
and approved by the London and South East Research Ethics Committee.  
 
4.2. Other approvals: The study and all amendments were reviewed and approved by the 
Medicines and Healthcare Products Regulatory Agency and the King’s College Research 
and Development office. 
 
4.3. Ethical conduct of the study: The study was conducted in accordance with the ethical 
principles that have their origins in the Declaration of Helsinki. 
 
4.4. Patient information and consent: Informed consent was obtained in three stages as 
follows: 
1. The first information sheet and consent forms asked for permission to use the 
screening data obtained from all prison inmates. From those inmates already 
screened (by the healthcare team), consent was obtained retrospectively from as 
many as could be contacted and agreed for their anonymised data to be used. This 
allowed us to complete an initial analysis of predicted prevalence of ADHD in young 
adult prisoners.  
 
2. The second information sheet and consent forms asked for permission to use the 
clinical interview data (from the diagnostic interview for ADHD) and to link these to 
prison and medical health records. This enabled us to complete an initial study on 
ADHD within the prison, whether participants wished to take part in the clinical trial or 
not. This part of the study (before the clinical trial) estimated the rate of ADHD in the 
prison.  
 
3. The third information sheet and consent forms asked permission to take part in the 
clinical trial. This was offered to all those that met the inclusion/exclusion criteria for 
the clinical trial, following the diagnostic assessments with the diagnostic interview for 
ADHD.  
 
The information sheets and consent forms are provided in Appendix 1 
 
5. INVESTIGATOR AND STUDY ADMINISTRATVIE STRUCTURE 
 
5.1. Trial management: The project was coordinated on a daily basis by Clare Evans (trial 
research coordinator) supervised by Professor Philip Asherson.  
 
5.2. Trial management group: The trial management group provided overall steering of the trial. 
This group consisted of Professor Asherson (chief investigator), Susan Young and Andrew 
Forrester (Co-investigators) and Clare Evans (trial research coordinator).  
 
5.3. Independent oversight: There was no independent oversight of the study (steering committed 
or DMEC). It was felt this was not required because of the nature and aims of the trial: an open 
label pilot study using a recognised first line treatment for ADHD. The protocol was classified 
as type A (low risk) by the Medicines and Healthcare Products Regulatory Agency (MHRA) 
 
5.4. Investigators:  
 Professor Philip Asherson. Responsible for the overall conduct of the study. 
 Dr Susan Young. Provided ongoing advise, interpretation and review of the findings.  
 Andrew Forrester. Provided ongoing advise, interpretation and review of the findings  
 Prof Declan Murphy. Main role in supporting the initiation of the trial  
 Dr Thomas Price. Main role in estimating sample size for protocol design. He left Kings 
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College London early in the study and was replaced by Prof Philip Asherson.  
 
5.5. Research assistants  
 Clare Evans: clinical research assistant and trial coordinator 
 Andrew Baird: research psychiatrist 
 
6. INTRODUCTION 
 
6.1. Background:  
ADHD is characterised by developmentally inappropriate levels of inattentive, hyperactive 
and impulsive symptoms that are often accompanied by mood instability and lead to clinical 
and psychosocial impairments culminating in long-term negative outcomes and comorbid 
disorders. ADHD is a common childhood disorder affecting 3-4% of children in the UK1. The 
disorder persists in two-thirds of cases, with an estimated adult prevalence of 2-4%2-4. ADHD 
occurs at disproportionately high rates in forensic populations, for example in convicted 
young offenders (~45%)5, adult males (~14-30%)6 and females (~10%)7.A recent meta-
analysis found an average prevalence among offenders of around 26%8. 
 
Failure to recognise and treat ADHD can have a wide-reaching impact on mental health and 
behaviour, and this is most notable in forensic populations where ADHD is associated with 
high rates of verbal and physical incidents of aggression and other disruptive behaviours. 
We previously reported that ADHD accounted for a 6-fold increase in such critical incidents 
among prison inmates, even after controlling for antisocial personality disorder6. This 
suggests that ADHD itself may lead directly to some forms of disruptive behaviour, 
potentially linked to difficulties with mood regulation (mood lability/volatile mood 
states/deficient emotional self-regulation) that are strongly associated with ADHD in adults9. 
Hence, untreated ADHD may explain a significant portion of aggressive behaviour in 
offenders both in the community and in institutional settings. Furthermore the symptoms of 
ADHA are known to interfere with both educational and employment activities due to a 
combination of restless overactivity and impulsivity, and the problems associated with 
inattention, forgetfulness and problems with self-organisation10,11.  
 
Within forensic settings, the violent behaviour associated with ADHD significantly impacts on 
the quality of life of the individual, but also on forensic services and society more widely as 
these individuals can be caught up in the ‘revolving door’ of the criminal justice system. 
However, ADHD is a treatable condition with the most recent NICE guidelines11 concluding 
that stimulant medication (methylphenidate or dexamphetamine) and atomoxetine provide 
cost-effective treatments for the control of ADHD symptoms in adults. Nevertheless ADHD 
often remains unrecognised and untreated, which means that known effective treatments for 
ADHD (and potentially also for the co-occurring challenging behaviours) are not provided. 
The NICE guidelines for ADHD highlighted the extent of this unmet need and the 
requirement to establish effective services for the diagnosis and treatment of ADHD in 
adults, to prevent both immediate and longer term impairments. Thus, we envisage that 
medical treatments used for ADHD in the general population will be effective in reducing 
both the core symptom of ADHD and some of the aggressive/antisocial behaviour and 
problems with engagement with educational activities associated with ADHD in forensic 
populations. To date, however, these questions have not been investigated among young 
offenders in the United Kingdom (although rates of ADHD will undoubtedly be high in this 
group) and there is very limited guidance from international research.   
 
6.2. Standard clinical care for adults with ADHD 
In this study we proposed to evaluate the treatment of ADHD in a prison population of 18-30 
year olds, using a standard treatment for ADHD. At the time the study started there were no 
medications licensed for the first time treatment of ADHD when the diagnosis is made for the 
first time in adulthood. This has since changed with marketing authorisation for first time use 
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in adults allowed for atomoxetine and lisdexamfetamine. The medication used in this clinical 
trial, Concerta XL, was however licensed for continued use in adults when ADHD was first 
diagnosed and treated during childhood or adolescence. In this study we proposed to 
include participants who met the clinical criteria for ADHD whether this was first recognised 
and treated during childhood and adolescence or not. The use of Concerta XL as an 
unlicensed treatment for ADHD when diagnosed for the first time in adults was standard 
clinical care in the UK. This is supported by guidelines from the British Association of 
Psychopharmacology (2006) and the National Institute of Health and Clinical Excellence 
(2009).  The titration protocol that we proposed was designed to match best clinical practice 
as recommended by NICE. The dose is within the limits outlined by NICE. The British 
National Formulary (63, March 2012) states that for over 18 year olds the dose is initiated at 
18 mg, then increased at weekly intervals according to response, to a maximum of 108 mg. 
The risks associated with this study are therefore not expected to be higher than standard 
medical care for this patient group.   
 
7. STUDY OBJECTIVES 
 
7.1. Study design: To conduct an open label pilot study of an extended release 
formulation of methylphenidate (Concerta XL) on aggression, in young male offenders with 
ADHD aged 18-30. The primary outcome measure was change in disruptive behaviour as 
recorded in the prison records (number of critical incidents defined as total number of 
adjudications reported in prison records). Secondary outcomes included measures of 
engagement with educational activities reported by staff within the prison educational 
programme; measures of aggressive behaviour collected using a behavioural report by 
prison and education programme staff, and the number of recorded reports of disruptive 
behaviour reported by the educational programme staff.   
 
Changes were measured using measures of ADHD and emotional dysregulation, that 
previous research has shown responds well to methylphenidate with an average effect size 
of around 0.5. This included ratings of the DSM-IV ADHD items from the observer version of 
the Connors Adult ADHD rating scale (CAARS-O); and the associated symptoms of 
‘emotional dysregulation’ from the Wender-Reimherr Adult Attention Deficit Disorder Scale 
(WRADDS).  
 
Further analyses explicitly test the mediation hypothesis that change in symptoms of ADHD 
and emotional dysregulation mediate changes in aggressive behaviour and engagement 
with educational activities; and provide estimates of the extent of any mediation effects 
(partial or complete mediation of the behavioural problems).  
 
Dose escalation from 18 mg to a maximum of 90 mg was intended to maximise the effect of 
the medication on ADHD symptoms levels while limiting potential adverse effects. 
 
7.2. The main hypotheses tested were: 
(1) That ADHD is found in high rates among young male offenders aged 18-30 (the initial 
stages of the project allow prevalence estimates for the disorder among the prison 
population to be estimated). 
(2) That treating ADHD with Concerta XL will lead to reductions in aggressive behaviour 
within the prison setting.  
(3) That treating ADHD with Concerta XL will lead to increased engagement with 
educational activities within the prison setting.   
(4) That treatment with Concerta XL will lead to reductions in ADHD symptoms within the 
prison setting. These changes will be similar in magnitude to those reported in previous 
clinical and prison populations of adults with ADHD. 
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(5) That treatment with Concerta XL will lead to reductions in symptoms of emotional 
dysregulation. These changes will be similar in magnitude to those reported in previous 
clinical trials of the effects of stimulants on symptoms of emotional dysregulation.  
(6) That the ADHD symptoms and emotional dysregulation symptoms will show strong 
co-variation during the treatment response. 
(7) That change in symptoms of ADHD and emotional dysregulation will mediate 
changes in the measures of aggression and engagement with educational activities. 
 
8. THE INVESTIGATIONAL PLAN 
 
8.1. Overall study design: A 12-week clinical trial consisting of open label treatment with 
Concerta XL in young male offenders meeting diagnostic criteria for ADHD. Young offenders 
meeting the inclusion/exclusion criteria for the study and providing fully informed consent for 
participation, after discussion of the study protocol (and up to 4-weeks to consider whether 
to participate or not) were treated with Concerta XL. The study medication was started at a 
dose of 18 mg for the first week, and subsequently increased by weekly increments of 18 
mg, to a maximum dose of 90 mg. 
 
8.2. Setting: The trial took place at HMPYOI Isis, which is in the Belmarsh prison cluster. 
This is a relatively new prison which opened in 2010 and holds sentenced young male adults 
and category C offenders. There are two house blocks with mixed single and double cells 
and the operational capacity was measured at 480 in August 2010. HMPYOI Isis has a 
broad based curriculum for young sentenced prisoners and available activities include 
mechanics, construction, bicycle repair, catering, broadcasting, job related studies and 
offending behaviour interventions. It therefore has a rehabilitation and resettlement 
emphasis, and all prisoners are offered a full time occupation. 
 
8.3. Assessment schedule: Assessments were performed at baseline, weekly during 
the first 5-weeks of the trial (weeks 1-5), then again at weeks 8 and 12. Following the end of 
the 12-week trial there was a 6-month open label extension trial following individual titration 
of the dose, with further evaluations at 3 months and 6 months. However we did not 
complete all 3 and 6 month evaluations as planned. 
 
8.4. Titration process: Treatment was started at an initial dose of 18 mg for 1 week, and 
then increased weekly in 18 mg increments to a maximum of 90 mg (i.e. 18 mg, 36 mg, 54 
mg, 72 mg, and 90 mg). Medication dose was not increased if in the opinion of the clinician 
(or the participant) there were minor adverse effects that could be exacerbated at a higher 
dose. Medication was reduced by 18 mg if there was a limiting adverse event, in which case 
there were no further increases in medication for the duration of the trial. Titration upwards 
was stopped once all ADHD symptoms were scored as negligible or absent (score of 0 or 1 
on all items of the CAARS). Participants with limiting adverse events from 18 mg of Concerta 
XL were withdrawn from the trial. 
 
8.5. The Primary outcome: The primary outcome was the change in the number of 
recorded critical incidents (records of disruptive behaviour) in prison records from baseline 
to 12-weeks. Each measurement point (baseline and 12-weeks) reflected behaviour over 
the previous 3-months (reported in units of 1-month). For cases of individuals new to 
custody presenting with significant behavioural problems linked to ADHD, the retrospective 
baseline reporting period was reduced to their reception date at HMP/YOI Isis to the date 
of the baseline assessment. 
 
8.6. Secondary outcomes: These included further measures of aggression, 
engagement with educational activities and ADHD and Emotional Dysregulation. A full list 
of baseline and outcome measures is listed in 2.  
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- Ratings of aggressive behaviour by prison and education staffs (Modified Overt 
Aggression Scale – MOAS) 
- Engagement with education activities over previous 12-weeks (Number of sessions 
attended, number of reports of disruptive behaviour in educational sessions).  
- Symptoms of ADHD (CAARS) 
- Symptoms of Emotional Dysregulation (WRAADS).   
 
 
 
8.7 Study Flow chart 
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8.8. Trial visits: This is a single arm protocol. The visits and decision points delineated in 
the flow diagram are described in more detail below:  
 
 
Diagnostic Step: 
 
Screening 
step   
ADHD screening measure(s) completed by prison mental health team and 
research team, consent obtained. Used for initial identification of potential cases 
of ADHD within the prison. Individuals that screen positive for ADHD invited to 
take part in a diagnostic interview for ADHD either as part of the research 
protocol, or otherwise by the healthcare team as part of their usual treatment 
program.   
 
Visit 1 Information sheets reviewed with potential participants by a member of the 
mental health or research team, for the first part of the study. 
  
Visit 2 Consent for first part of study obtained. This was signed at the end of Visit 1, or 
after a period of time (no time limit), if potential participants wish to take more 
time.  
 
Once consent signed, an appointment was made for a clinical diagnostic 
interview. Patients who did not wish to proceed with the study referred back to 
the clinical care team for further follow-up.   
Visit 3  Diagnostic assessment completed by the mental health or research team, using 
the Diagnostic Interview for ADHD (DIVA interview).  
Mental 
health team 
For those that met DIVA diagnostic criteria for ADHD, a senior clinical 
psychiatrist (specialist registrar or higher grade) with training in the diagnosis of 
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review ADHD, and working with the prison mental health team, reviewed the diagnostic 
information to confirm/refute the diagnosis having considered potential 
comorbid diagnoses and differential diagnoses. If the patient is thought to meet 
criteria for the study an appointment will be arranged with one of psychiatrists.  
 
Visit 4 Assessment by psychiatrist for final confirmation of the diagnosis and check of 
all inclusion and exclusion criteria for the study. Potential participants that met 
entry criteria for the clinical trial given the information sheet and consent form. 
 
 
Clinical trial: 
 
Visit 5 The content of the information sheet was discussed and the study explained. 
This visit usually occurred at the end of Visit 4. 
 
Visit 6 Information sheets reviewed and consent obtained for clinical trial.   
Visit 7 Start of Clinical Trial. Baseline data collected from participants (including 
physical health checks), prison records and members of staff. Trial prescription 
completed once all baseline data completed and given to pharmacy. Medication 
should start within 1-week of Visit 7. 
Visit 8 1-week after start of medication, dose adjusted. Pulse, blood pressure and 
Adverse Events Scale. Further 1-week prescription. 
Visit 9 2-weeks after start of medication to complete CAARS-O, and adjust medication. 
Pulse, blood pressure and Adverse Events Scale. Further 1-week prescription. 
Visit 10 3-weeks after start of medication to complete CAARS-O and adjust medication. 
Pulse, blood pressure and Adverse Events Scale. Further 1-week prescription 
Visit 11 4-weeks after start of medication to complete CAARS-O and adjust medication. 
Pulse, blood pressure and Adverse Events Scale. Further 1-week prescription. 
Visit 12 5-weeks after start of medication to complete CAARS-O, WRAADS, ALS and 
QbTest (optional) measures. Pulse, blood pressure and Adverse Events Scale. 
Further 7-week prescription. 
Visit 13 8-weeks after start of medication to complete CAARS-O, WRAADS, ALS and 
QbTest (optional). Pulse, blood pressure and Adverse Events Scale.  
Visit 14 12-weeks after start of medication to repeat baseline measures (see chart on p. 
19 for list of measures at this time point). 
 
Start of open label extension study. Medication reviewed by clinician and 
changes made if the clinician considers adjustments would be beneficial to the 
participant, following discussion with the participant and agreement on further 
changes.  
Visit 15 3-months after start of open label study  
Visit 16 6-months after start of open label study  
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8.9. Trial Medication 
 
8.9.1. Investigational Medicinal Product: The study uses usual commercial stocks of Concerta 
XL, supplied as 18 mg and 36 mg capsules. Capsules have the dose in mg written in small writing 
in the side of the capsule; 18 mg capsules are yellow and 36 mg capsules are white. Packaging will 
be as for usual commercial stock and separated out and labelled using usual pharmacy procedures 
for each participant. Prescriptions will be provided, signed off by medical members of the research 
staff, on standard pharmacy prescription forms used in the prison. These will be provided weekly 
for the first 5-weeks, to allow for titration procedures to be followed; then provided for 7-weeks at 
the maintenance dose. Trial medication will be given out by the prison pharmacy to the healthcare 
nurses, to store and dispense from the pharmacy hatches based on the two house blocks. 
Prisoners will be observed taking the trial medication and will not be given medication to take away. 
 
8.9.2. Dosing Regimen: Treatment started at an initial dose of 18 mg for 1 week, and be increased 
weekly in 18 mg increments to a maximum of 90 mg (i.e. 18 mg, 36 mg, 54 mg, 72 mg, and 90 mg). 
Medication will be reduced by 18 mg if there is a limiting adverse event, in which case there will be 
no further increase in medication for the duration of the trial. Titration upwards will be stopped if all 
18 ADHD symptoms are scored as negligible (score of 0 or 1 on the CAARS) or absent. 
Participants with limiting adverse events from 18 mg of Concerta XL will be withdrawn from the trial.  
A maximum dose of 90 mg included for this trial because previous clinical trials have indicated that 
a proportion of adults respond better at higher doses without unacceptable levels of adverse 
events; and because current licensing for Concerta XL up to 54 mg is based on dose levels for 
children and adolescents, rather than adults. NICE recommend a daily dose of methylphenidate in 
adults to a maximum of 100 mg per day11 and for Concerta XL the British National Formulary (No 
62, September 2011) recommends doses up to a maximum of 108 mg in adults.   
 
8.9.3. Drug Accountability: All aspects of treatment and accountability for managing the 
medication storage and delivery managed locally by the prison pharmacy and mental health team, 
as per standard HMPYOI practice for this. IMP accountability recorded and verified. 
 
8.9.4. Subject Compliance: All aspects of treatment compliance and recording of treatment 
administration/refusal managed by the prison mental health team and locally by healthcare staff as 
per standard practice for this site.   
 
8.9.5. Concomitant Medication: All concomitant medications recorded. Use of the following 
medications in the 4-weeks prior to the start of treatment with Concerta will lead to exclusion from 
the clinical trial, based on potential adverse drug interactions:  
 
- Clonidine 
- Coumarins 
- Monoamine oxidase inhibitors 
- Moclobemide 
- Rasagline  
 
8.9.6. Randomisation Procedure/Code Break: This was an open trial with no randomisation 
procedure 
 
9. DISCUSISON OF STUDY DESIGN 
 
There was limited prior experience of treating young adult prisoners meeting diagnostic 
criteria for ADHD in the United Kingdom. Within HMYOI Isis, ADHD was rarely diagnosed 
or treated prior to this trial. There was no commissioned diagnostic or treatment service 
for ADHD. The study was established with several overarching aims, with the intention of 
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generating sufficient pilot data to support the application for funding of a definitive 
randomised controlled trial. The main aims were to evaluate feasibility, safety and provide 
a preliminary assessment of treatment effects. We therefore started with a screening and 
diagnostic phase, designed to screen all young adult offenders within the prison, and to 
establish the rate of ADHD following gold standard diagnostic procedures. We then 
invited all prisoners meeting the study inclusion and exclusion criteria into an open label 
treatment trial that followed the most common procedures for treating adults with ADHD 
in the UK, adhering closely to NICE guidelines (2008). In effect the trial was designed to 
evaluate common outcomes, following an approach that was very close to treatment as 
usual. We were particular interested to evaluate the potential for treatment effects on 
behaviour within the prison setting, rather the ADHD, so selected as the number 
adjudications (prison reports of bad or aggressive behaviour) as the primary outcome.  
 
The open trial design allowed a preliminary evaluation of the process of delivering a 
standard medication to a group with complex needs, behavioural and mental health 
problems. The study was run as an open label trial so that the study team would become 
familiar with the process of titrating onto treatment, evaluating participant responses to 
the treatment protocol and the level of support they required and evaluation of risk and 
compliance to treatment with the prison settings.  
 
The open trial design limits any conclusions about effectiveness, but did provide for the 
first time an evaluation of the pre-post treatment outcomes for patients being treated with 
OROS-methylphenidate within a prison setting in the UK. The study design does not 
allow strong inferences to be drawn about the levels of recruitment or retention for a 
future placebo controlled study. A further limitation was that for this pilot study we did not 
attempt to retain individuals in the study if they dropped out of treatment leading to a 
substantial amount of missing data at the endpoint, potentially inflating clinical effects, 
particularly for per protocol analyses.  
  
10. SELECTION OF STUDY POPULATION 
 
10.1. Selection of Participants: Participants were recruited from HMPYOI Isis, Western 
Way, Thamesmead, SE28 0EB. Screening questionnaire data collected by the prison mental 
health team will be used to identify those who screen positive for ADHD. Patients who 
screen positive will be invited to take part in the clinical trial if they meet diagnostic criteria for 
ADHD following a research diagnostic interview and clinical review by the prison mental 
health team and meet all inclusion and exclusion criteria.   
 
10.2. Inclusion Criteria  
 Male 
 Aged between 18 and 30 years.  
 English speaking.  
 Able to provide informed consent to participate (understand the protocol and make 
an informed decision taking into account pros and cons of study participation).  
 Meet clinical diagnostic criteria for ADHD following screening questionnaires for 
ADHD and diagnostic interview using the DIVA interview. DSM-IV criteria, revised to 
take into account recommendations from NICE and proposed DSM-V criteria, will use 
the following criteria:  
- 6 or more symptoms of ADHD in either the inattention or hyperactivity-impulsivity 
symptom domains as children. 
- 4 or more symptoms of ADHD in either domain as adults.  
- Where it is not possible to gain sufficient clinical information to score childhood 
symptoms of ADHD, the operational criteria will be adapted to include evidence 
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of some significant symptoms with impairment starting before the age of 12 
years, and 6 or more symptoms currently with significant impairment currently.  
- Persistent trait like (non-episodic) course of symptoms. 
- Impairments in two or more clinical or psychosocial domains and two or more 
settings from symptoms of ADHD. 
- Onset of symptoms before the age of 12 years (following recent national and 
international guidelines). 
- Symptoms of ADHD not secondary to another medical or mental health condition.  
 
10.3. Exclusion Criteria  
 Lack capacity to give informed consent  
 Moderate or severe learning disability (defined as IQ < 65) 
 Not English speaking 
 Serious risk of violence to the researcher 
 Pure inattentive subtype, with 2 or less symptoms of hyperactivity-impulsivity 
 Pure hyperactive impulsive subtype, with 3 or less symptoms of inattention 
 Current major depression, psychosis, mania, and episodic hypomania as part of 
bipolar II disorder 
 Past history of bipolar I or schizophrenia  
 Contraindications to the use of stimulants (glaucoma, hypertension, cardiovascular 
disease or structural heart problem). 
 
10.4. Withdrawal of Subjects  
Participants had the right to withdraw from the study at any time for any reason. Healthcare 
staff had the right to withdraw patients from the trial if they considered the trial was having an 
adverse effect on the participants. For patients who decided to withdraw from the study, all 
efforts were made to report the reason for withdrawal as thoroughly as possible. Anyone 
withdrawn from the clinical trial was reviewed by the prison healthcare team to ensure their 
safety.  
 
Participants with limiting adverse effects from 18 mg of Concerta XL during the first week of 
the clinical trial were withdrawn from the trial. When this occurred they were replaced with 
another participant. All participants informed that they had the right to withdraw from the 
study at any time. For participants who withdrew, the patient data used was from the date of 
withdrawal of the study carried forward. Participants who withdrew from the study were not 
replaced with the exception of intolerance to 18 mg of Concerta in the initial 1 week of the 
study. 
 
10.5. Protocol deviations: The Adverse Effects Scale (AES) data was not collected at the 
baseline visit. This was a deviation from the protocol that did not present a risk to patients, or 
impact on the scientific aims of the protocol. The AEs was collected at all other data 
collection points. The omission of the baseline data means that we cannot make any 
inference about the presence of adverse effects prior to starting medication.  
 
11.  TREATMENTS 
 
11.1. Treatments administered: The study used usual commercial stocks of Concerta XL, 
supplied as 18 mg and 36 mg capsules. Capsules have the dose in mg written in small 
writing in the side of the capsule; 18 mg capsules are yellow and 36 mg capsules are white. 
Packaging was as for usual commercial stock and separated out and labelled using usual 
pharmacy procedures for each participant. Prescriptions were provided, signed off by 
medical members of the research staff, on standard pharmacy prescription forms used in the 
prison. These were provided weekly for the first 5-weeks, to allow for titration procedures to 
be followed; then provided for 7-weeks at the maintenance dose. Trial medication wad given 
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out by the prison pharmacy to the healthcare nurses, to store and dispense from the 
pharmacy hatches based on the two house blocks. Prisoners will be observed taking the trial 
medication and will not be given medication to take away. 
 
11.2. Dosing: Treatment was started at an initial dose of 18 mg for 1 week, and then 
increased weekly in 18 mg increments to a maximum of 90 mg (i.e. 18 mg, 36 mg, 54 mg, 72 
mg, and 90 mg). Medication dose was not increased if in the opinion of the clinician (or the 
participant) there were minor adverse effects that could be exacerbated at a higher dose. 
Medication was reduced by 18 mg if there was a limiting adverse event, in which case there 
were no further increases in medication for the duration of the trial. Titration upwards was 
stopped once all ADHD symptoms were scored as negligible or absent (score of 0 or 1 on all 
items of the CAARS). Participants with limiting adverse events from 18 mg of Concerta XL 
were withdrawn from the trial.  
 
11.3. Treatment Compliance: Participants are given medication daily by the health care 
team nursing staff. They observe and record when medication is taken on a daily basis. 
Medication was taken between 08:00 - 12:00.  
 
11.4. Concomitant medication: All concomitant medications recorded. Use of the 
following medications in the 4-weeks prior to the start of treatment with Concerta will lead to 
exclusion from the clinical trial, based on potential adverse drug interactions: Clonidine, 
Coumarins, Monoamine oxidase inhibitors, Moclobemide and Rasagline.  
 
12. EFFICACY AND SAFETY MEASURES 
12.1. Primary Effectiveness Parameters: The primary outcome parameter was the 
change in the number of recorded critical incidents (records of disruptive behaviour) in prison 
records from baseline to 12-weeks. Each measurement point (baseline and 12-weeks) will 
reflect behaviour over the previous 3-months.  
 
12.2. Secondary Effectiveness Parameters: These include the following baseline to 12-
week difference scores. See Appendix 2 for complete list of measures.  
 Ratings of aggressive behaviour by prison and education staffs (Modified Overt 
Aggression Scale – MOAS). 
 Engagement with education activities over previous 3-months (number of sessions 
attended, number of reports of disruptive behaviour in educational sessions).  
 Symptoms of ADHD (CAARS).  
 Symptoms of Emotional Dysregulation (WRAADS).   
 
12.3. Procedures for Assessing Efficacy Parameters: The WRAADS is an investigator 
rated scale, following an assessment interview. This will take around 10 minutes. Other data 
from participants was collected using self-rated rated assessment scales, apart from the 
cognitive performance test (QbTest), and the observer rated ADHD symptoms (CAARS-O) 
and Clinical Global Impression scale (CGI). The self-rated questionnaires take around 40 
minutes to complete; the CAARS-O and CGI take around 25 minutes.  
 
QbTest is a 20 minute computer administered attention test that is done in front of a 
computer screen. During the test a high resolution infrared camera monitors the movement 
of the patient and measures activity, attention and impulsivity calculated based on the 
performance on the task and level of activity. The data are then processed and compared 
with a normative group of the same age and sex. Key outcome variables are reaction time 
mean, reaction time variability, omission errors, commission errors, anticipatory responses 
and measures of activity level. The prisoners with ADHD found the test difficult to complete, 
with much of the date being of poor quality. Analyses of these data are ongoing and are not 
presented in this report.  
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12.4. Assessment of Safety: Patients were monitored daily by the prison mental and 
healthcare teams. Safety checks were conducted in line with NICE Guidelines (2008): 
1. Checks before commencing treatments: pulse and blood pressure; and review of pre-
study health checks. 
2. Any evidence of cardiovascular abnormalities evaluated for risk and if necessary an 
opinion obtained from a cardiologist prior to commencing treatment (not required).  
3. The clinical team check pulse and blood pressure once a week and whenever there 
is a dose change. After 1-month, the cardiovascular checks will be completed at 8 
and 12 weeks.  
4. Other safety checks included monitoring of common adverse events during 
assessments using adverse events scale. In addition, participants were monitored 
daily by prison staff and any potential adverse events will be reported to the prison 
healthcare and mental healthcare teams.  
  
12.5. Specification, Timing and Recording of Safety Parameters: With regards to the 
research aspect of the study (i.e. obtaining follow-up data) there is little risk to participant safety. 
Participants will be aware that should they wish to withdraw from the study they may do so. 
Participants who become upset or distressed by the questions in the research were offered 
support by the researchers and by the prison mental health team.  
 
The healthcare team followed national guidelines on safety, which is predominantly related to 
monitoring of cardiovascular function. More specifically the clinical care followed these 
procedures:  
1. Checks before commencing treatments pulse and blood pressure and review of 
healthcare records. 
2. Potential cardiovascular abnormalities will be evaluated for risk and if necessary an 
opinion obtained from a cardiologist prior to commencing treatment.  
3. The clinical team will check pulse and blood pressure once a week and whenever there is 
a dose change. After 1-month, the cardiovascular checks will be completed during the 8, 
12, 24 and 36 week assessments.  
5. Other safety checks will include monitoring of adverse events during assessments. In 
addition, participants will be monitored daily by prison staff and any potential adverse 
events will be reported to the prison healthcare team.   
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12.6. Data quality assurance: The electronic report forms allowed on possible responses. 
All data was entered immediately preceding completion on any given day. All data entered 
was done so by one member of the research team and checked for accuracy by another. 
 
13. STATISTICAL METHODS 
 
13.1. Sample Size: The study was designed as an open clinical trial with a single open label 
treatment arm. The main objectives were to provide preliminary data on the effects of a standard 
treatment for ADHD on aggression, within the prison setting. These data will be used to estimate 
the effects on the primary and secondary outcomes, explore the mediation model (whereby 
reductions in ADHD symptoms are hypothesised to lead to reductions in aggression), and generate 
feasibility data for future randomised clinical trials (RCTs) of the effects of treatments for ADHD on 
important behavioural outcomes within prison settings.   
 
We proposed a sample size of 100 which is well powered to detect changes in ADHD symptoms 
and emotional dysregulation within an open study design. Based on previous controlled studies of 
methylphenidate versus placebo, we estimated that the likely reduction in ADHD and emotional 
dysregulation scores to be between 18 (using the WRAADS scores) in a methylphenidate 
treatment group and 13 in a placebo group (changes from 45 at baseline to 27 and 32, 
respectively; Figure 2, Rösler et al., 2009 12). The estimated difference in treatment efficacy 
between two arms in a placebo controlled trial would therefore be 5 points. We have assumed that 
the intraindividual change scores have a standard deviation similar to that of measure at baseline, 
namely 7 (Table 1, Rösler et al., 2009 12).  This is however a conservative estimate, because in the 
previous study, 25% of the subjects in the placebo arm dropped out due to non-efficacy of their 
treatment, so that these figures likely over-state the reduction of symptoms in the placebo group, 
and there may be more variability in the data with larger standard deviations.  
 
In the study here, where there is no placebo arm, we expected to generate larger effect sizes for 
baseline versus endpoint measures, due to the additional non-specific effects of the treatment-trial 
protocol. However we have powered the study for effects on the proposed mediator (ADHD 
symptoms and emotional dysregulation) of the effects on aggression, based on the Rösler 2009 
study.  
 
Figure 1 shows power curves assuming standard deviations ranging from 5 to 25 and alpha = .05, 
for the difference between baseline and endpoint measures. This indicates that over a wide range 
of parameters we have sufficient power to detect mean differences of 5 or more points on the 
WRAADS scores. This indicates that we have a very high level of confidence in detecting 
significant baseline to outcome effects on ADHD symptoms and emotional dysregulation.    
 
Determining power for the potential effects on aggression and other outcomes, such as 
engagement with educational activities, is far more difficult to estimate. The effect size is entirely 
unknown and estimates of effect size on the behavioural problem measures are one of the primary 
outcomes of this study – that will then be used for designing a fully powered randomised control 
trial, to estimate the size of the specific effects from drug treatment and separate these from the 
non-specific effects of the clinical trial.  
 
Figure 1: Power estimates for mean 
differences of 5 and 7, by standard 
deviation 
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13.2. Analysis plan: Analyses were conducted planned to be conducted by Tom Price 
(statistician). We planned an interim analysis at the half way stage of the planned study 
(when data from approximately 50 participants were available for the primary endpoint). If 
these are sufficient to address the main aims of the study (dependent on the effect size on 
the primary and secondary measures) the trial may have been ended at this point – and 
further funding sought to initiate a controlled trial.  
 
The main Intention to treat (ITT) analyses will be the changes in scores for the primary and 
secondary outcomes measures from baseline to endpoint at 12-weeks; using paired T-
scores. Effect size is estimated as the difference in the baseline versus endpoint means 
scores divided by the standard deviation of the change scores. For ITT analyse the last 
observation carried forward (LOCF) approach was taken. Additional analyses using the ITT  
and per protocol approaches included: 
- Estimates of the effect size for WRAADS inattention, hyperactivity-impulsivity and 
emotional-dysregulation subscales, separately. 
- Change in DSM-IV ADHD items 
 
For secondary analyses that seek to investigate the co-variation of one variable with another 
during the treatment process (e.g. ADHD with critical incidents), or to consider mediating 
hypotheses (e.g. that any effects on critical incidents are mediated by change in measures of 
emotion dysregulation) will use a per protocol approach. These include all analyses 
designed to investigate the co-variation of one variable with another during the treatment 
process. Hypotheses to be tested here include the following: 
 
- Change in critical incidents correlates with change in emotional dysregulation 
- Change in emotional dysregulation is correlated with change in ADHD symptoms 
- Change in critical incidents is mediated by change in ADHD symptoms. 
 
13.3. Change in the conduct of the study or planned analyses: This study was 
designed as an open label pilot study of an extended release formulation of oros-
methylphenidate (Concerta XL) designed to look at the aggression in young male offenders 
with ADHD aged 18-30. This clinical 12-week trial aimed to titrate 100 participants on to 
Concerta XL to an optimal dose (of between 18mg to 90mg, balancing effectiveness against 
potential adverse effects) during the first 5-weeks, with a maintenance phase for the 
following 7-weeks. The 12-week trial was then planned to be followed by an open label 
extension for 6-months.  
 
The high drop-out rate by 12-weeks 9see below) led to a decision to extend the recruitment 
above 100 cases, to aim for 100 according to the per protocol analysis. This decision was 
made by the project management group. The extension trial was abandoned at the end of 
the trial as funding was not available for the continued follow-up. This was felt to be 
reasonable since the main aims of the study had been achieved during the 3-month study, 
as planned. This decision was made the study management group.  
 
We have not yet completed analysis of the QbTest data. This is being quality checked by a 
PhD student and will be made available during 2016.  
 
14. STUDY PATIENTS 
 
14.1. Disposition of patients: The trial took place at HMP YOI Isis which is part of the 
Belmarsh prison cluster. It is a relatively new prison that opened in 2010 with two house 
blocks and a focus on resettlement and rehabilitation. When work began at Isis, the prison’s 
operational capacity was 402 male inmates between the ages of 18-25. By completion 620 
offenders aged of 18-30 were housed within the walls, with a constant flow of releases and 
transfers in and out. 
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Prior to starting the research and throughout the process, screening questionnaires for 
ADHD were administered by the research team, with the assistance of healthcare staff, to all 
prison inmates. A total of 1922 inmates were screened via the Barkley Adult Current ADHD 
18 point questionnaire over the course of two years. The screener is a self-report 
questionnaire based upon current (past 6 month) DSM ADHD criteria (9 in each domain of 
inattention and hyperactivity/impulsivity), and uses a 4-point rating scale to indicate the 
frequency of symptoms (‘never/rarely’, ‘sometimes’, ‘often’ and ‘very often’). The Barkley 
Symptom scale offers a total symptom count for the Inattentive and Hyperactive/Impulsive 
domains (0-9 for each; based on ‘often’ and ‘very often’ endorsements only). The cut-off 
criterion applied to this study was four or more ADHD symptoms for either domain. We 
applied this relaxed cut-off of 4 symptoms (as opposed to the DSM-IV criteria of 6 or the 
DSM-5 criteria of 5 symptoms) because all those with positive symptom endorsement at this 
stage were then offered a full diagnostic interview. The lower cut off rate was intended to 
increase sensitivity at the screening stage. 
 
Individuals that screened positive for ADHD (n=473) were offered a clinical diagnostic 
interview and a psychiatric review for ADHD. The Diagnostic Interview for ADHD (DIVA), 
followed by a clinical review by a Psychiatrist was offered to all those that met initial 
screening criteria for ADHD or had been referred by the prison with behaviours suggestive of 
ADHD. Three hundred and ninety eight individuals agreed to take part at this stage and 
consent was gained to examine demographic and assessment details.  
 
Participants receiving a clinical assessment (n=398) were all male, between the age of 18 to 
30 years and with ethnicity classified as white n=183 (46%), Asian n= 26 (7%), Black n=108 
(27%), Mixed Race n=61 (15%), Other Ethnicity n=16 (4%) and Missing Ethnicity n=4 (1%).  
 
The Diagnostic Interview for ADHD in Adults (DIVA; Kooij et al, 2005) administered to this 
group is a semi-structured clinical interview that evaluates each of the 18 DSM ADHD 
symptom items for both current and childhood  symptoms, as well as asking additional 
questions to establish whether impairment exists and age of onset. We initially applied 
adapted DSM-IV criteria of 6 symptoms in Inattentive and/or Hyperactive/Impulsive domains 
in adulthood and childhood, with onset prior to age 12 and impairment in at least two areas. 
With the release of the new DSM-5 criteria, we lessened the symptom level in adulthood to 5 
to reflect changes. In this particular study we also applied a more relaxed inclusion criterion 
whereby if participants scored 6 or more symptoms in adulthood with clear impairment but 
symptoms in childhood were unclear, they were still diagnosed with ADHD if there was 
overall evidence that they showed inattentive, hyperactive and impulsive behaviour as 
children. For example in cases who could not recall the details of their childhood behaviour a 
judgment was made as to whether current ADHD symptoms were a continuity of symptoms 
and impairments that started during childhood. In such cases efforts were made to contact 
family members to shed light on childhood symptom presence, but where this was not 
possible, participants with current symptoms and impairment were not penalised for recall 
issues.  
The diagnostic criterion allowed for one of three classifications: ADHD predominantly 
Inattentive type n=44 (11%), ADHD predominantly Hyperactive/Impulsive type n=29 (7.3%) 
and ADHD Combined type n=193 (48.5%).  Including those who met the more relaxed 
diagnostic criteria of 6 or more in adulthood but unclear in childhood category n=40 (10%), a 
total of three hundred and six participants met diagnostic inclusion criteria for the clinical 
trial. The remaining 92 participants scored accordingly: DIVA negative n=58 (14.7%), 
unclear n=8 (2%) and those in remission (symptom presence in childhood only) n=26 
(6.5%).   
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Figure 2: Percentage outcomes from the DIVA diagnostic interview in 398 screen 
positive cases. 76.8% of those completing the DIVA interview met diagnostic criteria for 
ADHD.  
 
Following assessment and review those that met clinical diagnostic criteria for ADHD were 
checked against other inclusion and exclusion criteria and where appropriate, were invited to 
take part in the clinical trial. One hundred and twenty one adult male offenders meeting 
criteria for Adult ADHD opted to take part in the clinical trial of Concerta XL. All participants 
were willing to try Concerta XL for the proposed period of 12 weeks and were sentenced 
prisoners with at least three months remaining in custody. Those with fewer than 3 months 
remaining on their sentence or who failed to meet other specific inclusion criteria were 
treated where possible outside of the trial.  
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10.2. Patient numbers at each stage of recruitment and assessment: 
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14.3. Estimated prevalence of ADHD among prison inmates at HMP Isis: 1922 offenders 
were screened over a two year period in HM YOI Isis: 473 screened positive for Adult 
ADHD, giving an estimated prevalence rate of 25% at screening level. We were able to 
administer 398 (84% of positive screens) with a full Diagnostic Assessments (DIVA), 266 
met full criteria (67% of those assessed), a further 40 met current criteria with evidence of a 
lifelong pattern of ADHD starting during childhood (10%), 92 (23%) came out as negative or 
in remission.  
 
Based on the 306 who fulfilled diagnostic eligibility for the clinical trial, we estimated an 
ADHD prevalence rate of 19.2% meeting diagnostic criteria for ADHD in the population we 
sampled. Of the 306 meeting initial criteria for the clinical trial, we were able to recruit a total 
of 121 participants to the CIAO trial: 81 reached week 8. 73 completed the endpoint 
assessments. Data was obtained for 75 on the primary outcome (from prison records) at 
endpoint.  
 
14.4. Protocol deviations 
 Participant 9 left the study at 8 weeks but concluded all week 12 endpoint 
assessments. This data was included in the per protocol analysis for week 12 
endpoint data. 
 
 The Adverse Effects Scale (AES) data was not collected at the baseline visit. This 
was a deviation from the protocol that did not present a risk to patients, or impact on 
the scientific aims of the protocol. The AEs was collected at all other data collection 
points. The omission of the baseline data means that we cannot make any inference 
about the presence of adverse effects prior to starting medication.  
 
  
15. EFFICACY EVALUATIONS 
 
15.1. Data collection: Assessments were performed at baseline, weekly during the first 5 
weeks of titration (weeks 1-5) and then again at weeks 8 and 12. Treatment started at an 
initial dose of 18 mg for 1 week, and was increased weekly in 18 mg increments to a 
maximum of 90 mg (i.e. 18 mg, 36 mg, 54 mg, 72 mg, and 90 mg). Medication was not 
increased if in the opinion of the clinician (or the participant) there were minor adverse 
effects that could be exacerbated at a higher dose. Medication was reduced by 18 mg if 
there was a limiting adverse event. Titration upwards was stopped if all ADHD symptoms 
were scored as negligible or absent (score of 0 or 1 on all items of the CAARS). Participants 
with limiting adverse events from 18 mg of Concerta XL were withdrawn from the trial. 
Following the end of the 12-week trial there was a 6-month open label extension, with further 
evaluations at 3 months and 6 months for those who opted to participate. 
 
15.2. Outcome measures: The primary outcome measure was the number of recorded 
critical incidents (records of disruptive behaviour) in prison records from baseline to 12-
weeks; as recorded by prison staff on the National Offender Management Information 
System (NOMIS). Each measurement point (baseline, 12-weeks, week 24 and 36) reflected 
behaviour over the previous 3-months (reported in units of 1-month). Incident and Earned 
Privileges; (Negative and Positive) assigned for inappropriate or good behaviour respectively 
were recorded. Adjudication data included: frequency of fights, assaults, serious assaults, 
self-harm, damage to property, disobeying an order, drug taking and referral to police. This 
particular data was then collated into two categories: Sum of Physical aggression and Sum 
of all Adjudications.   
 
For new inmates presenting with significant behavioural problems linked to ADHD, the 
retrospective baseline reporting period was reduced to their reception date, so as not to 
exclude those in dire need of treatment.  
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Secondary measures were also collected on aggressive behaviour of participants as rated 
on the Modified Overt Aggression Scale (MOAS) completed by prison staff, recorded 
engagement with educational activities, scores on the Maudsley Violence self-rating scale 
(MVQ) in two areas, (acceptance of violence and machismo), ADHD symptoms and 
Emotional Dysregulation.  
 
We administered the Brief Symptom Inventory designed to assess nine individual symptom 
groups (somatization, obsession-compulsion, interpersonal sensitivity, depression, anxiety, 
hostility, phobic, anxiety, paranoid ideation and psychoticism) and global severity index 
(the best single indicator of the respondent's level of distress) were administered at 
baseline, week 12 and in the extension phase. The Clinical Global Impression scale was 
also used by Clinician’s at baseline, week 12 and the extension phase, assessing the 
overall improvements resulting from treatment. 
 
Symptoms of ADHD were monitored on a weekly basis from week 0-5 and then at week 8, 
12 and in the extension phase via the Connors Adult ADHD Rating Scale (CAARS). The 
CAARS measures the presence and severity of symptoms in adults and is based on the 
observer’s assessment of the self-reported changes in participant behaviour between 0 
(never/rarely) to 3 (very often). Emotional dysregulation was monitored via the Wender-
Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) and the Affective Lability 
Scale (ALS) at baseline, weeks 5, 8 and 12 (when medication had been titrated) and then 
again in the extension phase. The WRAADDS asks participants about instances of 
attention, temper, affective lability, emotional over reactivity, disorganisation and 
impulsivity issues and the frequency of these over the past week. The ALS asks about 
rapid mood changes. 
 
Measures of intelligence (WASI-11 IQ test using 2 dimensions- vocabulary and matrix 
reasoning), Socialisation (Gough SO scale- measuring anti-social tendencies) and 
childhood conduct disorder (Barkley CD subscale) were also taken at baseline to build a 
more descriptive picture of those opting to take part. 
 
15.3. Datasets analysed: 5 participants dropped out after baseline assessment and 
before starting medication; they were replaced. 7 dropped out during week 1 of 
medication and were replaced. 121 participants began the trial of Concerta XL at 
baseline and continued beyond week 1. Only 72 completed all the way through to 
week 12. Primary outcome data was obtained on 75 participants. Reasons for 
dropping out of the protocol were as follows: 
 
 Eighteen participants stopped due to side effects; participants seemed to experience 
these more acutely in this setting. Side effects such as appetite reduction, sleep 
disruption and headaches, are arguably more notable among participants whose 
activities are restricted and, unlike those in the community, have less opportunity to 
distract themselves from adverse effects.   
 Eighteen participants left the prison unexpectedly. This was mainly due to unplanned 
transfers but a couple was also either released early or returned to court on other 
charges. 
 Eight participants decided they didn’t want to carry on due to a dislike of the programme 
(namely the gaps in research visits). 
 Three were removed by the investigator due to non-compliance or the drug proving 
unsuitable 
 One dropped out due to family advice  
 One was removed from the study due to concealing medication.  
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15.4. Primary outcome: The primary outcome data was collected at baseline and at 12-
weeks. Data collection was not continued for patients who dropped out of the protocol prior 
to the 12-week outcome, as the measure recorded reported behaviour over the previous 
12-weeks. The final dataset with both baseline and 12-week adjudication data was n=72 
(per protocol). 
 
15.5. Secondary outcomes: Secondary outcome data was collected baseline 5, 8 and 
12-weeks for rating and interview measures; and at baseline and 12-weeks for some of the 
prison record data. The figure in section 10.2 list the number with data collected at each 
stage. There were a total of 121 for LOCF analysis, 83 for 5-week data, 81 for 8-week data 
and 72 for 12-week data.    
 
15.6. Demographic and baseline data: The diagnostic criterion allowed for one of three 
classifications: ADHD predominantly Inattentive type n=44 (11%), ADHD predominantly 
Hyperactive/Impulsive type n=29 (7.3%) and ADHD Combined type n=193 (48.5%).  
Including those who met the more relaxed diagnostic criteria of 6 or more in adulthood but 
unclear in childhood category n=40 (10%), a total of three hundred and six participants met 
diagnostic inclusion criteria for the clinical trial. The remaining 92 participants scored 
accordingly: DIVA negative n=58 (14.7%), unclear n=8 (2%) and those in remission 
(symptom presence in childhood only) n=26 (6.5%).   
 
 
 
Figure 2: Percentage outcomes from the DIVA diagnostic interview in 398 screen positive 
cases. 76.8% of those completing the DIVA interview met diagnostic criteria for ADHD.  
 
 
Following assessment and review those that met clinical diagnostic criteria for ADHD were 
checked against other inclusion and exclusion criteria and where appropriate, were invited to 
take part in the clinical trial. One hundred and twenty one adult male offenders meeting 
criteria for Adult ADHD opted to take part in the clinical trial of Concerta XL. All participants 
were willing to try Concerta XL for the proposed period of 12 weeks and were sentenced 
prisoners with at least three months remaining in custody. Those with fewer than 3 months 
remaining on their sentence or who failed to meet other specific inclusion criteria were 
treated where possible outside of the trial. The mean age of 121 participants was 21 years; 
64 (52.9%) were White, 3 (2.5%) Asian, 33 (27.3%) Black, 18 (14.9%) were Mixed Race and 
3 (2.5%) were from other ethnic backgrounds.  
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Table 1: Demographic data for trial participants (n=121)  
 
 
 
 
 
15.7. Baseline characteristics: At baseline, as well as those measures we intended to 
repeat to observe for change, we also calculated scores of Socialization, Conduct disorder 
and IQ for all of the 121 participants. According to the Gough Socialization Scale the mean 
score was 35.2 (SD=4.252). The Gough Socialisation measure is normally calculated in 
such a way that higher scores indicate greater socialisation and lower scores delinquency 
(as well possible anti-social personality disorder traits). In previous research a score of 25 
and lower has been used to indicate delinquent tendencies, for this particular research we 
have calculated total scores in the opposite direction as such the reverse rules apply and an 
equivalent of 29 (out of 54) or higher is used to indicate delinquent behaviours. The mean 
score of 35.2 indicates that the majority of our sample evidence delinquent behaviour, with 
91% scoring above a total of 29. 
 
The mean scores on the Barkley Conduct Disorder were 18.8 (SD=7.833). The maximum 
score on the Barkley CD is 45; higher scores indicate greater likelihood of childhood conduct 
disorder. Although the mean scores appear lower than expected, 21% of participants scored 
above 25 on the scale suggesting they exhibited certain behaviours indicative of conduct 
disorder between sometimes and often. The mean IQ of our sample was 90 (SD= 11.77).  
 
We ran correlations to understand the relationship between ADHD symptoms of Inattention 
and Hyperactivity/Impulsivity and Socialization and Conduct Disorder. These correlations 
indicate positive correlations between both CAARS Hyperactivity/Impulsivity and Inattentive 
symptoms and socialisation and conduct problems (see Table 2). 
 
Characteristic of participants Frequency  Percentage 
Diagnostic criteria     
DIVA Combined Type 95 78.50% 
DIVA Inattentive sub-type 11 9.10% 
DIVA Hyperactive/Impulsive  6 5% 
DIVA 6+ Adult symptoms unclear 
childhood 9 7.40% 
Education level     
Below GCSE level 69 57% 
Up GCSE level 33 27.30% 
Up to A level 2 1.70% 
Missing data 17 14 
Employment status prior to custody     
In paid employment 12 9.90% 
Self-employed 1 0.80% 
Unemployed 103 85.10% 
Missing 5 4.10% 
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15.8. Substance use case-control differences: Consent was taken from 414 participants 
at either screening level or at DIVA assessment to compare characteristics of those meeting 
criteria for the ADHD clinical trial or those screening negative for the disorder. Data from 267 
individuals meeting criteria were combined with 147 negative screens (control). We tested to 
see whether there was an association between a diagnosis of ADHD and a history of 
substance and/or alcohol use when compared to controls. We used chi-squared tests on our 
data to look for associations.  
 
Daily cannabis use  (X2= 61.850, df=1, p<0.0000), alcohol use (X2=13.548, df=1, p<0.0002), 
alcohol abuse (X2=5.325, df=1, p<0.021), CNS depressant (X2=5.971, df=1, p<0.015) and 
CNS stimulant use (X2=24.263, df=1, p<0.000001) were all found to be significantly higher 
among those with an ADHD diagnosis. There were no significant associations with ADHD 
diagnosis and the use of hallucinogens or opiates. In an additional analysis we found a 
statistically significantly relationship between a positive ADHD diagnosis and non-drug 
related offences (X2=25.943, df=1, p<0.000). Those with ADHD are perhaps less likely to be 
involved or caught for this particular offence. Overall it is arguably a crime that requires a 
level of planning rather than spur of the moment action.  
 
15.9. Prevalence of ADHD among prison inmates at HMP Isis: 1922 offenders were 
screened over a two year period in Isis: 473 screened positive for Adult ADHD, giving an 
estimated prevalence rate of 25% at screening level. We were able to administer 398 (84% 
of positive screens) with a full Diagnostic Assessments (DIVA), 266 met full criteria (67% of 
those assessed), a further 40 met relaxed criteria highly suggestive of ADHD (10%), 92 
(23%) came out as negative or in remission.  
 
Based on the 306 who fulfilled diagnostic eligibility for the clinical trial, we estimated an 
ADHD prevalence rate of 19.2% meeting diagnostic criteria for ADHD in the population we 
sampled. Of the 306 meeting initial criteria for the clinical trial, we were able to recruit a total 
of 121 participants to the CIAO trial: 81 reached week 8, 72 completed the full 12 weeks. 
 
15.10. Efficacy analyses: We applied non-parametric tests (due to the skewed 
distribution of the outcome variables), looking at changes in symptoms and behavioural 
outcomes from baseline through to week 12 endpoint. Tests at each measurement point 
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allowed us to extract symptom level data on those who did not complete to the full 12 
weeks. Analyses were completed according to both ITT and per protocol analyses. 
Bootstrapped paired t-tests were completed for baseline to outcome data. Pre-post effect 
sizes were calculated using Cohen’s d.  
 
15.11. Titration Levels: The first 5 weeks involved titrating participants to an optimal dose 
that both they, and the clinician were happy with. This decision involved weighing up 
treatment effects and adverse effects to agree on an optimal dose for each participant. Of 
the 121 participants who took part in medication trial, 27 (22.3%) were titrated to a stable 
dose of 18mg, 41 (33.9%) to 36mg, 24 (19.8%) to 54mg, 24 (19.8%) to 72mg and 5 (4.1%) 
to 90mg. Overall there was an unanticipated preference toward lower doses, a trend we had 
not anticipated, indicating a potentially heightened sensitivity to side effects but also minimal 
diversion. 
 
15.12. Summary of 12-week endpoint outcomes: ITT and per protocol effect sizes and 
significance values are listed in Table 3 for major outcomes of interest in this study. ITT 
analyses used last observation carried forward (LOCF) 
. 
 Per protocol analysis Intention to treat analysis 
 Cohen’s 
d 
Unadjusted p-
value < 
Cohen’s 
d 
Unadjusted-
value < 
Sum of adjudications 
(primary) 
0.53 .0005 0.30 .005 
Hyperactivity/impulsivity 2.78 .0001 2.29 .001 
Emotional dysregulation 1.71 .0001 1.19 .001 
WRAADS total 2.27 .0001 1.51 .001 
Affective lability scale 1.65 .0001 1.21 .002 
BSI – global severity index 1.07 .0001 0.63 .001 
MVQ-machismo 0.98 .0001 0.62 .001 
MVQ-acceptance of violence 0.40 .0001 0.25 .003 
Sum of disobey orders 0.49 .002 0.28 .024 
Percentage of attended 
activities 
0.36 .062 0.09 .390 
Sum of positive IEPs -0.35 .009 -0.31 .009 
Days in enhanced regime 0.25 .025 -0.11 .181 
 
 
 
 
15.13. Primary outcome: For the intention to treat (ITT) analysis findings were small to 
moderate reductions in the number of adjudications from baseline to 12 weeks: p<.005, 
d=0.29. Using the per protocol (pp) analysis there was a moderate change indicating a 
reduction in the sum of adjudication after a period of 12 weeks: t (71) =3.664, p=0.0005, 
d=0.53. 
 
15.14. Symptom level change  
Measures of core symptoms of ADHD were measured via the CAARS observer scale, 
teamed with the WRAADDS and Affective Lability scales to better understand the emotional 
dysregulation associated with ADHD. Wilcoxon signed rank tests, conducted on all of these 
measures as normality tests, revealed that the data was skewed. Data available below week 
12 was analysed to understand treatment effects of those who for whatever reason, did not 
complete the full trial period.  
 
Analysis of symptom change according to the CAARS Inattention and 
Hyperactivity/Impulsivity, revealed significant differences from week 0 to week 5, and 8. The 
Table 3: Summary of the ITT and per protocol effect sizes and significance levels of the main primary and 
secondary outcomes 
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Wilcoxon signed-rank test showed that 5 weeks of treatment elicited a significant reduction 
in ADHD symptom level (Z=-8.424, P=0.00), which remained at week 8 (Z=-7.844, P=0.000). 
 
Wilcoxon signed rank tests were also performed on week 0-5, 0-8 WRAADDS scales 
(Wender-Reimherr Adult Attention Deficit Disorder Scale); a measure that not only 
incorporates questions around the symptoms traditionally associated with ADHD but also 
emotional dysregulation. Although the WRAADDS has 6 components (attention, temper, 
affective lability, over-reactivity, disorganisation and impulsivity), for the purpose of analysis 
we looked at WRAADDS total scores and WRAADDS emotional dysregulation (a total of 
temper+ affective lability + over- reactivity scores). Analysis revealed a significant reduction 
in WRAADDS total scores between baseline and week 5 and baseline and week 8, results of 
the non-parametric tests are indicated respectively; (Z= -8.421, P= 0.000) and (Z=-7.773, 
P=0.000). Changes were also observed in emotional dysregulation scores at week 5 and at 
week 8; (Z=-8.403, P=0.000) and (Z= -7.632, P=0.000).  
Affective lability is seen as unstable and rapidly changing emotions over a very short period; 
in this way it is easily distinguished from depression or mania in bipolar. Affective lability is 
seen frequently in those with ADHD and was examined at baseline and throughout the 
treatment process.  Wilcoxon signed rank tests were performed on baseline to week 5 and 
baseline to week 8 pairs, revealing a significant total score reduction at by both week 5 and 
week 8; (Z= -7.525, P=0.000) and (Z=-7.104, P=0.000). 
 
15.15. Comorbid health problems: It is often thought that those suffering from ADHD may 
also exhibit symptoms of other co-morbid mental health conditions.  In this particular study 
we tried to get a sense of this through the Brief Symptom Inventory (BSI); a quick 
psychological self-report symptom scale used to measure nine primary symptom dimensions 
(somatization, obsessive-compulsive behavior, interpersonal sensitivity, depression, anxiety, 
hostility, phobic anxiety, paranoid ideation, and psychoticism) and a Global Severity Index 
(widely considered to be the best single indicator of distress). The validity of the subscales 
has been questioned, so we only report the global severity index.  
 
We ran correlational tests on the 121 participants baseline data to see if there were any 
evident associations between the BSI dimensions and the core symptoms of Inattention, 
Hyperactivity/Impulsivity (as measured by the CAARS observer scale) and emotional 
dysregulation prior to treatment. The tests revealed that the WRAADDS measure of 
emotional dysregulation correlated with all nine BSI dimensions and the global severity 
index. The CAARS Hyperactivity/Impulsivity and inattention correlated with the Global 
Severity Index (r=.249 and .292 respectively).  
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Protocol Mean N
Std. 
Deviation
Std. Error 
Mean p-value (>) d
als.0 42.56 96 9.953 1.016
als.5 pp 30.58 96 10.694 1.092 0.0001 1.16
als.0 41.94 81 10.190 1.132
als.8 pp 27.73 81 10.901 1.211 0.0001 1.35
als.0 41.88 73 9.580 1.121
als.12 pp 26.88 73 8.295 .971 0.0001 1.67
als.0 42.34 121 9.491 .863
als.12.locf ITT 30.45 121 10.401 .946 0.0001 1.19
GSI.0 1.26 73 .669 .078
GSI.12 pp .59 73 .553 .065 0.0001 1.09
GSI.0 1.24 121 .605 .055
GSI.12.locf ITT .83 121 .727 .066 0.0001 0.61
HI.0 18.58 96 4.350 .444
HI.5 pp 6.50 96 4.549 .464 0.0001 2.71
HI.0 18.48 81 4.348 .483
HI.8 pp 6.43 81 4.384 .487 0.0001 2.76
Hi.0 18.59 73 4.278 .501
HI.12 pp 6.10 73 4.688 .549 0.0001 2.78
HI.0 18.96 121 4.306 .391
HI.12.locf ITT 7.98 121 5.954 .541 0.0001 2.11
INN.0 18.15 96 3.899 .398
INN.5 pp 5.49 96 4.316 .441 0.0001 3.08
INN.0 18.02 81 3.889 .432
INN.8 pp 5.09 81 4.912 .546 0.0001 2.92
INN.0 18.19 73 4.002 .468
INN.12 pp 4.96 73 4.920 .576 0.0001 3.00
INN.0 18.65 121 3.911 .356
INN.12.locf ITT 6.98 121 6.140 .558 0.0001 2.27
ED.0 18.5625 96 5.37208 .54829
ED.5 pp 7.9688 96 5.71140 .58292 0.0001 1.84
ED.0 18.3827 81 5.37254 .59695
ED.8 pp 7.7037 81 6.70903 .74545 0.0001 1.99
ED.0 18.4658 73 5.55298 .64993
ED.12 pp 8.2192 73 6.25221 .73177 0.0001 1.73
ED.0 18.6529 121 5.33809 .48528
ED.12.locf ITT 10.8264 121 7.60885 .69171 0.0001 1.47
WT.0 26.8125 96 6.76261 .69021
WT.5 pp 10.3333 96 6.95802 .71015 0.0001 2.40
WT.0 26.4444 81 6.71379 .74598
WT.8 pp 10.0864 81 8.05326 .89481 0.0001 2.21
WT.0 26.5753 73 6.84332 .80095
WT.12 pp 10.0685 73 7.57065 .88608 0.0001 2.29
WT.0 26.9835 121 6.77985 .61635
WT.12.locf ITT 13.9835 121 10.26563 .93324 0.0001 1.49
MVQ-A.0 11.56 75 2.213 .256
MVQ-A.12 pp 10.61 75 2.842 .328 0.002 0.37
MVQ-A.0 11.66 121 2.015 .183
MVQ-A.12.locf ITT 11.07 121 2.520 .229 0.002 0.26
MVQ.M.0 21.44 75 9.208 1.063
MVQ-M.12 pp 12.57 75 8.910 1.029 0.0001 0.98
MVQ-M.0 21.42 121 8.774 .798
MVQ-M.12.locf ITT 15.93 121 9.598 .873 0.0001 0.60
Table 4: * [0,5,8,12] refers to week of assessment. Symptom scores: per protocol (pp) and 
intention to treat (ITT) analyses. ALS-affective lability scale; BSI=Behavioural symptom 
inventory (global index score); HI=hyperactivity/impulsivity; INN=inattention; ED=Wender 
Reimherr Adult ADHD Diagnostic Scale (WRAADS)-emotional dysregulation scale; 
WT=WRAADS total symptom score; MVQ-A=Maudsley Violence Questionnaire-acceptance 
of violence scale; MVQ-M=Maudsley Violence Questionnaire-Machismo scale 
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15.16. Adjudication and prison record data: For all those completing the full twelve weeks 
of the trial we evaluated change also on records of adjudications (the primary outcome) and 
educational attendance. Paired t-tests with bootstrapping were administered on baseline to 
week 12 data. In terms of changes in disruptive behaviour and levels of engagement in 
educational activities, we focus on particular areas recorded regularly by Isis prison staff. 
This allowed us to gain as much data as possible for the 12 weeks prior to baseline to then 
compare to the 12 week period of treatment.  
We looked at the following measures:  
 Sum of Physical Aggression (including all records on the prison system of, serious 
assaults, assaults and fights) 
 Sum of Adjudications (including all physical aggression and also records of self-
harm, damage to property, taking drugs, disobeying orders, referrals to police and 
other).  
 The number of negative Incident and Earned Privileges (IEPs-given at the officer’s 
discretion for continued negative behaviour but are separate from other adjudication 
records) 
 Positive IEPs (given for good behaviour) 
 Total number of days on enhanced regime (awarded to those when consistently well 
behaved) 
 Total occasions spent in segregation (solitary confinement for severe incidents that 
cannot be managed elsewhere) 
 Total number of disobeyed order (the most commonly reported problem in prison)  
 Modified Overt Aggression Scales (completed by officers on participant behaviour). 
 
The following measures were not significantly affected over the treatment period: 
 Sum of Physical Aggression: t (71) =1.123, p=.265 
 Negative IEP totals: t (71) =-6.91, p=.492 
 Total occasions sent to segregation: t (71) =1.538, p=.128 
 Modified Overt Aggression: t (68) =.908, p=.367 (Note: there were continued issues 
getting the same officer to complete the measure at the two time points due to staff 
sickness and rotas. Staff also commented that the measure did not feel like a 
suitable reflection of behaviours exhibited). 
 
There were significant changes indicating a reduction in occurrences of the following after 12 
weeks of treatment: 
 Sum of all adjudications: t (71) =3.664, p=0.0005 
 Total disobeying of order: t (71) = 3.220, p=0.002 
 Total number of positive IEPs being awarded during the treated period compared to 
baseline; t (71) =-2.682, p=0.009  
 Number of days spent on standard regime; t (71) =-2.314, p=0.024. 
 
Further questions focused on engagement with educational activities. To address these 
questions we analysed the percentage of attended activities over the 12 weeks pre and 
during treatment. Unfortunately due to difficulty in obtaining this information from education 
staff and prison records, we were only able to collect these data on 54 participants. When 
analysed results indicated an increase in percentage attendance during the treatment phase: 
t (53) =-1.971, p=.054. 
 
Aside from these objective measures of disruptive behaviours, we also measured 
participants’ opinions toward violence on the MVQ. This measure taken at both baseline and 
week 12 (post treatment phase) calculates Acceptance of Violence and Machismo scores 
according to responses to true and false questions. According to bootstrapped paired tests 
there was a significant reduction in both domains by week 12, results are reportedly here 
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respectively: t (71) =4.021, p=0.0001 and t (71) =12.090, P=0.0000 (see Table 4, section 
11.7.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol Mean N Std. Deviation Std. Error Mean
p-value 
(<) d
moas.po.0 8.25 73 18.57 2.174
moas.po.12 pp 5.56 73 12.56 1.47 0.30 0.17
moas.po.0 9.34 118 20.37 1.876
moas.po.12.locf ITT 7.68 118 17.47 1.608 0.63 0.09
total_basic.0 7.92 75 16.29 1.882
total_basic.12 pp 7.55 75 12.28 1.418 0.89 0.03
total_basic.0 10.48 120 19.69 1.797
total_basic.LOCF ITT 10.24 120 17.82 1.627 0.39 0.03
total_standard.0 59.73 75 29.34 3.388
total-standard.12 pp 68.93 75 31.19 3.601 0.01 -0.3
total_standard.0 56.48 120 29.85 2.725
total_standard.LOCF ITT 62.23 120 31.90 2.912 0.02 -0.19
total_enhanced.0 8.84 75 25.10 2.898
total_enhanced.12 pp 14.33 75 31.22 3.605 0.21 0.19
total_enhanced.0 9.06 120 25.92 2.366
total_enhanced.LOCF ITT 12.6 120 29.84 2.724 0.05 -0.13
sum_alladj.0 1.45 75 2.09 0.242
sum_alladj.12 pp 0.56 75 1.12 0.129 0.01 0.83
sum_alladj.0 1.38 120 2.12 0.194
sum_alladj.LOCF ITT 0.82 120 1.63 0.149 0.00 0.3
total_negbeh.0 2.05 75 2.68 0.31
total_negbeh.12 pp 2.24 75 2.41 0.278 0.80 -0.07
total_negbeh.0 1.84 120 2.54 0.232
total_negbeh.LOCF ITT 1.96 120 2.38 0.217 0.20 -0.05
total_posbeh.0 0.52 75 0.91 0.105
total_posbeh.12 pp 0.93 75 1.31 0.151 0.01 -0.36
total_posbeh.0 0.45 120 0.82 0.075
total_posbeh.LOCF ITT 0.7 120 1.14 0.104 0.01 -0.25
total_segregation.0 0.45 75 0.92 0.106
total_segregation.12 pp 0.29 75 0.71 0.082 0.13 0.19
total_segregation.0 0.79 120 3.54 0.323
total_segregation.LOCF ITT 0.68 120 3.52 0.321 0.26 0.03
Percent_attendofsched.0 56.46 57 27.00 3.576
Percent_attendofsched.12 pp 66.03 57 29.81 3.948 0.05 -0.34
Percent_attendofsched.0 53.46 113 26.96 2.536
Percent_attendofsched.LOCF ITT 51.32 113 34.11 3.208 0.55 0.07
Table 5: ITT and pp analyses for prison record data. moas=modified overt aggression scale; 
total_basic=n days on basic regime; total-standard=n days on standard regime; total_enhanced=n days 
on enhanced regime; sum_alladj=total n adjudications; total_negbeh=n negative IEPS; total-posbeh=n 
positive IEPs; total-segregation=days in segregation unit; percent attendofsched=proportion of 
scheduled education/work/rehabilitation activities attended. 0=baseline, 12=12 week pp outcomes; 
LOCF=12 week LOCF outcomes  
CIAO study report- Clare Evans, Philip Asherson and Susan Young on behalf of the CIAO project group 
28.02.2016 
15.17. Correlations: In order to understand whether there was any relationship between 
core symptoms of ADHD (as measured by the CAARS), associated emotional dysregulation 
(as measured via the WRAADDS and ALS) and our primary adjudication outcomes, we 
calculated change scores (baseline minus week 12 scores) on all variables in order to run 
further tests to identify any significant associations of interest. Prior to running these 
correlations, initial descriptives were run and data appeared to be skewed. Formal tests of 
normality were then carried out and data was then transformed on baseline, week 12 and 
change score variables accordingly: 
 
Having normalised the skewed data we ran initial correlations on the change scores and 
found two interesting associations between measures of emotional dysregulation and 
adjudication data. According to these correlations, the Sum of all Adjudication change scores 
was positively correlated with the WRAADDS emotional dysregulation (r = .278), suggesting 
that high scores of emotional lability equated to an increase in overall adjudications. We also 
found that days on enhanced regime were negatively associated (r = -.260*) with reports of 
affective lability or unstable mood. This implies that as days on enhanced (the preferred 
regime awarded to well-behaved individuals) increased, affective lability decreased. 
 
We ran further correlations on a mixture of baseline and change scores to try and establish if 
there were any moderating effects of the Socialisation (GSS), Conduct Disorder (recorded 
on the Barkley CD) or IQ on change scores for primary adjudication outcomes. We found no 
correlations with any of our adjudication outcomes with either the GSS or Barkley Conduct 
disorder measure but we did find that IQ negatively correlated with the sum of all 
adjudication change scores (r = -.329**). While initial correlations indicate that the 
WRAADDS emotional dysregulation has a mediating effect on sum of all adjudications, IQ 
has a moderating effect (as total intelligence quota scores increase, sum of all adjudications 
change scores decrease and vice versa). 
 
15.18. Regressions: Regressions were then run to establish whether the correlations that 
came up in our analysis were statistically significant. A multiple regression was run to predict 
whether the change score for the sum of adjudications can be explained by the WRAADDS 
emotional dysregulation change scores, WASII IQ scores and WRAADDS emotional 
dysregulation at baseline. These variables statistically significantly predicted Sum of 
Adjudication change scores, F (3, 68) =5.130, P=0.003, R2 =.185. Looking closer at these 
results we also found that WRAADDS emotional dysregulation change scores and WASII IQ 
(without WRAADDS baseline) also significantly predicted change in sum of adjudications 
F(2,69)=6.768,  p= 0.002, R2= .164, as did WRAADDS emotional dysregulation change 
scores alone F(1,70)=5.882, P=0.018, R2=.078, however goodness of fit increased with the 
addition of variables. The significant prediction value of these values confirms that 
WRAADDS emotional dysregulation has a mediating effect on the sum of adjudication 
scores while IQ has a moderating effect. 
 
We also ran a regression to see if we could explain the number of days spent on enhanced 
regime change score from ALS change scores and Age. These variables significantly 
predicted Days spent on Enhanced Regime change scores, F (2, 69) =2.505, p=0.089, 
R2=.068. However ‘Age’ only had an additive effect whereas Affective Lability change scores 
alone provided a statistically significant explanation for the corresponding change in number 
of days spent on enhanced regime, F(1,70)=5.081, p=0.027, R2=.068. This suggests that 
Affective Lability has a mediating effect on the number of days spent on enhanced regime. 
 
 
16. EFFICACY CONCLUSIONS 
This is an open label single arm trial so no conclusions can be drawn on efficacy of the trial 
medication on either the primary or secondary outcomes.  
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The primary outcome was the total number of adjudications reported by prison officers in the 
electronic prison records. The effects were d=0.53 using the per protocol analysis but only 
0.29 using the ITT analysis. Here the confidence that such change are accounted for by the 
study medication is uncertain. Adjudication rates are relatively low and it may be that the 
prison regime is good at responding to adjudications events once they occur. Taking part in 
the clinical trial with weekly visits form research staff may further impact in a beneficial way 
on aggressive or antisocial behaviour. However we did not select on the primary outcome, 
so adjudications rates could have gone up as well as down. Taking into account the small 
effect on the primary outcome for the ITT analysis, and the moderate effect in the pp 
analysis it is clear that no conclusions can be drawn from the analysis here. A larger, 
placebo controlled trial is required to address this question. 
 
With regard secondary behavioural outcomes reported by prison and education staff, the 
same arguments apply as for adjudications. No conclusion can be drawn. Overall these 
findings on behavioural outcomes (aggression, antisocial behaviour and engagement with 
education) indicate the need for a larger definitive trial powered and designed to address 
these questions.    
 
In contrast, the effects on symptoms, particular core ADHD symptoms, but also other 
domains were substantial, being in the range of d = 1.5 to 2.  For example if we consider the 
effect in core ADHD symptoms measured using the investigator rated Conners ADHD rating 
scale. The results of the single arm open label pilot study shows a mean decrease of 25.0 
points with a standard deviation of 9.1. This suggested a standardised effect size of d=2.75. 
It could then reasonably be assumed that at least 20% of this effect might be attributed to 
the effects of MPH since previous meta-analyses show an average effect around d=0.5. On 
this basis, a study of around 200 would be powered to detect a standardised effect size of 
d=0.55 assuming a 25% drop-out rate from treatment and a standard deviation of 9.0. This 
would translate into a treatment4%) difference of 5.0 points.  
 
17. SAFETY DATA 
 
17.1. Minor adverse effects in week 1 and week 8 are listed in Table 5. Following 
initiation of medication there are high levels of headaches (14%), dryness of the mouth 
(21%), thirst (23%), appetite reduction (13%), frequent urination (4%), sleep difficulties 
(19%), mood instability (6%), Irritability (9%), agitation (5%), sadness (2%), heart palpitations 
(1%) and feeling worse when medication wears off (7%). These have greatly reduced by 
week 8, although this could be due to participants experiencing such adverse effects leaving 
the trial.     
 
17.2. Serious adverse events: No serious adverse events were recorded during the trial.  
 
17.3. Adverse event log: This is found in the Appendix 
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N 
events N % N events N %
N 
events N %
Headache 2 111 1.80% 8 93 8.60% 2 69 2.90%
Dryness of the skin 1 111 0.90% 6 93 6.45% 0 69 0.00%
Dryness of the eyes 1 111 0.90% 1 93 1.08% 0 69 0.00%
Dryness of the mouth 22 111 19.82% 21 93 22.58% 11 69 15.94%
Thirst 26 111 23.42% 22 93 23.66% 8 69 11.59%
Sore throat 0 111 0.00% 0 93 0.00% 0 69 0.00%
Dizziness 1 111 0.90% 3 93 3.23% 1 69 1.45%
Nausea 3 111 2.70% 2 93 2.15% 3 69 4.35%
Stomach aches 0 111 0.00% 0 93 0.00% 1 69 1.45%
Vomiting 0 111 0.00% 1 93 1.08% 0 69 0.00%
Sweating 2 111 1.80% 2 93 2.15% 2 69 2.90%
Appetite reduction 14 111 12.61% 18 93 19.35% 6 69 8.70%
Weight loss 0 111 0.00% 2 93 2.15% 0 69 0.00%
Weight gain 1 111 0.90% 0 93 0.00% 0 69 0.00%
Diarrhea 1 111 0.90% 0 93 0.00% 0 69 0.00%
Frequent urination 11 111 9.91% 6 93 6.45% 0 69 0.00%
Tics 1 111 0.90% 1 93 1.08% 0 69 0.00%
Sleep difficulties 21 111 18.92% 10 93 10.75% 6 69 8.70%
Mood instability 6 111 5.41% 5 93 5.38% 1 69 1.45%
Irritability 2 111 1.80% 5 93 5.38% 2 69 2.90%
Agitation/excitability 6 111 5.41% 4 93 4.30% 0 69 0.00%
Sadness 2 111 1.80% 3 93 3.23% 0 69 0.00%
Heart palpitations 1 111 0.90% 2 93 2.15% 0 69 0.00%
Increased blood 
pressure 1 111 0.90% 0 93 0.00% 0 69 0.00%
Sexual dysfunction 0 111 0.00% 1 93 1.08% 0 69 0.00%
Feeling worse or 
different when the 
medication wears off 
(rebound) 9 111 8.11% 3 93 3.23% 2 69 2.90%
Week 1 Week 5 12-week endpoint
Table 6: List of reported adverse events on the Adverse Event Scale recorded at week 1, 8 and 12. 
AE coded as present if scored 3 (often) or 4 (all the time) on the adverse events scale.  
CIAO study report- Clare Evans, Philip Asherson and Susan Young on behalf of the CIAO project group 
28.02.2016 
18 QUALITATIVE DATA 
 
18.1. Feedback from Prison Inspectorate: Important feedback from Her Majesty’s Prison 
Inspectorate group was provided on the impact of the CIAO treatment project at HMP Isis 
following a visit in early 2014. Inspectors acknowledged the work done by the CIAO study:  
 
”All prisoners were offered screening for attention deficit hyperactivity disorder (ADHD) 
through the specialist Concerta (an ADHD treatment) in adult offenders (CIAO) trial…” 
“Some prisoners on the CIAO programme to whom we spoke were experiencing some 
stability of behaviour for the first time in their lives”. “There should be efforts to ensure the 
continued prescribing of medication and ongoing specialist support for prisoners started on 
the Ciao trial following their release.” 
 
18.2. Experiences of participants reaching week 12: Although 72 individuals reached 
week 12, there were still some unexpected barriers along this journey. The strict prison 
regime at times had an impact on compliance but also prisoner experiences of the 
medication. Within a prison setting medication times for administering a controlled drug such 
as Concerta XL are very strict. If an individual did not wake up on time or was not unlocked 
due to bad behaviour they had difficulty accessing their medication. Understanding this issue 
and overcoming it involved a great deal of work with front line prison staff. There was a need 
to explain that while on one level their reluctance to unlock those who were badly behaved 
may prove easier in the short term, in the long run treatment should improve their behaviour. 
We were also able to negotiate with front line nursing staff to allow some level of flexibility in 
terms of medication times, improving compliance and the likelihood of participants 
successfully completing the trial.  
 
Participants reported expected side effects such as, headaches, dry mouth, thirst, appetite 
reduction, sleep difficulties and feeling slightly sick. However, those on trial also described 
“over-thinking” as an unwanted effect. Interestingly when we asked participants about this 
“over-thinking” it became apparent that perhaps in less controlled environments this would 
have been experienced as a positive improvement in focus. Conversely for them, this 
represented something that was extremely unnerving; allowing them to think clearly through 
the potentially distressing realities of the past, present and future. If un-managed some felt 
paranoid and stressed, but once they understood this shift and were able to apply their 
attention in appropriate way, they described the experience as a positive one.  
 
This un-anticipated take on improved focus meant the titration period (first five weeks) when 
participants were seen weekly by the research team became a crucial period. Rapport with 
participants was integral in helping them process and understand this change. Those who 
were able to understand this process and the possibilities of thinking things through were 
generally able to make it through to the full 12 weeks (if there were not too many other side 
effects). Individuals who did not like the experience of thinking through their actions 
(particularly in potentially violent situations), or those who had not fully aligned themselves 
with this change by week 5, were more likely to drop out.   
 
Participants reaching week 12 in general described benefits from the programme. We asked 
all week 12 completers to fill out a brief feedback form on their experience of the research 
project including questions on: how beneficial they found the project on a scale from 0 (not at 
all) to 6 (extremely), how much they trusted the research team between 0 (not all) and 6 
(completely), how they in their own words felt the CIAO programme helped them, and 
between 0-6 how likely they were to seek treatment outside. This data was not collected for 
the purposes of research but provided a useful added insight into how participants found the 
process. All participants rated between points 4-6 on how beneficial they found the project 
and levels of trust in the research team. Around half the participants said they were quite or 
extremely likely to seek treatment outside, but a surprising number stated that they remained 
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undecided. Reasons why individuals remained on the fence about continued treatment in the 
community were unclear but anecdotally at assessment stage, many of them stated they 
previously used cannabis to manage symptoms.  
Below are some of quotes from the comments section of the feedback forms: 
“I am able to concentrate for longer periods” 
“More calmer and relaxed” 
“Calmed me down” 
“They help me a lot and support me in every area I need to be supported” 
“It helped me” 
“It calmed me down and helped me get my job and settle down” 
“It helps me sleep and think before I do things” 
“Calmed me down so I am not running around all the time” 
“It is really good help, I hope other people can get the same from it as what I have” 
“I have benefitted from it because I am much more calm and relaxed now so it has helped 
me a lot” 
“I believe I have benefitted from this project because I am now able to direct my attention 
and focus more sufficiently” 
“Concentration has got better” 
“I’m more organised and more focused on what I’m doing, I am also less angry” 
“I find it easier to concentrate in class” 
“Got calmer” 
“I have been able to control my thoughts” 
“I have benefitted from it because it keeps me more focused than I was before” 
“I think my concentration is better and I’m able to focus a lot more” 
 
We also looked at some case studies of those entered and completed the trial either to 
twelve weeks or through into the treatment as usual after the end of 12 week trial.  
 
(1)  Mr. A came into Isis June 13  
• Was assessed for ADHD at the End of August 2013- positive for Combined 
Inattentive and Hyperactive/Impulsive ADHD 
• Was reviewed by Psychiatrist and started on medication in September 2013 
• Prior to starting, measures were taken not only on core symptoms of ADHD 
but also affective lability (mood swings), Violence- acceptance of and 
machismo and incidents. 
At baseline Mr A: 
• reported extreme issues with mood instability,  
• Symptomatic in terms of Inattention and Hyperactivity/Impulsivity 
• medium scores of machismo (25) and acceptance of violence (13) 
• In the 3 months prior he had had 1 fight and another adjudication, as well as 
3 Negative IEPS  
By week 12 
• Symptoms of Hyperactivity and Inattention have now significantly reduced 
• At 12 weeks he now reports minimal mood instability, managing his mood 
(despite being given bad news) 
• His machismo scores have reduced to a minimum (3) Acceptance of 
violence (9) 
• He now has got and maintained a job as a cleaner 
• Has had no adjudications 
• Has had 2 negative IEPs but also 2 positive IEPs 
• Has now been made a Violence Reduction Rep 
 
(2) Mr. F came into Isis June 13  
• Was assessed for ADHD mid July 2013- positive for Combined Inattentive 
and Hyperactive/Impulsive ADHD (had and was diagnosed as a child) 
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• Was reviewed by Psychiatrist and started on medication in August 2013 
At baseline Mr F: 
• reported minimal mood instability,  
• A number of Inattentive and Hyperactive/Impulsive ADHD symptoms 
• Medium/high scores of machismo (34) and medium scores on acceptance 
of violence (14) 
• In the 3 months prior he had been restrained, had an adjudication, had 
been on basic for 20 days of the previous 12 weeks 
• He had two negative IEPs and little engagement in education 
Mr F was on trial for 36 weeks 
• Symptoms of Hyperactivity and Inattention have now significantly reduced 
• At 24 weeks he now reports no mood instability 
• His machismo scores have reduced to a minimum (7)  
• He now has got and maintained a job as a cleaner 
• Has had no adjudications 
• No days on basic 
• Has had No negative IEPs 
• 1 positive IEP 
 
(3) Mr. J came into Isis in April 2013 
• Was assessed for ADHD in May 2013- positive for Combined Inattentive 
and Hyperactive/Impulsive ADHD  
• Was reviewed by Psychiatrist and started on medication in June 2013 and 
has been doing well on medication ever since 
       At baseline Mr J: 
• reported high levels of mood instability,  
• A number of Inattentive and Hyperactive/Impulsive symptoms 
• Low to medium scores of machismo (14) and medium scores on 
acceptance of violence (11) 
• 1 negative entry for disobeying orders 
Mr J was on trial for the full 36 weeks 
• At 36 weeks he now reports very minimal mood instability 
• No ADHD symptoms 
• His machismo scores have reduced to a minimum (5)  
• He now has had and maintained a job in the kitchens, trained as a listener 
and also got a wing orderly job and maintained a job as a cleaner 
• Has had no adjudications 
• No days on basic 
• Has achieved and maintained his enhanced status 
• Has had No negative IEPs in the last three months and has had 1 
positive IEP 
 
(4) Mr. D came into Isis in August 2013 
• Was assessed for ADHD in September 2013- positive for Combined 
Inattentive and Hyperactive/Impulsive ADHD  
• Was reviewed by Psychiatrist and started on medication at the end of 
October 2013 and has been doing well on medication ever since 
 At baseline Mr D: 
• reported high levels of mood instability,  
• A number of Inattentive and Hyperactive/Impulsive symptoms 
• Medium to high levels of Machismo (35) and medium scores on 
acceptance of violence (12) 
 
(5) Mr D has was on trial for just over 36 weeks 
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• At 12 weeks (the most recent measures taken) he now reports minimal mood 
instability 
• Managed and minimal ADHD symptoms 
• His machismo scores have reduced significantly (10)  
• He now has had and maintained a job in the staff kitchens, is planning for 
meaningful activity on release in training and work. He wants to continue 
treatment on the outside. 
• Has had no adjudications 
• No days on basic 
• Has achieved and maintained his enhanced and has been placed on D 
SPUR 
• Has had 1 negative IEP in the last three months but also 2 positive IEPs 
 
 
18. DISCUSSION 
We set out to investigate the prevalence of ADHD in a young adult inner London prison and 
to investigate whether treatment of the disorder with Concerta XL reduced adjudications and 
increased educational attendance (supporting the rehabilitation agenda at HMP Isis). The 
study was set up as an open label clinical trial designed as a pilot of the process of 
diagnosing and treating prisoners with ADHD and estimating effect sizes for a future 
randomised placebo controlled trial. The study medication was oros-methylphenidate 
(Concerta XL) one of the drug treatments recommended as first line for ADHD by NICE 
guidelines.  
 
We found an estimated 19% of prisoners met ADHD diagnostic criteria. This is a gross over 
representation compared with 2 to 4% in general adult populations but falls slightly short of 
previous studies that suggest rates of around 26% in convicted young offenders. The 
population sample was more ethnically diverse than previous studies and the age group (18-
30 years) fits neither the young offender nor adult offender category completely. The rates 
indicate diagnostic levels above that of the general population, indicating a specific 
relationship between ADHD and offender populations. 
 
In this study the treatment of ADHD with long acting methylphenidate (Concerta XL) was 
shown not only to reduce core symptoms of ADHD and emotional dysregulation but also 
total sums of all adjudications, number of disobeyed orders, as well as increasing the 
number of positive incident earned privileges awarded. Contrary to previous findings, total 
sums of physical aggression, negative incident earned privileges and reports from officers of 
participant’s levels of modified overt aggression, did not significantly change with treatment. 
During the 12 week treatment period percentage of attended activities significantly 
increased. Overall, these findings suggest that the treatment of ADHD with oros-
methylphenidate may have a positive impact on rehabilitation agendas within prisons.  
 
Effects were very large for clinical symptoms of ADHD and emotional dysregulation, as well 
as the machismo scale of the Maudsley violence questionnaire. We were able to use these 
data to support a large scale randomised controlled trial. on the basis that the results 
reported here show a decrease of 25.0 points on the CAARS ADHD symptoms scale with a 
standard deviation of 9.1. This suggested a standardised effect size of d=2.75. It could 
reasonably be assumed that 20% of this effect might be attributed to the effects of MPH. On 
this basis we estimated that a sample size of 200 in a randomised placebo controlled trial 
(with 25% drop out rate) would be powered to detect a standardised effect size of d=0.55. 
Assuming a standard deviation of 9.1, this would translate into a treatment difference of 5.0 
points. This effect size is consistent with the results of a recent meta-regression analysis of 
the effects of methylphenidate in ADHD, which estimates the effect of treatment to be 
d=0.49 (95% CI 0.08, 0.64).  
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The correlation and regression models suggest a link between the emotional dysregulation 
of those with ADHD, a reduction in adjudications as a whole and an increase in days 
awarded on enhanced regimes.  
 
The study is limited by its small sample size and high drop-out rate. The sample may be 
biased as potentially those in most need of treatment were either unable to take part or did 
not complete as they were not able to deal with the shift in behaviour caused by medication. 
These influences might have resulted in a sample that was underpowered to detect all the 
areas of adjudication data anticipated. When collecting adjudication information in the future, 
appropriateness of research assessment tools such as the Modified Overt Aggression Scale 
may also have to be considered. Having the same prison officer complete this tool at all-time 
points proved extremely difficult and staff (due to busy schedules) often rushed its 
completion or commented that the examples were not particularly relevant to the 
environment.  
The large effect sizes on symptom measures suggest a much higher impact of treatment 
than previous research into methylphenidate has indicated. This may be due to the large 
amount of psychosocial support that was required in this Open label feasibility trial to help 
participants deal with behavioural and thought process shifts from taking medication. It might 
also be accounted for by the severity of ADHD in this young adult prisoner sample. On the 
other hand, effects on adjudications (the primary outcome) and other prison behavioural 
measures were small to moderate and might not be clinically significant in a future placebo 
controlled trial. For example there may be non-specific effects of being treated in the trial, ‘or 
the prison response to ‘bad’ behaviour, may both bring about improvements not due to 
medication. A definitive study will need to include a placebo control group to establish true 
effect sizes.  
 
The outcome of this pilot trial has ultimately been a success because it laid the foundation 
for funding from the National Institute of Health Research for a larger randomised clinical trial 
of 200 prisoners with ADHD. The full application and protocol approved by NIHR is 
appended to this report.  
 
Previous community studies demonstrate the efficacy of MPH and the study drug, OROS-
MPH, in children, adolescents and adults with ADHD 11. However there is still no definitive 
trial data for the treatment of ADHD in young offenders presenting with a more complex mix 
of psychosocial, mental health and behavioural problems. To date there has been only one 
randomised controlled trial of MPH in a forensic population, consisting of a sample of 30 
Swedish prisoners with ADHD which showed a large effect (Cohen’s d=2.1)13,14. While this 
study supported the treatment of ADHD in offenders it cannot be considered definitive for the 
treatment of young offenders because of the small sample size, older age group and 
selection of severe ADHD cases with long term sentences treated in a special prison unit in 
Sweden. The current study now provides additional support by showing a large effect 
(d=2.75) on ADHD symptoms, although somewhat smaller on the primary outcome of total 
adjudications. However these findings are sufficient to suggest that clinically significant 
effects will be observed in a randomised placebo controlled trial.   
 
The benefits of treatment are expected to extend to a range of secondary outcomes beyond 
the core symptoms of ADHD and their associated impairments. An epidemiological study 
indicated the potential benefits of treating ADHD among offenders. This large survey of 
25,656 Swedish patients with ADHD found a 6-fold higher rate of criminal convictions in 
ADHD patients compared to controls and a 32% reduction during periods of drug treatment 
for ADHD with either MPH or atomoxetine; but not when antidepressants were prescribed, 
suggesting the specificity of these findings to the treatment of ADHD 15. In our own 
prevalence study of ADHD in prison we found a 6-fold increase in critical incidents among 
prison inmates even after controlling for antisocial personality disorder 6. Other studies have 
also reported significant effects of MPH on emotional dysregulation in adolescents and 
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adults with ADHD, including problems with temper control, mood lability and emotional over-
reactivity 9. Hence, treatment of offenders with ADHD might lead to significant reductions in 
emotional dysregulation and potentially aggressive or violent behaviour. The symptoms of 
ADHD are also known to interfere with education and employment due a combination of 
restlessness, reduced attention span, forgetfulness  and problems with planning and 
organisation10,11. Treatment might therefore lead to greater positive engagement with 
educational and rehabilitation programs within prison. In the current study we also found 
significant effects on all the secondary outcomes proposed for this study including measures 
of emotional dysregulation, critical incidents and engagement with the education and 
rehabilitation program.  
 
20. Compliance and adherence to the protocol 
Adherence to medication: We found that adherence was a challenge for around 20% of 
participants. Some offenders may not have felt motivated to continue to follow the study 
protocol if they experienced adverse effects or did not feel they were improving. They also 
took medication intermittently because of the strict prison regime that allows for only a short 
time-window for leaving their cells to obtain medication from the medicine hatch on the 
prison wings. However, most of these cases were able to continue in the trial to provide 
follow-up data, hence not contributing to missing data. 
20.1. Missing data: Loss to follow-up usually resulted from unexpected transfers out of the 
prison, plus a few cases that had problems with adherence to the protocol. We outline below 
some of the findings and lessons from this pilot study:    
 
20.2. Maximizing adherence to medication and minimizing loss to follow-up: In this 
pilot study we accrued considerable experience in managing the expectation of offenders 
and providing the support needed to help participants adhere to the protocol. The following 
steps are recommended to minimise loss to follow-up and adherence to future trial protocols 
in this population:  
(1) In the pilot study 12% left the prison unexpectedly. Missing data was loss at random 
because transfers out of the prison (to other prisons or the community) were unrelated 
to recent behaviour that might be influenced by the trial protocol, such as further 
pending court cases; and we did not obtain follow-up data following transfers. In future 
studies we will limit this source of missing data by retaining participants who leave the 
prison in the study, whenever possible.  
(2)  In the pilot, minor adverse effects (13%) were the most common reason for non-
adherence to medication. This was linked to the observation that this population may be 
more sensitive to minor adverse effects, particularly changes in appetite, than 
community samples; perhaps reflecting the importance of meal times to prisoners. To 
maximise adherence to the protocol and minimise this as a potential source of missing 
data, future studies should take care to identify the early signs of minor adverse effects 
such as appetite loss and adjust the medication dose accordingly.    
(3)  Seven percent of the pilot sample did not wish to take medication in the mornings 
(08:00), which was the initial protocol followed in the pilot study. We then adjusted the 
protocol to allow for 12:00 medication for those that got up later in the day, worked 
mainly in the afternoons or had a strong preference for a 12:00 dosing, which resolved 
the problem. This flexibility in dosing time more accurately reflects dosing decisions in 
the community and provided a better match to patient’s daily routines.    
(4)  During the pilot study, prison staff did not always let patients out of their cells to receive 
medication or remind participants to get up on time. To resolve this problem we initiated 
the use of research staff to assist in the delivery of medication by checking that 
prisoners were always out of their cells on time to receive trial medication.    
(5)  In the pilot study, treatment was disrupted for the Ramadan festival for several 
participants. Future studies need to take care to check that participants are not started 
on trial medication where religious holidays might interfere with adherence to the trial 
protocol.  
CIAO study report- Clare Evans, Philip Asherson and Susan Young on behalf of the CIAO project group 
28.02.2016 
(6) In the pilot study, daily adherence to the trial medication reduced when participants were 
not reviewed weekly. One of the findings in the pilot study was the importance that 
prisoners gave to the weekly follow-up meetings when they are able to discuss their 
ADHD and response to the treatment process, in addition to completing study 
assessments. Future studies should plan for weekly review meetings with offenders 
throughout the 8-week trial.  
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Participant Information Sheet 
The CIAO Project 
 
Project Title: A Pilot Study of Concerta XL in Adult Offenders with ADHD 
 
You are invited to take part in a research study. If you agree to take part there are three stages. First, a 
screener will be used to indicate possible ADHD; and from which we would like to use your anonymised 
data.  
Before you decide whether you want to take part, it is important to understand why the research is 
being done and what it will involve. Please take time to read this information about the study and 
discuss it with others if you wish. Ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether you wish to take part in the study.  Taking part in this study is 
your choice - it will not affect your prison sentence or health care if you decide you do not wish to take 
part in the study. Thank you for reading this. 
 
What is the purpose of the study? 
You are invited to take part in a research study looking at the rate of Attention Deficit Hyperactivity 
Disorder (more often known as ADHD) in prison. It is thought that many people in prison may have 
ADHD that has not been recognised or treated. However this has not been studied in Belmarsh 
HMPYOI Isis and there is limited information from other prisons.   
 
Where we find that someone has ADHD we will offer them treatment. The treatment can be given either 
by taking part in a clinical trial of medication for ADHD, or alternatively by the prison healthcare team.    
 
What is ADHD? 
ADHD is a problem that usually starts in early childhood and causes problems with concentration and 
being too active or impulsive in everyday situations. ADHD affects about 1 in 50 adults in England and 
is thought to affect more people in prisons.  
 
The problems with concentration can make it difficult for people with ADHD to complete everyday tasks. 
People with ADHD often feel irritable, frustrated, aggressive or angry, as well as having problems with 
their concentration, being forgetful or losing things and finding it difficult to plan and organise their day. 
In prison people with ADHD may find it difficult to manage work activities, get bored and frustrated very 
quickly or have times when they can’t control their anger.      
 
Social Genetic and Developmental Psychiatry Research 
Centre & Division of Psychological Medicine, Section of 
Brain Maturation, Institute of Psychiatry, King’s College 
London 
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Why have I been chosen? 
You have been invited to take in this study because you are inmate at HMP/YOI Isis and we are aiming 
to screen the entire prison.  This information will enable us to estimate possible rates of ADHD within 
this prison.  
 
Do I have to take part? 
No, it is up to you to decide whether to take part.  
 
If you do decide to take part, we will give you this information sheet and ask you to sign a form agreeing 
to take part in the study. You will still be free to leave the study at any time without giving a reason, if 
you wish.  
 
Taking part in this study or not will have no effect on your care in the prison or the length of your prison 
sentence.   
 
What will I be asked to do if I take part? 
If you decide to take part, we will ask you to sign a consent form. We will complete a quick five minute 
screener with you.  
 
What are the possible benefits of taking part? 
You do not have to take part in this research to complete the screener for ADHD. However we hope 
that you will take part in the study, as this will enable us to find out more about ADHD in prison so what 
we can better help people with ADHD in the future.  
 
If we find you screen positive for ADHD, we may with invite you for a full assessment and may be able 
to offer you treatment if a diagnosis is confirmed. We will invite those that have ADHD to receive 
treatment as part of a clinical trial, or alternatively as part of the usual treatments provided by the prison 
healthcare team.   
 
What are the possible disadvantages and risks of taking part? 
We are asking you to give us your time to review this information sheet. You may also feel that you do 
not want to complete an ADHD screener. The screener for ADHD involves answering questions about 
problems related to ADHD and some people might find this difficult to cope with or distressing to 
discuss.     
 
Confidentiality  
If you agree to take part in this project, the research team will look at your medical and prison records. 
This is because we wish to find out more about the way ADHD affects people in prison and the way 
they manage in education and work. 
 
Other authorised people may need to look at your medical and prison records to check that the study is 
being carried out correctly.  
 
All personal information about you will be strictly confidential and will be stored in a secure place. This 
means that outside of the immediate healthcare team involved in this research, no one will be able to 
match your personal information (your name and prison number for example) with the information that 
we gather for the research. After we have completed the study any personal information we hold will be 
destroyed.  
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Your personal details will only be used to contact you about the study. Your personal details will not be 
linked to your clinical or prison records in our research records.  The clinical data and prison records 
that we use for research will be identified using a study ID code and not your name or prison number.  
We will be able to link your personal details to the study ID code - however this is kept separately to 
any information from the study or your health care or prison records.  
 
What will happen to the results of the research study? 
The research will be analysed by the ADHD research group at King’s College London, led by Professor 
Philip Asherson. He is one of the leading experts on ADHD and will work with the prison healthcare 
team for the duration of the project. The results of the study will be published in scientific journals. All 
personal information will remain strictly confidential so you will not be recognised in any of the research 
reports.   
 
Research data in a form that cannot be traced back to you as an individual may be shared with other 
scientists or research groups where this helps us to understand the findings of the study; and may also 
be used in combination with data from other studies. We will be able to send you a report of the study 
findings after the research has been completed if you are interested and give us permission to keep 
your contact details for this reason.  
 
Who is organising the research? 
This research is organised by the Institute of Psychiatry, King’s College London and South London and 
Maudsley NHS Foundation Trust.  
 
Who is funding the research? 
The research is funded by an NIHR programme grant, Janssen-Cilag who is providing the medication, 
the South London Maudsley NHS Trust, and research funds held by Professor Declan Murphy. The 
study is being undertaken by Professor Asherson and his team at the Institute of Psychiatry, King’s 
College London in collaboration with Professor Declan Murphy.  
.  
Who has reviewed the study? 
The study has been subject to peer review by expert referees at the Institute of Psychiatry. Ethical 
approval has been granted by the NRES Committee London – South East. 
What do I do now? 
We will discuss the project with you to make sure you understand the aims of the project and what is 
involved. If you wish to take part we will ask you to sign a consent form that is attached with this 
information sheet. We hope that you will be able to take part in this important project. 
  
Contact for further information:  
If you have any questions about the CIAO Project please feel free to contact the research coordinator, 
Clare Evans (email: clare.2.evans@kcl.ac.uk; tel: 020 7848 5362; by post: SGDP Centre, P080, 
Institute of Psychiatry, De Crespigny Park, London SE5 8AF). 
 
If you have any further queries and would like to seek independent advice on whether to take part in 
this study, please contact the SLaM Patient Liaison Service (tel: 0800 7312864; email: 
pals@slam.nhs.org.uk). 
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Consent to participate in the CIAO Project 
 
Project Title: A Pilot Study of Concerta XL in Adult Offenders with ADHD 
 
Participant ID: ____________ 
 Please initial box 
 
1. I confirm that I have read and understand the information sheet dated 4th 
of June 2013, version 1.4, for the above study and have had the 
opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. 
 
3. I understand that sections of my medical notes may be updated to include 
the results of this Attention Deficit Hyperactivity Disorder (ADHD) 
screener. To enable monitoring of the conduct of the study, I give 
permission for regulatory authorities or individuals from the South London 
and Maudsley NHS Foundation Trust to access my clinical and research 
records. 
 
4. I agree to take part in the above study. 
 
5.  I agree that my anonymised research data from this study will be stored 
securely and may be shared with other scientists or research groups 
where this helps us to understand the findings of the study. The 
data may also be used in combination with data from other similar 
studies. In the event of publication, I understand that due care will be 
taken to preserve the confidentiality of my information 
 
 
________________________ ____________________    ____________________ 
Name of Participant Date Signature 
 
 
_________________________ ____________________    ____________________ 
Name of Person taking consent Date Signature 
(If different from Researcher) 
 
I have explained the study to the participant and have answered their questions honestly and fully. 
 
 
 
 
Social Genetic and Developmental Psychiatry 
Research Centre & Division of Psychological 
Medicine, Section of Brain Maturation, 
Institute of Psychiatry, King’s College London 
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_________________________ _____________________
 ____________________ 
Researcher Date Signature 
 
 
 
                 
 
 
 
 
 
Participant Information Sheet 
The CIAO Project 
 
Project Title: A Pilot Study of Concerta XL in Adult Offenders with ADHD 
 
You are invited to take part in a research study. If you agree to take part there are two stages. First, a 
diagnostic assessment or test that will be used to confirm the diagnosis of ADHD; and from which we 
would like to use your data. Following this, if the diagnosis of ADHD is confirmed there is a second part 
– a treatment stage – where you will be given the medication Concerta XL. Not everyone who has the 
diagnostic test will be suitable for this second part that involves drug treatment. This information sheet 
is about the first stage of the study. 
 
Before you decide whether you want to take part, it is important to understand why the research is 
being done and what it will involve. Please take time to read this information about the study and 
discuss it with others if you wish. Ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether you wish to take part in the study.  Taking part in this study is 
your choice - it will not affect your prison sentence or health care if you decide you do not wish to take 
part in the study. Thank you for reading this. 
 
What is the purpose of the study? 
You are invited to take part in a research study looking at the rate of Attention Deficit Hyperactivity 
Disorder (more often known as ADHD) in prison. It is thought that many people in prison may have 
ADHD that has not been recognised or treated. However this has not been studied in Belmarsh 
HMPYOI Isis and there is limited information from other prisons.   
 
Where we find that someone has ADHD we will offer them treatment. The treatment can be given either 
by taking part in a clinical trial of medication for ADHD, or alternatively by the prison healthcare team.    
 
What is ADHD? 
ADHD is a problem that usually starts in early childhood and causes problems with concentration and 
being too active or impulsive in everyday situations. ADHD affects about 1 in 50 adults in England and 
is thought to affect more people in prisons.  
 
The problems with concentration can make it difficult for people with ADHD to complete everyday tasks. 
People with ADHD often feel irritable, frustrated, aggressive or angry, as well as having problems with 
their concentration, being forgetful or losing things and finding it difficult to plan and organise their day. 
Social Genetic and Developmental Psychiatry Research 
Centre & Division of Psychological Medicine, Section of 
Brain Maturation, Institute of Psychiatry, King’s College 
London 
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In prison people with ADHD may find it difficult to manage work activities, get bored and frustrated very 
quickly or have times when they can’t control their anger.      
 
Why have I been chosen? 
You have been invited to take in this study because you completed an assessment with the prison 
healthcare team that indicate that you might have ADHD. In order to find out whether you have ADHD 
we would like to complete a clinical assessment by asking you detailed questions about problems 
related to ADHD.  This information will enable us to estimate the rates of ADHD within this prison and to 
find out more about the way that ADHD can affect people in prison.   
 
We would also like your permission to link the data on ADHD to your prison and healthcare records. 
This will enable us to find out more about the problems that people with ADHD have in prisons. We will 
look at whether ADHD or other health problems affect your behaviour within the prison and your ability 
to take part in educational and other activities.  
 
Do I have to take part? 
No, it is up to you to decide whether to take part.  
 
If you do decide to take part, we will give you this information sheet and ask you to sign a form agreeing 
to take part in the study. You will still be free to leave the study at any time without giving a reason, if 
you wish.  
 
Taking part in this study or not will have no effect on your care in the prison or the length of your prison 
sentence.   
 
What will I be asked to do if I take part? 
If you decide to take part, we will ask you to sign a consent form. We will complete a diagnostic 
assessment for ADHD which usually takes around 1 hour, but can take longer. We will also ask you for 
permission to use information from your health care and prison records for this research.   
 
What are the possible benefits of taking part? 
You do not have to take part in this research to complete an assessment for ADHD. However we hope 
that you will take part in the study, by giving permission for us to your medical and prison records for 
this research. This will enable us to find out more about ADHD in prison so what we can better help 
people with ADHD in the future.  
 
If we find that you have ADHD, we may be able to offer you treatment. We will invite those that have 
ADHD to receive treatment as part of a clinical trial, or alternatively as part of the usual treatments 
provided by the prison healthcare team.   
 
What are the possible disadvantages and risks of taking part? 
We are asking you to give us your time to review this information sheet. You may also feel that you do 
not want to complete an assessment for ADHD. The assessment for ADHD involves answering 
questions about your problems related to ADHD and some people might find this difficult to cope with or 
distressing to discuss.     
 
Confidentiality  
If you agree to take part in this project, the research team will look at your medical and prison records. 
This is because we wish to find out more about the way ADHD affects people in prison and the way 
they manage in education and work. 
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Other authorised people may need to look at your medical and prison records to check that the study is 
being carried out correctly.  
 
All personal information about you will be strictly confidential and will be stored in a secure place. This 
means that outside of the immediate healthcare team involved in this research, no one will be able to 
match your personal information (your name and prison number for example) with the information that 
we gather for the research. After we have completed the study any personal information we hold will be 
destroyed.  
 
Your personal details will only be used to contact you about the study. Your personal details will not be 
linked to your clinical or prison records in our research records.  The clinical data and prison records 
that we use for research will be identified using a study ID code and not your name or prison number.  
We will be able to link your personal details to the study ID code - however this is kept separately to 
any information from the study or your health care or prison records.  
 
What will happen to the results of the research study? 
The research will be analysed by the ADHD research group at King’s College London, led by Professor 
Philip Asherson. He is one of the leading experts on ADHD and will work with the prison healthcare 
team for the duration of the project. The results of the study will be published in scientific journals. All 
personal information will remain strictly confidential so you will not be recognised in any of the research 
reports.   
 
Research data in a form that cannot be traced back to you as an individual may be shared with other 
scientists or research groups where this helps us to understand the findings of the study; and may also 
be used in combination with data from other studies. We will be able to send you a report of the study 
findings after the research has been completed if you are interested and give us permission to keep 
your contact details for this reason.  
 
Who is organising the research? 
This research is organised by the Institute of Psychiatry, King’s College London and South London and 
Maudsley NHS Foundation Trust.  
 
Who is funding the research? 
The research is funded by an NIHR programme grant, Janssen-Cilag who is providing the medication, 
the South London Maudsley NHS Trust, and research funds held by Professor Declan Murphy. The 
study is being undertaken by Professor Asherson and his team at the Institute of Psychiatry, King’s 
College London in collaboration with Professor Declan Murphy.  
.  
Who has reviewed the study? 
The study has been subject to peer review by expert referees at the Institute of Psychiatry. Ethical 
approval has been granted by the NRES Committee London – South East. 
What do I do now? 
We will discuss the project with you to make sure you understand the aims of the project and what is 
involved. If you wish to take part we will ask you to sign a consent form that is attached with this 
information sheet. We hope that you will be able to take part in this important project. 
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Contact for further information:  
If you have any questions about the CIAO Project please feel free to contact the 
research coordinator, Clare Evans (email: clare.2.evans@kcl.ac.uk; tel: 020 7848 
5362; by post: SGDP Centre, P080, Institute of Psychiatry, De Crespigny Park, 
London SE5 8AF). 
 
If you have any further queries and would like to seek independent advice on whether to take part in 
this study, please contact the SLaM Patient Liaison Service (tel: 0800 7312864; email: 
pals@slam.nhs.org.uk). 
 
 
 
           
 
 
 
Consent to participate in the CIAO Project 
 
Project Title: A Pilot Study of Concerta XL in Adult Offenders with ADHD 
 
 
Participant ID: ____________ 
 Please initial box 
 
6. I confirm that I have read and understand the information sheet dated 4th 
of June 2013, version 2.5, for the above study and have had the 
opportunity to ask questions. 
 
7. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. 
 
8. I understand that sections of my medical notes may be looked at to check 
the inclusion and exclusion criteria for the study. I give permission for 
Professor Asherson and his research team to have access to my medical 
and prison records. To enable monitoring of the conduct of the study, I 
give permission for regulatory authorities or individuals from the South 
London and Maudsley NHS Foundation Trust to access my clinical and 
research records. 
 
9. I agree to take part in the above study. 
 
10.  I agree that my anonymised research data from this study will be stored 
securely and may be shared with other scientists or research groups 
where this helps us to understand the findings of the study. The 
data may also be used in combination with data from other similar 
studies. In the event of publication, I understand that due care will be 
taken to preserve the confidentiality of my information 
 
________________________ ____________________    ____________________ 
Name of Participant Date Signature 
 
 
 
 
 
 
Social Genetic and Developmental Psychiatry 
Research Centre & Division of Psychological 
Medicine, Section of Brain Maturation, 
Institute of Psychiatry, King’s College London 
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_________________________ ____________________   
 ____________________ 
Name of Person taking consent Date
 Signature 
(If different from Researcher) 
 
 
I have explained the study to the participant and have answered their questions honestly and fully. 
 
 
_________________________ _____________________ ____________________ 
Researcher Date Signature 
 
 
 
 
 
 
 
Participant Information Sheet 
The CIAO Project 
 
Project Title: A Pilot Study of Concerta XL in Adult Offenders with ADHD 
 
You are invited to take part in a research study. Before you decide whether you want to take part, it is 
important to understand why the research is being done and what it will involve. Please take time to 
read this information about the study and discuss it with others if you wish. Ask us if there is anything 
that is not clear or if you would like more information. Take time to decide whether you wish to take part 
in the study.  Taking part in this study is your choice - it will not affect your prison sentence or health 
care if you decide you do not wish to take part in the study. Thank you for reading this. 
 
What is the study about?  
You are invited to take part in a study to find out about the effects of a drug treatment for a common 
disorder seen in young adults, called Attention Deficit Hyperactivity Disorder – more often known as 
ADHD.  
 
ADHD is a common condition that effects concentration, being too fidgety or restless, and having 
problems controlling reactions to different people or situations – for example being too angry, talking 
too much, interrupting people all the time, or feeling irritable when having to wait in queues. People with 
ADHD are often disorganised in the way they go about things and find it difficult to start or complete 
tasks, complete paper forms, manage their money and focus on jobs or education activities.    
 
We already know that certain medical drugs can help to reduce these problems in people with ADHD. 
However few people with ADHD in prisons are offered treatment. We therefore want to find out whether 
medical treatment for ADHD can help people with ADHD – by reducing the symptoms and problems 
related to ADHD.    
 
In this study we want to find out more about the effects of treatment for ADHD using a medication that 
is often used to treat children and adults. If the medication is helpful we will provide support so that 
treatment can be continued after you leave the prison.    
 
Social Genetic and Developmental Psychiatry Research 
Centre & Division of Psychological Medicine, Section of 
Brain Maturation, Institute of Psychiatry, King’s College 
London  
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What is ADHD? 
ADHD is a problem that usually starts in early childhood and causes problems with concentration and 
being too active or impulsive in everyday situations. ADHD affects about 1 in 50 adults in England and 
is thought to affect more people in prisons.  
 
The problems with concentration can make it difficult for people with ADHD to complete everyday tasks. 
People with ADHD often feel irritable, frustrated, aggressive or angry, as well as having problems with 
their concentration, being forgetful or losing things and finding it difficult to plan and organise their day. 
In prison people with ADHD may find it difficult to manage work activities, get bored and frustrated very 
quickly or have times when they can’t control their anger.      
 
The usual treatment for ADHD is a drug called methylphenidate, or MPH for short. Most people have 
heard of Ritalin that is sometimes given to children with ADHD – Ritalin is in fact the same as MPH, but 
there are several other drugs also made of MPH, including one called Concerta XL. We will use 
Concerta XL in this study.       
 
Drugs like Ritalin and Concerta XL reduce the problems related to ADHD. Some of the benefits include:  
 Improved concentration  
 Improved ability to focus on tasks and not get distracted  
 Having a less busy and more focused mind  
 Feeling less restless and fidgety 
 Being more patient when waiting 
 Being less irritable or angryFinding it easier to work with other people and engage in work 
activities 
 Feeling more calm and better able to control emotions such as feeling too irritable or angry or 
having mood swings    
 
Why have I been invited to take part in this study? 
We are inviting you to take part in this study because your assessment by the prison healthcare service 
found that you have ADHD. We are inviting all people who have ADHD and who might benefit from 
treatment to take part in this study.   
 
Do I have to take part? 
No, it is up to you to decide whether to take part.  
 
If you do decide to take part, we will give you this information sheet and ask you to sign a form agreeing 
to take part in the study. You will still be free to leave the study at any time without giving a reason, if 
you wish.  
 
Taking part in this study or not will have no effect on your care in the prison or the length of your prison 
sentence.    
 
What will happen to me if I take part? 
If you take part in this study you will be given Concerta XL to be taken each day for a period of 3 
months initially. This can then be extended for another 6 months if you wish. 
 
Concerta XL is a drug that is recommended for the treatment of ADHD in England. If you take part in 
the study and start Concerta XL, we will follow you up for 3 months to see whether the medication helps 
you.  After that we will ask you if you are willing to remain in the study for another 6 months.   
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During the study you will be given Concerta XL each morning. The effects of the drug last around 10 
hours and then wear off.  The most common effect is for people to find they can concentrate better and 
feel calmer with a more stable mood. We will closely watch the effects that Concerta XL has on you 
with weekly medical assessments for the first 4 weeks of the study.  We will check to see if there are 
side effects that you do not like or might be dangerous to your health. We will check your pulse and 
blood pressure during these assessments and ask you about problems related to ADHD.   
 
During the first 4 weeks we will slowly increase the dose of medication to find that dose that is best for 
you. After the first 4 weeks the dose will then remain the same.  
 
The main part of the study last for 3 months. After that time you will be asked whether you wish to 
continue in the study for a further 6 months.  Once you decide to leave the study or at the end of the 9 
months, you will be seen by a medical doctor to determine if you have benefited from taking the 
medication. Should you and the doctor wish to continue the medication, this can then be continued. We 
will also help you to obtain your medication once you leave the prison.  
 
What will I be asked to do if I take part in the study? 
We will ask you to take Concerta XL each morning for a period of 12 weeks or more. You will be able to 
continue with any other medications you already take. We will check to make sure any other drugs do 
not interact with Concerta XL in a bad way.  
 
We will be asking you questions about your ADHD and will also ask you to complete some forms about 
how you are feeling and managing in the prison (we can help you with this). This will be done at the 
following times:   
 before starting the medication 
 once a week for the first five weeks of the study  
 after 8 weeks and 12 weeks of the study    
 
At weeks 0, 5, 8 and 12, there will be an optional computer task that will look at how fidgety you are and 
how well you can concentrate. You do not have to complete the computer task to be in the study but it 
will help us to understand how the medication is working.  
 
If you decide to continue the medication and remain in the study after 12 weeks, we will repeat the 
questions and computer task after another 3 months and 6 months.   
 
How much time will this take? 
There is a lot to do if you take part in this study.  We will see you at least eight times in the first part of 
the study, which lasts for 3 months.  Please remember this when you decide if you want to take part.  
 
Before you start the treatment for ADHD we will meet you and ask you questions about your ADHD and 
also ask to complete several forms about yourself (which we can help you with). We will also take your 
pulse and blood pressure and ask you if you want to complete the computer task. This will take about 2 
hours.  
 
We will again ask you some of the same questions and ask you to do the computer task after 3 months, 
so we can see how the medication may have helped you. If you decide to remain in the study we will do 
this again after another 3 months and 6 months.  
 
Once the treatment is started, at the beginning of the study, we will see you each week for about 30 
minutes, to ask you questions about the effects of the medication and whether there are side effects.  
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We will also take your pulse and blood pressure. We will do this once a week for 5 weeks. During this 
time we will slowly increase the dose of the medication as long as there are no side effects. You will be 
able to discuss this with one of the doctors in the mental health team.   
 
The study will take up to 9 hours of your time over a 9-month period if you stay in the study to the end.  
 
What are the possible benefits of taking part? 
Concerta XL is one of the most widely used drug treatments for ADHD in England. Concerta XL is not 
licensed for use in adults who were not treated for ADHD as children. However drug treatment with 
Concerta XL is recommended for use in England by the National Institute for Clinical Excellence 
(NICE). This means that doctors have been told that this drug can be used to treat adults with ADHD, 
even though this is outside of its licensed use.   
    
In people with ADHD, the usual effect after taking the medication is to feel calmer and in more control 
of your emotions; to have better concentration and find it easier to focus your thoughts on what you are 
doing; and to feel less fidgety and restless. Some people find it easier to get off to sleep.   
 
By taking part in this study you will find out whether Concerta XL can help you with the problems 
related to ADHD. It will also help us to find out whether this drug can help other people with ADHD who 
are in prison.  We hope that the treatment will help you feel less stressed and better able to manage 
your life.   
 
If you find the treatment helpful, we will make arrangements for continuation after the study has ended 
and when you leave the prison. 
 
What are the possible disadvantages and risks of taking part? 
Like all drug treatments, Concerta XL can cause side effects.  
 
Many of the common side effects stop after 1 or 2 weeks, however some may continue. You may also 
have side effects that stop you using Concerta XL because they are not nice to experience or have a 
bad effect on your health. In some rare cases more severe side effects can occur that would lead us to 
stop the drug immediately.  
 
Side effects go from very common to very rare. They include the following:   
  
• Very common side effects: Affect more than 1 in 10 people. Include headache, nervous 
feelings and difficulty sleeping.  
• Common side effects: Less than 1 in 10 people. Include dizziness, drowsiness, blurred vision, 
loss of appetite, weight loss, increased aggression or hostility, stomach pain or upset, inability 
to develop or maintain an erection, heart palpitations, increased blood pressure and heart rate.  
• Uncommon side effects: Less than 1 in 100 people. Concerta XL can cause chest pain, 
hallucinations or delusions, worsening of tics, blood disorders or inflammation of blood vessels 
in the brain.  
• Rare side effects: Less than 1 in 1,000 people may feel unusually excited, out of control or 
manic. 
• Very rare side effects: Less than 1 in 10,000 people have very serious side effects. Those 
that have been reported include heart attack, sudden death and liver failure.  
 
You will be monitored closely by medical and nursing staff to ensure that any side effects are found 
early and treated quickly. If serious side effects occur, the medication will be discontinued immediately. 
CIAO study report- Clare Evans, Philip Asherson and Susan Young on behalf of the CIAO project group 
28.02.2016 
If at any time you think you may have side effects or unwanted effects of the drug, you should contact 
the prison mental health team. 
 
During the assessment we will ask you about problems related to ADHD and other mental health 
problems. Some of the questions we ask you about yourself may bring up sensitive issues. If you 
become upset and wish to talk to someone, we will tell you where you can get support and advice. 
 
Confidentiality  
If you agree to take part in this project, the research team will look at your medical and prison records. 
We will also be talking to prison and education staff to find out how you have been doing. This is 
because part of the research is to see whether treatment for ADHD can help you with your education 
and work programme, and to see whether you experience fewer problems like becoming very angry or 
aggressive (if you have this problem).   
 
 
Other authorised people may need to look at your medical and prison records to check that the study is 
being carried out correctly.  
 
All personal information about you will be strictly confidential and will be stored in a secure place. This 
means that outside of the immediate healthcare team involved in this research, no one will be able to 
match your personal information (your name and prison number for example) with the information that 
we gather for the research. After we have completed the study any personal information we hold will be 
destroyed.  
 
Your personal details will only be used to contact you about the study. Your personal details will not be 
linked to your clinical or prison records in our research records.  The clinical data and prison records 
that we use for research will be identified using a study ID code and not your name or prison number.  
We will be able to link your personal details to the study ID code - however this is kept separately to 
any information from the study or your health care or prison records.  
 
Any information you give the research team will remain entirely confidential and not shared with other 
prison staff. The only times the research team would need to break this confidentiality and disclose 
information to prison staff, is if you were to make a threat by intending to harm yourself or someone 
else, or were a threat to security.  
 
What will happen to the results of the research study? 
The research will be analysed by the ADHD research group at King’s College London, led by Professor 
Philip Asherson. He is one of the leading experts on ADHD and will work with the prison healthcare 
team for the duration of the project. The results of the study will be published in scientific journals. All 
personal information will remain strictly confidential so you will not be recognised in any of the research 
reports.   
 
Research data in a form that cannot be traced back to you as an individual may be shared with other 
scientists or research groups where this helps us to understand the findings of the study; and may also 
be used in combination with data from other studies. We will be able to send you a report of the study 
findings after the research has been completed if you are interested and give us permission to keep 
your contact details for this reason.  
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Who is organising the research? 
This research is organised by the Institute of Psychiatry, King’s College London and South London and 
Maudsley NHS Foundation Trust.  
 
Who is funding the research? 
The research is funded by an NIHR programme grant, Janssen-Cilag who is providing the medication, 
the South London Maudsley NHS Trust, and research funds held by Professor Declan Murphy. The 
study is being undertaken by Professor Asherson and his team at the Institute of Psychiatry, King’s 
College London in collaboration with Professor Declan Murphy.  
 
Who has reviewed the study? 
The study has been subject to peer review by expert referees at the Institute of Psychiatry. Ethical 
approval has been granted by the NRES Committee London – South East. The study is registered as a 
clinical trial and is guided by the regulations for clinical trials in the UK. 
 
 
What do I do now? 
We will discuss the study with you to make sure you understand what is involved. If you wish to take 
part we will ask you to sign a consent form that is attached with this information sheet. We hope that 
you will take part in this important project. 
 
What do I do if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to someone in the 
research team who will do their best to answer your questions. You may ask to see one of the research 
team by contacting the prison healthcare team. You may also call the telephone number 020 7848 
5362 to speak to the study coordinator.  
 
If you remain unhappy and wish to complain formally, you can do this by contacting the Trust's 
Complaints Department (tel:  020 3228 2444/2499 or email: Complaints@slam.nhs.uk). 
 
In the event that something does go wrong and you are harmed during the research and this is due to 
someone‘s negligence then you may have grounds for a legal action for compensation against the 
Trust, but you may have to pay your legal costs. The normal NHS complaints mechanisms will still be 
available to you.  
 
Contact for further information:  
If you have any questions about the Ciao Project please feel free to discuss the project with a member 
of the mental health team. You may contact the research coordinator, Clare Evans (email: 
clare.2.evans@kcl.ac.uk; telephone: 020 7848 5362; by post: SGDP Centre, P080, Institute of 
Psychiatry, De Crespigny Park, London SE5 8AF) for further information.  
 
If you have any further queries and would like to seek independent advice on whether to take part in 
this study please contact the SLaM Patient Liaison Service (telephone: 0800 7312864; email: 
pals@slam.nhs.org.uk). 
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Consent to participate in the CIAO Project 
 
Project Title: A Pilot Study of Concerta XL in Adult Offenders with ADHD 
 
Participant ID: ____________ 
 Please initial box 
 
11. I confirm that I have read and understand the information sheet dated 4th 
of June, version 3.1, for the above study and have had the opportunity to 
ask questions. 
 
12. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. 
 
13. I understand that sections of my medical notes may be looked at to 
confirm the clinical diagnosis of ADHD and check the inclusion and 
exclusion criteria for the study. I give permission for Professor Asherson 
and his research team to have access to my medical and prison records. 
To enable monitoring of the conduct of the study, I give permission for 
regulatory authorities or individuals from the South London and Maudsley 
NHS Foundation Trust to access my clinical and research records. 
 
14. I agree to take part in the above study. 
 
15. I agree that my anonymised research data from this study will be stored 
securely and may be shared with other scientists or research groups 
where this helps us to understand the findings of the study. The 
data may also be used in combination with data from other similar 
studies. In the event of publication, I understand that due care will be 
taken to preserve the confidentiality of my information. 
 
________________________ ____________________    ____________________ 
Name of Participant Date Signature 
 
_________________________ ____________________    ____________________ 
Name of Person taking consent Date Signature 
(If different from Researcher) 
 
 
I have explained the study to the participant and have answered their questions honestly and fully. 
 
 
_________________________ _____________________ ____________________ 
Researcher Date Signature 
 
 
 
 
 
Social Genetic and Developmental Psychiatry 
Research Centre & Division of Psychological 
Medicine, Section of Brain Maturation, 
Institute of Psychiatry, King’s College London 
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Appendix 3:  
Adverse Events Log 
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id 
Event 
no Event name Status 
date 
started date ended Serious MED Intensity outcome 
1 1 
"superficial 
scratches on left 
arm" 1 
"2013-03-
10 
00:00:00" 
"2013-03-
11 
00:00:00" 1 1 1 0 
1 2 "appetite loss" 1 
"2013-03-
12 
00:00:00" "" 1 1 0 0 
1 3 
"hearing voices of 
brother (happened 
before)" 1 
"2013-03-
13 
00:00:00" "" 2 1 1 2 
5 1 
"watery eyes (005 
thinks is hayfever)" 1 
"2013-03-
13 
00:00:00" "" 1 1 0 2 
5 2 
"some loss of 
appetite" 1 
"2013-03-
14 
00:00:00" "" 1 1 0 0 
9 1 "Loss of appetite" 1 
"2013-03-
14 
00:00:00" "" 1 1 0 0 
12 1 "headache" 1 
"2013-03-
18 
00:00:00" 
"2013-03-
19 
00:00:00" 1 1 1 0 
12 2 "poor apetite" 1 
"2013-03-
18 
00:00:00" "" 1 1 0 2 
12 3 "sleep issues" 1 
"2013-03-
18 
00:00:00" "" 1 1 0 2 
5 3 "twitching" 1 
"2013-03-
19 
00:00:00" 
"2013-03-
20 
00:00:00" 2 1 1 0 
5 4 "agitation" 1 
"2013-03-
18 
00:00:00" 
"2013-03-
20 
00:00:00" 2 1 1 0 
1 4 
"cannot keep food 
down- asked him 
to try and eat. 
Research team to 
look into" 1 
"2013-03-
21 
00:00:00" "" 1 1 0 2 
5 5 
"Not being able to 
stay seated and 
focus" 1 
"2013-03-
19 
00:00:00" 
"2013-03-
20 
00:00:00" 2 1 1 0 
12 4 
"confusion and 
insomnia" 1 
"2013-03-
19 
00:00:00" "" 1 1 0 2 
1 5 
"vommiting at 
dinner" 1 
"2013-03-
21 
00:00:00" "" 1 1 0 2 
1 6 
"Reported wanting 
to self-harm and 
then acted on this. 
Self-harm by 
scratching" 1 
"2013-03-
25 
00:00:00" 
"2013-03-
26 
00:00:00" 2 1 1 0 
CIAO study report- Clare Evans, Philip Asherson and Susan Young on behalf of the CIAO project group 
28.02.2016 
12 5 
"over focus and 
severe sleep 
issues" 1 
"2013-03-
25 
00:00:00" 
"2013-03-
26 
00:00:00" 1 1 1 0 
5 6 
"Twitching of hand 
and sweating" 1 
"2013-03-
27 
00:00:00" 
"2013-03-
29 
00:00:00" 1 1 0 0 
1 7 
"vomitting up 
meals" 1 
"2013-03-
28 
00:00:00" 
"2013-03-
29 
00:00:00" 1 1 0 0 
5 7 
"very dry skin and 
lips" 1 
"2013-04-
04 
00:00:00" 
"2013-04-
04 
00:00:00" 1 2 0 0 
9 2 "dry skin patches" 1 
"2013-04-
04 
00:00:00" 
"2013-04-
04 
00:00:00" 1 2 0 0 
9 3 "possible hernia" 1 
"2013-04-
04 
00:00:00" "" 1 1 0 0 
31 1 
"feeling dizzy 
related to poor 
sleep" 1 
"2013-03-
27 
00:00:00" "" 1 2 0 0 
31 2 "leg pain" 1 
"2013-03-
29 
00:00:00" "" 1 2 1 0 
31 3 "leg pain" 2 
"2013-03-
31 
00:00:00" "" 1 2 1 0 
31 4 "leg pain" 2 
"2013-04-
03 
00:00:00" "" 1 2 1 0 
31 5 "headache" 1 
"2013-04-
04 
00:00:00" "" 1 2 0 0 
31 6 "headache" 1 
"2013-04-
09 
00:00:00" "" 1 2 0 0 
22 1 "ankle injury" 1 
"2013-04-
12 
00:00:00" "" 1 2 0 0 
19 1 "cold symptoms" 1 
"2013-03-
28 
00:00:00" "" 1 2 0 0 
19 2 "flu symptoms" 2 
"2013-03-
29 
00:00:00" "" 1 2 0 0 
19 3 "cold symptoms" 2 
"2013-03-
31 
00:00:00" "" 1 2 0 0 
19 4 "cold symptoms" 2 
"2013-04-
12 
00:00:00" "" 1 2 0 0 
9 4 "abdominal pain" 1 
"2013-04-
12 
00:00:00" "" 1 2 0 0 
28 1 "cold symptoms" 1 "2013-04- "2013-04- 1 2 0 0 
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04 
00:00:00" 
05 
00:00:00" 
28 2 "pain in trsticle" 1 
"2013-04-
12 
00:00:00" "" 1 2 0 0 
5 8 "twitches" 1 
"2013-03-
19 
00:00:00" 
"2013-03-
19 
00:00:00" 1 1 0 0 
5 9 "toothache" 1 
"2013-03-
24 
00:00:00" 
"2013-03-
24 
00:00:00" 1 2 0 0 
5 10 "headache" 1 
"2013-03-
24 
00:00:00" 
"2013-03-
24 
00:00:00" 1 2 0 0 
5 11 "toothache" 2 
"2013-03-
25 
00:00:00" 
"2013-03-
25 
00:00:00" 1 2 0 0 
5 12 "toothache" 1 
"2013-04-
12 
00:00:00" 
"2013-04-
12 
00:00:00" 1 2 0 0 
1 8 "toothache" 1 
"2013-03-
05 
00:00:00" 
"2013-03-
05 
00:00:00" 1 2 0 0 
1 9 "headache" 1 
"2013-03-
23 
00:00:00" 
"2013-03-
23 
00:00:00" 1 2 0 0 
1 10 "headache" 1 
"2013-03-
25 
00:00:00" 
"2013-03-
25 
00:00:00" 1 2 0 0 
1 11 "nausea" 1 
"2013-03-
27 
00:00:00" "" 1 1 0 0 
1 12 "toothache" 1 
"2013-03-
29 
00:00:00" 
"2013-03-
29 
00:00:00" 1 2 0 0 
1 13 
"self harm - 
superficial " 1 
"2013-03-
29 
00:00:00" 
"2013-03-
29 
00:00:00" 1 1 0 0 
1 14 "toothache" 1 
"2013-04-
03 
00:00:00" 
"2013-04-
03 
00:00:00" 1 2 0 0 
1 15 "headache" 1 
"2013-04-
04 
00:00:00" 
"2013-04-
04 
00:00:00" 1 2 0 0 
1 16 "headache" 1 
"2013-04-
07 
00:00:00" 
"2013-04-
07 
00:00:00" 1 2 0 0 
1 17 "headache" 1 
"2013-04-
10 
00:00:00" 
"2013-04-
10 
00:00:00" 1 2 0 0 
1 18 
"hearing voices 
telling him to harm 
himself" 1 
"2013-04-
10 
00:00:00" 
"2013-04-
10 
00:00:00" 2 1 1 2 
1 19 "Self-harmed " 1 
"2013-04-
14 
"2013-04-
14 2 1 1 0 
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00:00:00" 00:00:00" 
9 5 "dizziness" 1 
"2013-04-
15 
00:00:00" "" 1 1 0 2 
1 20 
"Voices telling him 
make weapons 
and hurt others " 1 
"2013-04-
16 
00:00:00" "" 2 1 2 2 
15 1 "dry skin" 1 
"2013-04-
29 
00:00:00" 
"2013-04-
30 
00:00:00" 1 2 0 0 
5 13 "tooch ache" 1 
"2013-04-
15 
00:00:00" 
"2013-04-
15 
00:00:00" 1 2 0 0 
5 14 "back pain" 1 
"2013-04-
19 
00:00:00" 
"2013-04-
19 
00:00:00" 1 1 0 0 
5 15 "head ache" 1 
"2013-04-
25 
00:00:00" 
"2013-04-
25 
00:00:00" 1 1 0 0 
5 16 "body ache" 1 
"2013-05-
03 
00:00:00" 
"2013-05-
03 
00:00:00" 1 2 0 0 
19 5 "head ache" 1 
"2013-04-
15 
00:00:00" 
"2013-04-
15 
00:00:00" 1 1 0 0 
15 2 "lump on genitals" 1 
"2013-05-
03 
00:00:00" 
"2013-05-
03 
00:00:00" 1 1 0 0 
22 2 "Eczema" 1 
"2013-05-
08 
00:00:00" 
"2013-05-
08 
00:00:00" 1 2 0 0 
33 1 "head ache" 1 
"2013-04-
25 
00:00:00" 
"2013-04-
25 
00:00:00" 1 2 0 0 
33 2 "anal fissure" 1 
"2013-04-
26 
00:00:00" 
"2013-04-
26 
00:00:00" 1 2 1 0 
33 3 "head ache " 1 
"2013-05-
07 
00:00:00" 
"2013-05-
07 
00:00:00" 1 2 0 0 
40 1 "head ache" 1 
"2013-05-
14 
00:00:00" 
"2013-05-
14 
00:00:00" 1 2 0 0 
40 2 "15/05/2013" 1 
"2013-05-
15 
00:00:00" 
"2013-05-
15 
00:00:00" 1 2 0 0 
15 3 "cold symptoms" 1 
"2013-05-
16 
00:00:00" 
"2013-05-
16 
00:00:00" 1 2 0 0 
15 4 "boil on left elbow" 1 
"2013-05-
19 
00:00:00" 
"2013-05-
21 
00:00:00" 1 2 0 0 
15 5 
"Eczema, dry 
scalp" 1 
"2013-05-
30 
00:00:00" 
"2013-05-
30 
00:00:00" 1 2 0 0 
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15 6 "headache" 1 
"2013-06-
09 
00:00:00" 
"2013-06-
09 
00:00:00" 1 2 0 0 
19 6 "toothache" 1 
"2013-06-
16 
00:00:00" 
"2013-06-
16 
00:00:00" 1 2 0 0 
19 7 "hayfever" 1 
"2013-06-
16 
00:00:00" 
"2013-06-
16 
00:00:00" 1 2 0 0 
33 4 "swollen knuckle" 1 
"2013-05-
16 
00:00:00" 
"2013-05-
16 
00:00:00" 1 2 0 0 
33 5 "headache" 1 
"2013-05-
31 
00:00:00" 
"2013-05-
31 
00:00:00" 1 2 0 0 
33 6 "headache" 1 
"2013-06-
29 
00:00:00" 
"2013-06-
29 
00:00:00" 1 2 0 0 
36 1 "toothache" 1 
"2013-06-
07 
00:00:00" 
"2013-06-
07 
00:00:00" 1 2 0 0 
40 3 "headache" 1 
"2013-05-
17 
00:00:00" 
"2013-05-
17 
00:00:00" 1 2 0 0 
40 4 
"pain in right 
shoulder" 1 
"2013-05-
26 
00:00:00" 
"2013-05-
26 
00:00:00" 1 2 0 0 
45 1 "back pain" 1 
"2013-07-
04 
00:00:00" 
"2013-07-
04 
00:00:00" 1 1 0 0 
48 1 "heartburn" 1 
"2013-06-
17 
00:00:00" 
"2013-06-
17 
00:00:00" 1 2 0 0 
48 2 "heartburn" 1 
"2013-06-
30 
00:00:00" 
"2013-06-
30 
00:00:00" 1 2 0 0 
48 3 "heartburn" 1 
"2013-07-
03 
00:00:00" 
"2013-07-
03 
00:00:00" 1 2 0 0 
48 4 "constipation" 1 
"2013-06-
19 
00:00:00" 
"2013-06-
19 
00:00:00" 1 2 0 0 
50 1 "headache" 1 
"2013-06-
29 
00:00:00" 
"2013-06-
29 
00:00:00" 1 2 0 0 
50 2 "headache" 1 
"2013-06-
07 
00:00:00" 
"2013-06-
07 
00:00:00" 1 2 0 0 
50 3 "cold symptoms" 1 
"2013-07-
04 
00:00:00" 
"2013-07-
04 
00:00:00" 1 2 0 0 
51 1 "toothache" 1 
"2013-06-
02 
00:00:00" 
"2013-06-
02 
00:00:00" 1 2 0 0 
51 2 "hayfever" 1 "2013-06- "2013-06- 1 2 0 0 
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09 
00:00:00" 
09 
00:00:00" 
51 3 "hayfever" 1 
"2013-07-
02 
00:00:00" 
"2013-07-
03 
00:00:00" 1 2 0 0 
51 4 "headache" 1 
"2013-06-
15 
00:00:00" 
"2013-06-
15 
00:00:00" 1 2 0 0 
51 5 "headache" 1 
"2013-07-
02 
00:00:00" 
"2013-07-
02 
00:00:00" 1 2 0 0 
46 1 "headache" 1 
"2013-06-
15 
00:00:00" 
"2013-06-
15 
00:00:00" 1 2 0 0 
46 2 "hayfever" 1 
"2013-06-
30 
00:00:00" 
"2013-06-
30 
00:00:00" 1 2 0 0 
46 3 "toothache" 1 
"2013-06-
30 
00:00:00" 
"2013-06-
30 
00:00:00" 1 2 0 0 
46 4 "hayfever" 1 
"2013-07-
01 
00:00:00" 
"2013-07-
01 
00:00:00" 1 2 0 0 
46 5 "indigestion" 1 
"2013-07-
03 
00:00:00" 
"2013-07-
03 
00:00:00" 1 2 0 0 
60 1 "swollen upper lip" 1 
"2013-06-
23 
00:00:00" 
"2013-07-
01 
00:00:00" 2 2 1 0 
60 2 "headache" 1 
"2013-06-
26 
00:00:00" 
"2013-06-
26 
00:00:00" 1 2 0 0 
60 3 "headache" 1 
"2013-06-
16 
00:00:00" 
"2013-06-
16 
00:00:00" 1 2 0 0 
62 1 "cold symptoms" 1 
"2013-06-
16 
00:00:00" 
"2013-06-
16 
00:00:00" 1 2 0 0 
19 8 "Hayfever" 1 
"2013-06-
23 
00:00:00" "" 1 2 0 0 
19 9 "Headache" 1 
"2013-07-
22 
00:00:00" "" 1 2 0 0 
33 7 "Acne" 1 
"2013-07-
01 
00:00:00" "" 1 2 0 1 
33 8 "Indigestion" 1 
"2013-08-
11 
00:00:00" 
"2013-08-
12 
00:00:00" 1 2 0 0 
33 9 "Acne" 1 
"2013-07-
01 
00:00:00" "" 1 2 0 1 
36 2 "Toothache" 1 
"2013-08-
05 
"2013-08-
05 1 2 0 0 
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00:00:00" 00:00:00" 
46 6 "Hayfever" 1 
"2013-07-
12 
00:00:00" 
"2013-08-
09 
00:00:00" 1 2 0 0 
46 7 "Stye on eye" 1 
"2013-07-
15 
00:00:00" 
"2013-07-
15 
00:00:00" 1 2 0 0 
46 8 "Toothache" 1 
"2013-08-
17 
00:00:00" 
"2013-08-
17 
00:00:00" 1 2 0 0 
48 5 "Constipation" 1 
"2013-07-
07 
00:00:00" 
"2013-07-
07 
00:00:00" 1 2 0 0 
48 6 "Headache" 1 
"2013-07-
10 
00:00:00" 
"2013-07-
10 
00:00:00" 1 2 0 0 
48 7 
"Abdominal 
cramping" 1 
"2013-07-
12 
00:00:00" 
"2013-08-
09 
00:00:00" 1 2 0 0 
48 8 "Low Mood" 1 
"2013-07-
17 
00:00:00" 
"2013-08-
14 
00:00:00" 1 2 1 0 
48 9 "Heartburn" 1 
"2013-07-
19 
00:00:00" 
"2013-07-
20 
00:00:00" 1 2 0 0 
48 10 "Headache" 1 
"2013-07-
27 
00:00:00" 
"2013-07-
27 
00:00:00" 1 2 0 0 
48 11 
"Abdominal 
Cramping" 1 
"2013-08-
09 
00:00:00" 
"2013-09-
06 
00:00:00" 1 2 0 1 
48 12 "Headache" 1 
"2013-08-
10 
00:00:00" 
"2013-08-
11 
00:00:00" 1 2 0 0 
48 13 "Toothache" 1 
"2013-08-
12 
00:00:00" 
"2013-08-
13 
00:00:00" 1 2 0 0 
48 14 "Heartburn" 1 
"2013-08-
14 
00:00:00" 
"2013-08-
15 
00:00:00" 1 2 0 0 
50 4 "Headache" 1 
"2013-07-
13 
00:00:00" 
"2014-07-
14 
00:00:00" 1 2 0 0 
50 5 "Headache" 1 
"2013-07-
16 
00:00:00" 
"2013-07-
17 
00:00:00" 1 2 0 0 
50 6 "Headache" 1 
"2013-07-
21 
00:00:00" 
"2013-07-
22 
00:00:00" 1 2 0 0 
50 7 "Headache" 1 
"2013-07-
27 
00:00:00" 
"2013-07-
28 
00:00:00" 1 2 0 0 
50 8 "Headache" 1 
"2013-08-
01 
00:00:00" 
"2013-08-
02 
00:00:00" 1 2 0 0 
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50 9 "Headache" 1 
"2013-08-
01 
00:00:00" 
"2013-08-
02 
00:00:00" 1 2 0 0 
50 10 "Headache" 1 
"2013-08-
07 
00:00:00" 
"2013-08-
08 
00:00:00" 1 2 0 0 
50 11 "Headache" 1 
"2013-08-
07 
00:00:00" 
"2013-08-
08 
00:00:00" 1 1 0 0 
51 6 "Hayfever" 1 
"2013-07-
03 
00:00:00" 
"2013-07-
03 
00:00:00" 1 2 0 0 
51 7 "Hayfever" 1 
"2013-07-
10 
00:00:00" 
"2013-07-
10 
00:00:00" 1 2 0 0 
51 8 "Headache" 1 
"2013-07-
22 
00:00:00" 
"2013-07-
23 
00:00:00" 1 2 0 0 
51 9 "Toothache" 1 
"2013-07-
25 
00:00:00" 
"2013-07-
26 
00:00:00" 1 2 0 0 
51 10 "Toothache" 1 
"2013-07-
27 
00:00:00" 
"2013-07-
28 
00:00:00" 1 2 0 0 
51 11 "Toothache" 1 
"2013-07-
28 
00:00:00" 
"2013-07-
29 
00:00:00" 1 2 0 0 
51 12 "Headache" 1 
"2013-07-
30 
00:00:00" 
"2013-08-
01 
00:00:00" 1 2 0 0 
51 13 "Headache" 1 
"2013-08-
04 
00:00:00" 
"2013-08-
06 
00:00:00" 1 2 0 0 
51 14 "Sore Throat" 1 
"2013-08-
08 
00:00:00" 
"2013-08-
12 
00:00:00" 1 2 0 0 
51 15 "Headache" 1 
"2013-08-
12 
00:00:00" 
"2013-08-
13 
00:00:00" 1 2 0 0 
51 16 "Cough" 1 
"2013-08-
12 
00:00:00" 
"2013-08-
14 
00:00:00" 1 2 0 0 
57 1 "Mouth Ulcer" 1 
"2013-08-
02 
00:00:00" 
"2013-08-
07 
00:00:00" 1 2 0 0 
60 4 "Constipation" 1 
"2013-08-
16 
00:00:00" 
"2013-08-
17 
00:00:00" 1 2 0 0 
60 5 "Constipation" 1 
"2013-08-
16 
00:00:00" 
"2013-08-
17 
00:00:00" 1 2 0 0 
67 1 "Stomach ache" 1 
"2013-06-
21 
00:00:00" 
"2013-06-
22 
00:00:00" 1 2 0 0 
79 1 "Toothache" 1 "2013-07- "2013-07- 1 2 0 0 
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24 
00:00:00" 
25 
00:00:00" 
81 1 "Acne" 1 
"2013-08-
14 
00:00:00" 
"2013-09-
11 
00:00:00" 1 2 0 0 
81 2 "Toothache" 1 
"2013-08-
17 
00:00:00" 
"2013-08-
18 
00:00:00" 1 2 0 0 
81 3 "Headache" 1 
"2013-08-
18 
00:00:00" 
"2013-08-
19 
00:00:00" 1 2 0 0 
86 1 "Headache" 1 
"2013-07-
25 
00:00:00" 
"2013-07-
26 
00:00:00" 1 2 0 0 
99 1 "Headache" 1 
"2013-08-
15 
00:00:00" 
"2013-08-
16 
00:00:00" 1 2 0 0 
48 15 "Heartburn" 1 
"2013-08-
14 
00:00:00" 
"2013-08-
15 
00:00:00" 1 2 0 0 
48 16 "Heartburn" 1 
"2013-08-
25 
00:00:00" 
"2013-08-
26 
00:00:00" 1 2 0 0 
40 5 "Headache" 1 
"2013-08-
26 
00:00:00" 
"2013-08-
27 
00:00:00" 1 2 0 0 
51 17 "Headache" 1 
"2013-08-
28 
00:00:00" 
"2013-08-
29 
00:00:00" 1 2 0 0 
46 9 "Toothache" 1 
"2013-08-
20 
00:00:00" 
"2013-08-
21 
00:00:00" 1 2 0 0 
46 10 "Toothache" 1 
"2013-08-
25 
00:00:00" 
"2013-08-
26 
00:00:00" 1 2 0 0 
46 11 "Sore Throat" 1 
"2013-08-
26 
00:00:00" 
"2013-08-
27 
00:00:00" 1 2 0 0 
81 4 "Acne" 1 
"2013-08-
28 
00:00:00" 
"2013-09-
25 
00:00:00" 1 2 0 1 
36 3 "Hayfever" 1 
"2013-08-
29 
00:00:00" 
"2013-08-
30 
00:00:00" 1 2 0 0 
36 4 "Toothache" 1 
"2013-08-
30 
00:00:00" 
"2013-08-
31 
00:00:00" 1 2 0 0 
50 12 "Headache" 1 
"2013-08-
16 
00:00:00" 
"2013-08-
17 
00:00:00" 1 2 0 0 
50 13 "Sore Throat" 1 
"2013-08-
21 
00:00:00" 
"2013-08-
22 
00:00:00" 1 2 0 0 
54 1 "Hand pain" 1 
"2013-08-
18 
"2013-08-
19 1 2 0 0 
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00:00:00" 00:00:00" 
54 2 
"Sleep difficulties 
and depression" 1 
"2013-08-
08 
00:00:00" 
"2013-09-
05 
00:00:00" 2 2 0 0 
60 6 "Headache" 1 
"2013-08-
23 
00:00:00" 
"2013-08-
24 
00:00:00" 1 2 0 0 
57 2 "Headache" 1 
"2013-08-
28 
00:00:00" 
"2013-08-
29 
00:00:00" 1 2 0 0 
99 2 
"Fungal nail 
infection" 1 
"2013-08-
21 
00:00:00" 
"2013-09-
18 
00:00:00" 1 2 0 0 
104 1 "Toothache" 1 
"2013-08-
24 
00:00:00" 
"2013-08-
25 
00:00:00" 1 2 0 0 
33 10 "Headache" 1 
"2013-08-
13 
00:00:00" 
"2013-08-
14 
00:00:00" 1 2 0 0 
32 1 "Headache" 1 
"2013-08-
26 
00:00:00" 
"2013-08-
27 
00:00:00" 1 2 0 0 
36 5 "Headache" 1 
"2013-09-
29 
00:00:00" 
"2013-09-
29 
00:00:00" 1 2 0 0 
40 6 "Headache" 1 
"2013-09-
20 
00:00:00" 
"2013-09-
20 
00:00:00" 1 2 0 0 
40 7 "Shoulder Pain" 1 
"2013-09-
21 
00:00:00" 
"2013-09-
23 
00:00:00" 1 2 0 0 
48 17 
"Abdominal 
Cramping" 1 
"2013-09-
06 
00:00:00" 
"2013-10-
04 
00:00:00" 1 2 0 1 
48 18 "Constipation" 1 
"2013-09-
08 
00:00:00" 
"2013-09-
08 
00:00:00" 1 2 0 0 
48 19 "Headache" 1 
"2013-09-
22 
00:00:00" 
"2013-09-
22 
00:00:00" 1 2 0 0 
48 20 "Constipation" 1 
"2013-09-
25 
00:00:00" 
"2013-09-
25 
00:00:00" 1 2 0 0 
48 21 "Stomach ache" 1 
"2013-09-
27 
00:00:00" 
"2013-09-
27 
00:00:00" 1 2 0 0 
50 14 "Headache" 1 
"2013-09-
01 
00:00:00" 
"2013-09-
01 
00:00:00" 1 2 0 0 
46 12 "Headache" 1 
"2013-09-
08 
00:00:00" 
"2013-09-
08 
00:00:00" 1 2 0 0 
46 13 "Headache" 1 
"2013-09-
13 
00:00:00" 
"2013-09-
13 
00:00:00" 1 2 0 0 
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46 14 "Headache" 1 
"2013-09-
15 
00:00:00" 
"2013-09-
15 
00:00:00" 1 2 0 0 
54 3 
"Sleep difficulties 
and depression" 1 
"2013-09-
05 
00:00:00" 
"2013-10-
31 
00:00:00" 2 2 0 0 
54 4 "Cough" 1 
"2013-09-
28 
00:00:00" 
"2013-09-
28 
00:00:00" 1 2 0 0 
83 1 "Coldsore" 1 
"2013-10-
18 
00:00:00" 
"2013-10-
21 
00:00:00" 1 2 0 0 
79 2 "Headache" 1 
"2013-09-
03 
00:00:00" 
"2013-09-
03 
00:00:00" 1 2 0 0 
79 3 "Headache" 1 
"2013-09-
20 
00:00:00" 
"2013-09-
20 
00:00:00" 1 2 0 0 
79 4 "Headache" 1 
"2013-09-
23 
00:00:00" 
"2013-09-
23 
00:00:00" 1 2 0 0 
79 5 "Headache " 1 
"2013-10-
06 
00:00:00" 
"2013-10-
06 
00:00:00" 1 2 0 0 
79 6 
"Headache and 
Cold symptoms" 1 
"2013-10-
11 
00:00:00" 
"2013-10-
11 
00:00:00" 1 2 0 0 
79 7 "Headache" 1 
"2013-10-
12 
00:00:00" 
"2013-10-
12 
00:00:00" 1 2 0 0 
66 1 "Pain in elbow" 1 
"2013-10-
21 
00:00:00" 
"2013-10-
21 
00:00:00" 1 2 0 0 
74 1 "Toothache" 1 
"2013-09-
11 
00:00:00" 
"2013-09-
11 
00:00:00" 1 2 0 0 
74 2 
"Groin pain - 
inguinal hernia" 1 
"2013-09-
11 
00:00:00" 
"2013-09-
18 
00:00:00" 1 2 0 0 
74 3 "Headache" 1 
"2013-09-
12 
00:00:00" 
"2013-09-
12 
00:00:00" 1 2 0 0 
74 4 
"Groin pain - 
inguinal hernia" 1 
"2013-09-
25 
00:00:00" 
"2013-10-
05 
00:00:00" 1 2 0 0 
86 2 "Headache" 1 
"2013-09-
18 
00:00:00" 
"2013-09-
18 
00:00:00" 1 2 0 0 
96 1 "Headache" 1 
"2013-09-
06 
00:00:00" 
"2013-09-
06 
00:00:00" 1 2 0 0 
96 2 
"Cold symptoms 
and headache" 1 
"2013-09-
23 
00:00:00" 
"2013-09-
26 
00:00:00" 1 2 0 0 
96 3 "Headache" 1 "2013-09- "2013-09- 1 2 0 0 
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30 
00:00:00" 
30 
00:00:00" 
96 4 "Headache" 1 
"2013-10-
03 
00:00:00" 
"2013-10-
03 
00:00:00" 1 2 0 0 
96 5 "Toothache" 1 
"2013-10-
03 
00:00:00" 
"2013-10-
03 
00:00:00" 1 2 0 0 
96 6 "Headache" 1 
"2013-10-
07 
00:00:00" 
"2013-10-
07 
00:00:00" 1 2 0 0 
104 2 "Toothache" 1 
"2013-09-
04 
00:00:00" 
"2013-09-
04 
00:00:00" 1 2 0 0 
104 3 "Headache" 1 
"2013-09-
11 
00:00:00" 
"2013-09-
11 
00:00:00" 1 2 0 0 
104 4 "Toothache" 1 
"2013-09-
12 
00:00:00" 
"2013-09-
12 
00:00:00" 1 2 0 0 
104 5 "Toothache" 1 
"2013-09-
15 
00:00:00" 
"2013-09-
15 
00:00:00" 1 2 0 0 
104 6 "Headache" 1 
"2013-09-
19 
00:00:00" 
"2013-09-
19 
00:00:00" 1 2 0 0 
104 7 "Toothache" 1 
"2013-09-
22 
00:00:00" 
"2013-09-
22 
00:00:00" 1 2 0 0 
104 8 "Headache" 1 
"2013-09-
26 
00:00:00" 
"2013-09-
26 
00:00:00" 1 2 0 0 
112 1 "Headache" 1 
"2013-10-
05 
00:00:00" 
"2013-10-
05 
00:00:00" 1 2 0 0 
110 1 "Muscle Pain" 1 
"2013-09-
15 
00:00:00" 
"2013-09-
15 
00:00:00" 1 2 0 0 
110 2 "Eye Problem" 1 
"2013-09-
16 
00:00:00" 
"2013-09-
17 
00:00:00" 1 2 0 0 
110 3 "Cold symptoms" 1 
"2013-09-
29 
00:00:00" 
"2013-09-
30 
00:00:00" 1 2 0 0 
110 4 "Headache" 1 
"2013-10-
04 
00:00:00" 
"2013-10-
08 
00:00:00" 1 2 0 0 
110 5 "Chest Infection" 1 
"2013-10-
07 
00:00:00" 
"2013-10-
14 
00:00:00" 1 2 0 0 
110 6 "Headache" 1 
"2013-10-
16 
00:00:00" 
"2013-10-
16 
00:00:00" 1 2 0 0 
110 7 
"Wound pains from 
fight" 1 
"2013-10-
17 
"2013-10-
17 1 2 0 0 
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00:00:00" 00:00:00" 
110 8 
"Pain in Sternum 
from fighting" 1 
"2013-10-
18 
00:00:00" 
"2013-10-
21 
00:00:00" 1 2 0 0 
111 1 "Headache" 1 
"2013-09-
28 
00:00:00" 
"2013-09-
28 
00:00:00" 1 2 0 0 
111 2 "Leg cramp" 1 
"2013-10-
02 
00:00:00" 
"2013-10-
02 
00:00:00" 1 2 0 0 
111 3 "Headache" 1 
"2013-10-
05 
00:00:00" 
"2013-10-
05 
00:00:00" 1 2 0 0 
111 4 "Headache" 1 
"2013-10-
12 
00:00:00" 
"2013-10-
13 
00:00:00" 1 2 0 0 
111 5 "Flu" 1 
"2013-10-
15 
00:00:00" 
"2013-10-
19 
00:00:00" 1 2 0 0 
105 1 
"Pains and 
swelling from 
fighting" 1 
"2013-10-
05 
00:00:00" 
"2013-10-
06 
00:00:00" 1 2 0 0 
105 2 "Headache" 1 
"2013-10-
08 
00:00:00" 
"2013-10-
08 
00:00:00" 1 2 0 0 
105 3 
"Complaints of 
pains" 1 
"2013-10-
16 
00:00:00" 
"2013-10-
17 
00:00:00" 1 2 0 0 
105 4 "Dry Skin" 1 
"2013-10-
18 
00:00:00" 
"2013-11-
15 
00:00:00" 1 2 0 0 
105 5 "Cold" 1 
"2013-10-
18 
00:00:00" 
"2013-10-
19 
00:00:00" 1 2 0 0 
123 1 "Headache" 1 
"2013-09-
16 
00:00:00" 
"2013-09-
16 
00:00:00" 1 2 0 0 
123 2 "Headache" 1 
"2013-09-
21 
00:00:00" 
"2013-09-
21 
00:00:00" 1 2 0 0 
123 3 "Headache" 1 
"2013-09-
24 
00:00:00" 
"2013-09-
24 
00:00:00" 1 2 0 0 
40 8 "Foot pain" 1 
"2013-10-
31 
00:00:00" 
"2013-10-
31 
00:00:00" 1 2 0 0 
40 9 "Headache" 1 
"2013-11-
06 
00:00:00" 
"2013-11-
06 
00:00:00" 1 2 0 0 
74 5 
"Moles and dry 
skin" 1 
"2013-10-
25 
00:00:00" 
"2013-11-
08 
00:00:00" 1 2 0 0 
74 6 
"Back pain from 
fall a few years 
ago" 1 
"2013-10-
25 
00:00:00" 
"2013-11-
08 
00:00:00" 1 2 0 0 
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96 7 "Headache" 1 
"2013-11-
10 
00:00:00" 
"2013-11-
10 
00:00:00" 1 2 0 0 
54 5 
"Cough and cold 
symptoms" 1 
"2013-10-
30 
00:00:00" 
"2013-11-
06 
00:00:00" 1 2 0 0 
54 6 
"Sleep Difficulties 
and depression" 1 
"2013-10-
31 
00:00:00" 
"2013-11-
28 
00:00:00" 2 2 0 0 
54 7 "Headache" 1 
"2013-11-
10 
00:00:00" 
"2013-11-
10 
00:00:00" 1 2 0 0 
86 3 "Toothache" 1 
"2013-10-
28 
00:00:00" 
"2013-10-
28 
00:00:00" 1 2 0 0 
109 1 "Hand Injury" 2 
"2013-09-
30 
00:00:00" 
"2013-11-
04 
00:00:00" 1 2 0 0 
74 7 
"Intermittent Heart 
Palpatations " 1 
"2013-11-
13 
00:00:00" 
"2013-11-
14 
00:00:00" 1 1 0 0 
79 8 "Headache" 1 
"2013-10-
31 
00:00:00" 
"2013-10-
31 
00:00:00" 1 2 0 0 
79 9 "Headache" 1 
"2013-11-
24 
00:00:00" 
"2013-11-
24 
00:00:00" 1 2 0 0 
110 9 "Wax in ear canal" 1 
"2013-10-
21 
00:00:00" 
"2013-10-
28 
00:00:00" 1 2 0 0 
110 10 "Backache" 1 
"2013-10-
22 
00:00:00" 
"2013-10-
23 
00:00:00" 1 2 0 0 
110 11 
"Complaints of 
pains" 1 
"2013-10-
23 
00:00:00" 
"2013-10-
23 
00:00:00" 1 2 0 0 
110 12 "Headache" 1 
"2013-10-
26 
00:00:00" 
"2013-10-
27 
00:00:00" 1 2 0 0 
110 13 
"Complaints of 
pains" 1 
"2013-10-
30 
00:00:00" 
"2013-10-
30 
00:00:00" 1 2 0 0 
109 2 "Toothache" 1 
"2013-11-
18 
00:00:00" 
"2013-11-
23 
00:00:00" 1 2 0 0 
109 3 "Hand Injury " 2 
"2013-11-
22 
00:00:00" 
"2013-11-
29 
00:00:00" 1 2 0 0 
135 1 "Acne" 2 
"2013-11-
13 
00:00:00" 
"2013-01-
08 
00:00:00" 1 2 0 2 
50 15 "Headache" 1 
"2013-11-
15 
00:00:00" 
"2013-11-
16 
00:00:00" 1 2 0 0 
50 16 "Fungal 1 "2013-11- "2013-11- 1 2 0 0 
CIAO study report- Clare Evans, Philip Asherson and Susan Young on behalf of the CIAO project group 
28.02.2016 
dermatosis - rash 
on chest" 
15 
00:00:00" 
29 
00:00:00" 
50 17 "Headache" 1 
"2013-11-
27 
00:00:00" 
"2013-11-
28 
00:00:00" 1 2 0 0 
62 2 "Headache" 1 
"2013-10-
28 
00:00:00" 
"2013-10-
28 
00:00:00" 1 2 0 0 
62 3 "Toothache" 1 
"2013-11-
07 
00:00:00" 
"2013-11-
07 
00:00:00" 1 2 0 0 
62 4 "Dry Skin" 1 
"2013-11-
15 
00:00:00" 
"2013-12-
13 
00:00:00" 1 2 0 0 
62 5 "Headache" 1 
"2013-12-
02 
00:00:00" 
"2013-12-
02 
00:00:00" 1 2 0 0 
62 6 "Toothache" 1 
"2013-12-
06 
00:00:00" 
"2013-12-
06 
00:00:00" 1 2 0 0 
110 14 "n/a" 1 
"2013-11-
01 
00:00:00" 
"2013-11-
01 
00:00:00" 1 2 0 0 
110 15 "n/a" 1 
"2013-11-
02 
00:00:00" 
"2013-11-
02 
00:00:00" 1 2 0 0 
110 16 "n/a" 1 
"2013-11-
22 
00:00:00" 
"2013-11-
22 
00:00:00" 1 2 0 0 
110 17 "n/a" 1 
"2013-11-
23 
00:00:00" 
"2013-11-
23 
00:00:00" 1 2 0 0 
111 6 "Backache" 1 
"2013-10-
25 
00:00:00" 
"2013-10-
25 
00:00:00" 1 2 0 0 
111 7 "Cold symptoms" 1 
"2013-10-
30 
00:00:00" 
"2013-10-
30 
00:00:00" 1 2 0 0 
111 8 "Headache" 1 
"2013-11-
01 
00:00:00" 
"2013-11-
01 
00:00:00" 1 2 0 0 
111 9 "Cough" 1 
"2013-11-
02 
00:00:00" 
"2013-11-
02 
00:00:00" 1 2 0 0 
111 10 "Headache" 1 
"2013-11-
22 
00:00:00" 
"2013-11-
22 
00:00:00" 1 2 0 0 
111 11 "Sore lips" 1 
"2013-11-
23 
00:00:00" 
"2013-11-
23 
00:00:00" 1 2 0 0 
111 12 "Headache" 1 
"2013-11-
24 
00:00:00" 
"2013-11-
24 
00:00:00" 1 2 0 0 
111 13 "Leg pain" 1 
"2013-12-
11 
"2013-12-
21 1 2 0 0 
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00:00:00" 00:00:00" 
105 6 "Headache" 1 
"2013-11-
02 
00:00:00" 
"2013-11-
02 
00:00:00" 1 2 0 0 
105 7 "Headache" 1 
"2013-11-
27 
00:00:00" 
"2013-11-
27 
00:00:00" 1 2 0 0 
54 8 "Sore throat" 1 
"2013-11-
23 
00:00:00" 
"2013-11-
23 
00:00:00" 1 2 0 0 
54 9 
"Sleep difficulties 
and depression" 2 
"2013-11-
28 
00:00:00" 
"2013-12-
26 
00:00:00" 2 2 0 0 
115 1 "Cold symptoms" 1 
"2013-10-
30 
00:00:00" 
"2013-11-
02 
00:00:00" 1 2 0 0 
115 2 "Headache" 1 
"2013-11-
10 
00:00:00" 
"2013-11-
10 
00:00:00" 1 2 0 0 
115 3 "Headache" 1 
"2013-11-
18 
00:00:00" 
"2013-11-
18 
00:00:00" 1 2 0 0 
115 4 "Headache" 1 
"2013-11-
25 
00:00:00" 
"2013-11-
25 
00:00:00" 1 2 0 0 
115 5 "Headache" 1 
"2013-12-
02 
00:00:00" 
"2013-12-
02 
00:00:00" 1 2 0 0 
115 6 "Headache" 1 
"2013-12-
08 
00:00:00" 
"2013-12-
08 
00:00:00" 1 2 0 0 
138 1 
"Allergic reaction 
to egg" 1 
"2013-12-
09 
00:00:00" 
"2013-12-
09 
00:00:00" 1 2 0 0 
129 1 "Gastric reflux" 1 
"2013-11-
08 
00:00:00" 
"2013-11-
08 
00:00:00" 1 2 0 0 
136 1 "Headache" 1 
"2013-12-
06 
00:00:00" 
"2013-12-
06 
00:00:00" 1 2 0 0 
136 2 "Sore throat" 1 
"2013-12-
06 
00:00:00" 
"2013-12-
09 
00:00:00" 1 2 0 0 
136 3 "Headache" 1 
"2013-12-
12 
00:00:00" 
"2013-12-
12 
00:00:00" 1 2 0 0 
153 1 "Heartburn" 1 
"2013-11-
25 
00:00:00" 
"2013-12-
23 
00:00:00" 1 2 0 0 
145 1 
"Acne on face and 
upper back" 1 
"2013-12-
18 
00:00:00" 
"2014-02-
12 
00:00:00" 1 2 0 0 
122 1 "Genital warts" 1 
"2013-12-
23 
00:00:00" 
"2013-12-
24 
00:00:00" 1 2 0 0 
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109 4 "Headache" 1 
"2013-12-
27 
00:00:00" 
"2013-12-
27 
00:00:00" 1 2 0 0 
50 18 "Toothache" 1 
"2013-12-
13 
00:00:00" 
"2013-12-
13 
00:00:00" 1 2 0 0 
50 19 "Sore throat" 1 
"2013-12-
14 
00:00:00" 
"2013-12-
14 
00:00:00" 1 2 0 0 
50 20 "Headache" 1 
"2014-01-
02 
00:00:00" 
"2014-01-
02 
00:00:00" 1 2 0 0 
62 7 "Headache" 1 
"2014-01-
03 
00:00:00" 
"2014-01-
03 
00:00:00" 1 2 0 0 
129 2 "Stomach ache" 1 
"2013-12-
20 
00:00:00" 
"2013-12-
20 
00:00:00" 1 2 0 0 
136 4 "Sore throat" 1 
"2013-12-
29 
00:00:00" 
"2013-12-
29 
00:00:00" 1 2 0 0 
150 1 "Sore thumb" 1 
"2013-12-
24 
00:00:00" 
"2013-12-
24 
00:00:00" 1 2 0 0 
150 2 "Toothache" 1 
"2013-12-
27 
00:00:00" 
"2013-12-
28 
00:00:00" 1 2 0 0 
83 2 "Toothache" 1 
"2014-01-
06 
00:00:00" 
"2014-01-
06 
00:00:00" 1 2 0 0 
83 3 "Toothache" 1 
"2014-01-
02 
00:00:00" 
"2014-01-
02 
00:00:00" 1 2 0 0 
123 4 "Toothache" 1 
"2014-01-
11 
00:00:00" 
"2014-01-
11 
00:00:00" 1 2 0 0 
123 5 "Toothache" 1 
"2013-11-
12 
00:00:00" 
"2013-11-
13 
00:00:00" 1 2 0 0 
36 6 "Headache" 1 
"2014-01-
05 
00:00:00" 
"2014-01-
06 
00:00:00" 1 2 0 0 
166 1 
"Fungal skin rash - 
dermatophytosis" 1 
"2014-01-
10 
00:00:00" "" 1 2 0 0 
50 21 "Sore throat" 1 
"2014-01-
13 
00:00:00" 
"2014-01-
15 
00:00:00" 1 2 0 0 
62 8 "Toothache" 1 
"2014-01-
04 
00:00:00" 
"2014-01-
04 
00:00:00" 1 2 0 0 
62 9 "Dry skin" 2 
"2014-01-
10 
00:00:00" "" 1 2 0 0 
105 8 "Cold symptoms 1 "2014-01- "2014-01- 1 2 0 0 
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with headache " 08 
00:00:00" 
17 
00:00:00" 
115 7 "Headache" 1 
"2014-01-
06 
00:00:00" 
"2014-01-
06 
00:00:00" 1 2 0 0 
129 3 "Headache" 1 
"2014-01-
06 
00:00:00" 
"2014-01-
06 
00:00:00" 1 2 0 0 
136 5 "Headache" 1 
"2014-01-
11 
00:00:00" 
"2014-01-
11 
00:00:00" 1 2 0 0 
136 6 
"Bruising to body 
from fighting" 1 
"2013-12-
31 
00:00:00" "" 1 2 0 0 
150 3 "toothache" 1 
"2014-01-
04 
00:00:00" 
"2014-01-
05 
00:00:00" 1 2 0 0 
150 4 "Cold symptoms" 1 
"2014-01-
09 
00:00:00" 
"2014-01-
10 
00:00:00" 1 2 0 0 
150 5 "Headache" 1 
"2014-01-
12 
00:00:00" 
"2014-01-
12 
00:00:00" 1 2 0 0 
138 2 "headache" 1 
"2013-11-
28 
00:00:00" 
"2013-11-
28 
00:00:00" 1 2 0 0 
135 2 "Tootache" 1 
"2014-01-
10 
00:00:00" 
"2014-01-
10 
00:00:00" 1 2 0 0 
105 9 "Headache" 1 
"2013-09-
01 
00:00:00" 
"2013-09-
01 
00:00:00" 1 2 0 0 
105 10 "Headache" 1 
"2014-01-
10 
00:00:00" 
"2014-01-
10 
00:00:00" 1 2 0 0 
138 3 
"Complaints of 
pains" 1 
"2014-01-
16 
00:00:00" 
"2014-01-
16 
00:00:00" 1 2 0 0 
111 14 "Headache" 1 
"2013-12-
14 
00:00:00" 
"2013-12-
14 
00:00:00" 1 2 0 0 
86 4 
"IGNORE WRONG 
ENTRY" 1 
"2013-11-
01 
00:00:00" 
"2013-11-
01 
00:00:00" 1 2 0 0 
113 1 "Feeling unwell" 1 
"2013-11-
01 
00:00:00" 
"2013-11-
01 
00:00:00" 1 1 0 0 
189 1 "Paranoia" 1 
"2014-02-
05 
00:00:00" 
"2014-02-
06 
00:00:00" 1 1 1 0 
136 7 "Toothache" 1 
"2014-01-
14 
00:00:00" 
"2014-01-
14 
00:00:00" 1 2 0 0 
136 8 "Sore throat" 1 
"2014-01-
23 
"2014-01-
23 1 2 0 0 
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00:00:00" 00:00:00" 
136 9 "Toothache" 1 
"2014-01-
31 
00:00:00" 
"2014-01-
31 
00:00:00" 1 2 0 0 
136 10 "Headache" 1 
"2014-02-
07 
00:00:00" 
"2014-02-
07 
00:00:00" 1 2 0 0 
136 11 "Headache" 1 
"2014-02-
09 
00:00:00" 
"2014-02-
09 
00:00:00" 1 2 0 0 
136 12 "Headache" 1 
"2014-02-
13 
00:00:00" 
"2014-02-
16 
00:00:00" 1 2 0 0 
83 4 "Toothache" 1 
"2014-01-
16 
00:00:00" 
"2014-01-
16 
00:00:00" 1 2 0 0 
150 6 "Toothache" 1 
"2014-01-
14 
00:00:00" 
"2014-01-
14 
00:00:00" 1 2 0 0 
150 7 "Headache" 1 
"2014-01-
14 
00:00:00" 
"2014-01-
18 
00:00:00" 1 2 0 0 
150 8 "Headache" 1 
"2014-01-
22 
00:00:00" 
"2014-01-
22 
00:00:00" 1 2 0 0 
129 4 "Dental abscess " 1 
"2014-01-
14 
00:00:00" 
"2014-01-
22 
00:00:00" 1 2 1 0 
129 5 
"Blocked and 
painful ears" 1 
"2014-01-
24 
00:00:00" 
"2014-01-
31 
00:00:00" 1 2 0 0 
96 8 "Toothache" 1 
"2014-01-
25 
00:00:00" 
"2014-01-
25 
00:00:00" 1 2 0 0 
96 9 "Headache" 1 
"2014-01-
25 
00:00:00" 
"2014-01-
25 
00:00:00" 1 2 0 0 
123 6 "Toothache" 1 
"2014-01-
31 
00:00:00" 
"2014-01-
31 
00:00:00" 1 2 0 0 
123 7 "Toothache" 1 
"2014-02-
07 
00:00:00" 
"2014-02-
07 
00:00:00" 1 2 0 0 
123 8 "Toothache" 1 
"2014-02-
11 
00:00:00" 
"2014-02-
11 
00:00:00" 1 2 0 0 
171 1 "Toothache" 1 
"2014-01-
19 
00:00:00" 
"2014-01-
20 
00:00:00" 1 2 0 0 
171 2 "Headache" 1 
"2014-01-
23 
00:00:00" 
"2014-02-
04 
00:00:00" 1 2 0 0 
171 3 
"Toothache (result 
of being hit round 
face with guitar)" 1 
"2014-02-
08 
00:00:00" 
"2014-03-
22 
00:00:00" 1 2 1 0 
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171 4 "Headache" 1 
"2014-02-
14 
00:00:00" 
"2014-02-
16 
00:00:00" 1 2 0 0 
169 1 
"Cold aggravates 
symptom" 1 
"2014-01-
25 
00:00:00" 
"2014-01-
26 
00:00:00" 1 2 0 0 
169 2 "Headache" 1 
"2014-02-
23 
00:00:00" 
"2014-02-
24 
00:00:00" 1 2 0 0 
176 1 "Headache" 1 
"2014-01-
28 
00:00:00" 
"2014-01-
29 
00:00:00" 1 2 0 0 
176 2 "Headache" 1 
"2014-02-
23 
00:00:00" 
"2014-02-
24 
00:00:00" 1 2 0 0 
191 1 "Back pain" 1 
"2014-02-
14 
00:00:00" 
"2014-02-
21 
00:00:00" 1 2 0 0 
192 1 
"Pityriasis simplex 
(dry and itchy 
scalp)" 1 
"2014-02-
05 
00:00:00" 
"2014-04-
02 
00:00:00" 1 2 0 0 
192 2 
"Pain in mouth due 
to small spot" 1 
"2014-02-
09 
00:00:00" 
"2014-02-
10 
00:00:00" 1 2 0 0 
50 22 "Sore throat" 1 
"2014-02-
05 
00:00:00" 
"2014-02-
06 
00:00:00" 1 2 0 0 
50 23 "Headache" 1 
"2014-02-
07 
00:00:00" 
"2014-02-
08 
00:00:00" 1 2 0 0 
62 10 "Cough" 1 
"2014-02-
07 
00:00:00" 
"2014-02-
08 
00:00:00" 1 2 0 0 
54 10 
"Cold aggravates 
symptoms and 
cough" 1 
"2014-02-
03 
00:00:00" 
"2014-02-
04 
00:00:00" 1 2 0 0 
54 11 "Tonsillitus" 1 
"2014-02-
10 
00:00:00" 
"2014-02-
18 
00:00:00" 1 2 1 0 
54 12 "Gum pain" 1 
"2014-02-
13 
00:00:00" 
"2014-02-
20 
00:00:00" 1 2 0 0 
115 8 "Headache" 1 
"2014-01-
17 
00:00:00" 
"2014-01-
18 
00:00:00" 1 2 0 0 
115 9 "Headache" 1 
"2014-01-
26 
00:00:00" 
"2014-01-
27 
00:00:00" 1 2 0 0 
115 10 "Headache" 1 
"2014-02-
08 
00:00:00" 
"2014-02-
09 
00:00:00" 1 2 0 0 
115 11 "Toothache" 1 
"2014-02-
09 
00:00:00" 
"2014-02-
10 
00:00:00" 1 2 0 0 
115 12 "Headache" 1 "2014-02- "2014-02- 1 2 0 0 
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13 
00:00:00" 
14 
00:00:00" 
115 13 "Headache" 1 
"2014-02-
20 
00:00:00" 
"2014-02-
21 
00:00:00" 1 2 0 0 
152 1 "Toothache" 1 
"2014-01-
24 
00:00:00" 
"2014-01-
25 
00:00:00" 1 2 0 0 
152 2 "Cough" 1 
"2014-02-
07 
00:00:00" 
"2014-02-
08 
00:00:00" 1 2 0 0 
164 1 "Cough" 1 
"2014-01-
15 
00:00:00" 
"2014-01-
25 
00:00:00" 1 2 0 0 
141 1 "Knee pain" 1 
"2014-01-
22 
00:00:00" 
"2014-01-
23 
00:00:00" 1 2 0 0 
191 2 "Headache" 1 
"2014-03-
02 
00:00:00" 
"2014-03-
02 
00:00:00" 1 2 0 0 
191 3 "Toothache" 1 
"2014-03-
02 
00:00:00" 
"2014-03-
03 
00:00:00" 1 2 0 0 
164 2 "Headache" 1 
"2014-02-
22 
00:00:00" 
"2014-02-
23 
00:00:00" 1 2 0 0 
123 9 "Headache" 1 
"2014-03-
10 
00:00:00" 
"2014-03-
11 
00:00:00" 1 2 0 0 
123 10 "Swollen ankle" 1 
"2014-03-
21 
00:00:00" 
"2014-03-
02 
00:00:00" 1 2 0 0 
145 2 "Stomach ache" 1 
"2014-03-
10 
00:00:00" 
"2014-03-
11 
00:00:00" 1 2 0 0 
135 3 "Headache" 1 
"2014-03-
02 
00:00:00" 
"2014-03-
03 
00:00:00" 1 2 0 0 
171 5 "Headache" 1 
"2014-02-
25 
00:00:00" 
"2014-02-
26 
00:00:00" 1 2 0 0 
171 6 "Cold symptoms" 1 
"2014-03-
08 
00:00:00" 
"2014-03-
09 
00:00:00" 1 2 0 0 
171 7 "Headache" 1 
"2014-03-
09 
00:00:00" 
"2014-03-
10 
00:00:00" 1 2 0 0 
171 8 "Headache" 1 
"2014-03-
15 
00:00:00" 
"2014-03-
16 
00:00:00" 1 2 0 0 
171 9 "Headache" 1 
"2014-03-
21 
00:00:00" 
"2014-03-
22 
00:00:00" 1 2 0 0 
171 10 "Headache" 1 
"2014-04-
05 
"2014-04-
06 1 2 0 0 
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00:00:00" 00:00:00" 
169 3 "Headache" 1 
"2014-02-
28 
00:00:00" 
"2014-03-
01 
00:00:00" 1 2 0 0 
176 3 "Headache" 1 
"2014-03-
15 
00:00:00" 
"2014-03-
16 
00:00:00" 1 2 0 0 
176 4 "Headache" 1 
"2014-03-
15 
00:00:00" 
"2014-03-
16 
00:00:00" 1 2 0 0 
190 1 "Cold symptoms" 1 
"2014-03-
28 
00:00:00" 
"2014-03-
29 
00:00:00" 1 2 0 0 
192 3 "Headache" 1 
"2014-03-
04 
00:00:00" 
"2014-03-
05 
00:00:00" 1 2 0 0 
212 1 
"Dental abcess 
and toothache" 3 
"2014-03-
27 
00:00:00" "" 1 2 1 0 
212 2 "Headache" 1 
"2014-03-
31 
00:00:00" 
"2014-04-
01 
00:00:00" 1 2 0 0 
212 3 "Hayfever" 1 
"2014-04-
06 
00:00:00" 
"2014-04-
07 
00:00:00" 1 2 0 0 
184 1 "Back pain" 1 
"2014-03-
09 
00:00:00" 
"2014-03-
19 
00:00:00" 1 2 0 0 
177 1 
"Acne vulgaris 
(complain of spots 
on 6/3/14, referred 
to GP)" 1 
"2014-03-
06 
00:00:00" 
"2014-03-
27 
00:00:00" 1 2 0 0 
237 1 
"Abdominal Pain, 
referred to GP 
then medication 
given" 1 
"2014-03-
25 
00:00:00" 
"2014-03-
27 
00:00:00" 1 2 0 0 
230 1 "Watery eyes" 1 
"2014-04-
04 
00:00:00" 
"2014-05-
06 
00:00:00" 1 2 0 0 
54 13 "Rash on neck" 1 
"2014-04-
02 
00:00:00" 
"2014-04-
16 
00:00:00" 1 2 0 0 
54 14 "Finger pain" 1 
"2014-04-
04 
00:00:00" 
"2014-04-
05 
00:00:00" 1 2 0 0 
54 15 
"Dry and cracked 
lips" 1 
"2014-04-
06 
00:00:00" 
"2014-04-
20 
00:00:00" 1 2 0 0 
115 14 "Headache" 1 
"2014-04-
02 
00:00:00" 
"2014-04-
03 
00:00:00" 1 2 0 0 
152 3 "Headache" 1 
"2014-03-
10 
00:00:00" 
"2014-03-
11 
00:00:00" 1 2 0 0 
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152 4 "Sore throat" 1 
"2014-03-
09 
00:00:00" 
"2014-03-
10 
00:00:00" 1 2 0 0 
152 5 "Headache" 1 
"2014-02-
28 
00:00:00" 
"2014-03-
01 
00:00:00" 1 2 0 0 
152 6 "Cough" 1 
"2014-03-
15 
00:00:00" 
"2014-03-
17 
00:00:00" 1 2 0 0 
152 7 "Headache" 1 
"2014-03-
15 
00:00:00" 
"2014-03-
16 
00:00:00" 1 2 0 0 
152 8 "Headache" 1 
"2014-04-
11 
00:00:00" 
"2014-04-
12 
00:00:00" 1 2 0 0 
199 1 "headache" 1 
"2014-03-
07 
00:00:00" 
"2014-03-
08 
00:00:00" 1 2 0 0 
199 2 "Hand pain" 1 
"2014-03-
08 
00:00:00" 
"2014-03-
09 
00:00:00" 1 2 0 0 
145 3 "headache" 1 
"2014-05-
14 
00:00:00" 
"2014-05-
15 
00:00:00" 1 2 0 0 
145 4 "back pain" 1 
"2014-05-
18 
00:00:00" 
"2014-05-
19 
00:00:00" 1 2 0 0 
171 11 "headache" 1 
"2014-04-
15 
00:00:00" 
"2014-04-
16 
00:00:00" 1 2 0 0 
171 12 "toothache" 1 
"2014-04-
24 
00:00:00" 
"2014-04-
25 
00:00:00" 1 2 0 0 
171 13 "toothache" 1 
"2014-04-
26 
00:00:00" 
"2014-04-
27 
00:00:00" 1 2 0 0 
171 14 "toothache" 1 
"2014-04-
27 
00:00:00" 
"2014-04-
28 
00:00:00" 1 2 0 0 
171 15 "pain in wrist" 1 
"2014-05-
03 
00:00:00" 
"2014-05-
13 
00:00:00" 1 2 0 0 
171 16 "headache" 1 
"2014-05-
06 
00:00:00" 
"2014-05-
07 
00:00:00" 1 2 0 0 
171 17 "toothache" 1 
"2014-05-
12 
00:00:00" 
"2014-05-
13 
00:00:00" 1 2 0 0 
171 18 "headache" 1 
"2014-05-
13 
00:00:00" 
"2014-05-
14 
00:00:00" 1 2 0 0 
171 19 "headache" 1 
"2014-05-
16 
00:00:00" 
"2014-05-
17 
00:00:00" 1 2 0 0 
171 20 "earache" 1 "2014-05- "2014-05- 1 2 0 0 
CIAO study report- Clare Evans, Philip Asherson and Susan Young on behalf of the CIAO project group 
28.02.2016 
17 
00:00:00" 
18 
00:00:00" 
171 21 "headache" 1 
"2014-05-
18 
00:00:00" 
"2014-05-
19 
00:00:00" 1 2 0 0 
169 4 "headache" 1 
"2014-05-
06 
00:00:00" 
"2014-05-
07 
00:00:00" 1 2 0 0 
176 5 "Pain in testicle" 1 
"2014-04-
30 
00:00:00" 
"2014-05-
01 
00:00:00" 1 2 0 0 
176 6 "Headache" 1 
"2014-05-
02 
00:00:00" 
"2014-05-
03 
00:00:00" 1 2 0 0 
190 2 "Hayfever" 1 
"2014-05-
08 
00:00:00" "" 1 2 0 0 
192 4 
"Corns and 
callosities" 1 
"2014-04-
14 
00:00:00" 
"2014-05-
12 
00:00:00" 1 2 0 0 
212 4 "Headache" 1 
"2014-04-
26 
00:00:00" 
"2014-04-
27 
00:00:00" 1 2 0 0 
212 5 "Hayfever" 1 
"2014-04-
17 
00:00:00" "" 1 2 0 0 
184 2 "Headache" 1 
"2014-04-
24 
00:00:00" 
"2014-04-
25 
00:00:00" 1 2 0 0 
184 3 "headache" 1 
"2014-05-
14 
00:00:00" 
"2014-05-
15 
00:00:00" 1 2 0 0 
184 4 
"Sleeping 
difficulties" 1 
"2014-05-
16 
00:00:00" 
"2014-05-
23 
00:00:00" 1 2 0 0 
177 2 "Constipation" 1 
"2014-05-
04 
00:00:00" 
"2014-05-
07 
00:00:00" 1 2 0 0 
177 3 "Headache" 1 
"2014-05-
07 
00:00:00" 
"2014-05-
08 
00:00:00" 1 2 0 0 
241 1 
"Back disorder - 
mechanical (for 
previous back pain 
but been getting 
worse and now 
being treated)" 1 
"2014-04-
24 
00:00:00" "" 2 2 2 0 
241 2 "Headache" 1 
"2014-05-
16 
00:00:00" 
"2014-05-
19 
00:00:00" 1 2 0 0 
230 2 "Headache" 1 
"2014-04-
15 
00:00:00" 
"2014-04-
16 
00:00:00" 1 2 0 0 
223 1 "Toothache" 1 
"2014-04-
18 
"2014-04-
19 1 2 0 0 
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00:00:00" 00:00:00" 
223 2 "Headache" 1 
"2014-05-
19 
00:00:00" 
"2014-05-
20 
00:00:00" 1 2 0 0 
253 1 "Headache" 1 
"2014-05-
02 
00:00:00" 
"2014-05-
03 
00:00:00" 1 2 0 0 
253 2 "Toothache" 1 
"2014-05-
15 
00:00:00" 
"2014-05-
17 
00:00:00" 1 2 0 0 
253 3 "Headache" 1 
"2014-05-
20 
00:00:00" 
"2014-05-
21 
00:00:00" 1 2 0 0 
281 1 
"Hayfever 
symptoms" 1 
"2014-05-
19 
00:00:00" 
"2014-05-
20 
00:00:00" 1 2 0 0 
115 15 "Headache" 1 
"2014-04-
21 
00:00:00" 
"2014-04-
22 
00:00:00" 1 2 0 0 
115 16 "Headache" 1 
"2014-04-
27 
00:00:00" 
"2014-04-
28 
00:00:00" 1 2 0 0 
115 17 "Headache" 1 
"2014-05-
04 
00:00:00" 
"2014-05-
05 
00:00:00" 1 2 0 0 
115 18 "Headache" 1 
"2014-05-
07 
00:00:00" 
"2014-05-
08 
00:00:00" 1 2 0 0 
115 19 "Headache" 1 
"2014-05-
10 
00:00:00" 
"2014-05-
11 
00:00:00" 1 2 0 0 
115 20 "Headache" 1 
"2014-05-
11 
00:00:00" 
"2014-05-
12 
00:00:00" 1 2 0 0 
115 21 "Headache" 1 
"2014-05-
19 
00:00:00" 
"2014-05-
20 
00:00:00" 1 2 0 0 
199 3 "Rib pain" 1 
"2014-04-
22 
00:00:00" 
"2014-04-
23 
00:00:00" 1 2 0 0 
199 4 "Back pain" 1 
"2014-04-
23 
00:00:00" 
"2014-04-
24 
00:00:00" 1 2 0 0 
198 1 
"cough and blood 
in phlegm, chest 
pain, referred to 
GP, vital signs 
monitored, dx as 
Chest infection" 1 
"2014-05-
07 
00:00:00" 
"2014-05-
27 
00:00:00" 1 2 0 0 
235 1 "Headache" 1 
"2014-05-
20 
00:00:00" 
"2014-05-
21 
00:00:00" 1 2 0 0 
188 1 
"Cold symptoms - 
headache and 
sore throat" 1 
"2014-04-
18 
00:00:00" 
"2014-05-
05 
00:00:00" 1 2 0 0 
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263 1 "Abcess" 1 
"2014-04-
17 
00:00:00" 
"2014-04-
24 
00:00:00" 1 2 0 0 
263 2 "Headache" 1 
"2014-04-
23 
00:00:00" 
"2014-04-
24 
00:00:00" 1 2 0 0 
244 1 
"Damaged toe nail, 
saw podiatry, nails 
cut and filed" 1 
"2014-05-
01 
00:00:00" 
"2014-05-
01 
00:00:00" 1 1 0 0 
68 1 "Ankle Pain" 1 
"2014-05-
16 
00:00:00" 
"2014-05-
16 
00:00:00" 1 2 0 0 
68 2 "Headache" 1 
"2014-05-
24 
00:00:00" 
"2014-05-
24 
00:00:00" 1 2 0 0 
270 1 
"Shoulder pain, 
seen by physio 
and doctor" 1 
"2014-05-
16 
00:00:00" 
"2014-06-
13 
00:00:00" 1 2 0 0 
114 1 
"Right side of face 
slightly swelling, 
referred to doctor, 
serum, calcium 
and thyroid levels 
checked by doctor" 1 
"2014-03-
20 
00:00:00" 
"2014-04-
03 
00:00:00" 1 1 0 0 
114 2 
"Right side of face 
intermittent 
swelling" 1 
"2014-04-
30 
00:00:00" 
"2014-04-
30 
00:00:00" 1 2 0 0 
112 2 
"Lower back pain, 
referred to physio" 1 
"2014-04-
08 
00:00:00" 
"2014-05-
02 
00:00:00" 1 1 0 0 
112 3 "Fight" 1 
"2014-01-
19 
00:00:00" 
"2014-01-
19 
00:00:00" 1 1 1 0 
176 7 
"Restraint, no 
injury" 1 
"2014-02-
22 
00:00:00" 
"2014-02-
22 
00:00:00" 1 1 1 0 
152 9 "Headache" 1 
"2014-04-
11 
00:00:00" 
"2014-04-
11 
00:00:00" 1 2 0 0 
152 10 "Pain in right knee" 1 
"2014-04-
21 
00:00:00" 
"2014-04-
21 
00:00:00" 1 2 0 0 
152 11 
"Musculoskeletal 
pain" 1 
"2014-04-
30 
00:00:00" 
"2014-04-
30 
00:00:00" 1 2 0 0 
145 5 
"Rashes all over 
body and face, 
referred to GP" 1 
"2013-12-
16 
00:00:00" 
"2013-12-
16 
00:00:00" 1 1 0 0 
135 4 
"visible scars from 
acne, advised to 
continue taking 
medication as 
prescribed" 1 
"2014-02-
22 
00:00:00" 
"2014-02-
22 
00:00:00" 1 1 0 0 
135 5 
"complaint about 
spotson back, 1 
"2014-04-
28 
"2014-04-
28 1 1 0 0 
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referred to GP" 00:00:00" 00:00:00" 
169 5 
"Lumps on throat 
getting bigger, 
advised to gargle 
with salt water, 
seen by GP" 1 
"2014-05-
12 
00:00:00" 
"2014-05-
16 
00:00:00" 1 1 0 0 
212 6 
"Dry skin on face, 
neck and arms, 
referred to GP" 1 
"2014-05-
09 
00:00:00" 
"2014-05-
09 
00:00:00" 1 1 0 0 
184 5 
"neck pain 
following exercise, 
pain worsened 
since onset, 
referred to GP" 1 
"2014-04-
24 
00:00:00" 
"2014-04-
24 
00:00:00" 1 1 0 0 
184 6 
"Verbally abusive 
to nursing staff" 1 
"2014-05-
20 
00:00:00" 
"2014-05-
20 
00:00:00" 1 1 0 0 
253 4 
"Loose dentures, 
staff to find out if 
fixedent supplied 
by pharmacy" 1 
"2014-04-
26 
00:00:00" 
"2014-04-
26 
00:00:00" 1 1 0 0 
241 3 
"Diagnosed HSV 
in sexual health 
clinical" 1 
"2014-05-
16 
00:00:00" 
"2014-05-
16 
00:00:00" 1 1 0 0 
226 1 
"low mood, 
referred to 
psychologist" 1 
"2014-05-
23 
00:00:00" 
"2014-05-
23 
00:00:00" 1 1 0 0 
62 11 
"Broken, painful 
teeth, seen by 
dentist temporary 
filling given" 1 
"2013-12-
12 
00:00:00" 
"2013-12-
12 
00:00:00" 1 1 0 0 
62 12 
"dry skin and 
spots, seen by 
nurse, request 
repeat prescription 
from GP" 1 
"2014-02-
28 
00:00:00" 
"2014-02-
28 
00:00:00" 1 1 0 0 
62 13 
"Fight, nose bleed, 
seen by nurse" 1 
"2014-04-
15 
00:00:00" 
"2014-04-
15 
00:00:00" 1 1 1 0 
54 16 "fight, no injury" 1 
"2013-07-
09 
00:00:00" 
"2013-07-
09 
00:00:00" 1 1 1 0 
54 17 
"sore throat, 
referred to GP" 1 
"2014-02-
07 
00:00:00" 
"2014-02-
07 
00:00:00" 1 1 0 0 
54 18 
"ACCT document 
open (because 
individual is seen 
as a risk to self or 
other) due to low 
mood, self harm 
and tied kettled 
cord around neck" 1 
"2014-01-
17 
00:00:00" 
"2014-01-
29 
00:00:00" 1 1 1 0 
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54 19 
"tied ligature 
around neck, 
restrained, no 
injuries" 1 
"2014-01-
18 
00:00:00" 
"2014-01-
18 
00:00:00" 1 1 2 0 
54 20 "fight, no injuries" 1 
"2013-12-
26 
00:00:00" 
"2013-12-
26 
00:00:00" 1 1 1 0 
66 2 
"cyst in mouth, 
seen by GP" 1 
"2014-03-
24 
00:00:00" 
"2014-04-
04 
00:00:00" 1 1 0 0 
66 3 
"sweaty palms, 
seen by GP" 1 
"2014-04-
04 
00:00:00" 
"2014-04-
04 
00:00:00" 1 1 0 0 
66 4 
"lump in left 
testicle, seen by 
GP referred for 
scan" 1 
"2013-11-
13 
00:00:00" 
"2013-11-
22 
00:00:00" 1 1 0 0 
66 5 
"cut lip from play 
fighting" 1 
"2013-10-
31 
00:00:00" 
"2013-10-
31 
00:00:00" 1 1 0 0 
199 5 
"ACCT document 
(a document that is 
opened when 
individual poses a 
risk to self or 
other) review, kept 
open upon review 
on 13/2/14" 1 
"2014-02-
13 
00:00:00" 
"2014-02-
20 
00:00:00" 1 1 1 0 
199 6 
"ACCT document 
(a document that is 
opened when 
individual poses a 
risk to self or 
other) reopened 
due to suicide note 
found in cell" 1 
"2014-02-
28 
00:00:00" 
"2014-03-
11 
00:00:00" 1 1 1 0 
199 7 
"ACCT document 
(a document that is 
opened when 
individual poses a 
risk to self or 
other)  reopened" 1 
"2014-03-
14 
00:00:00" "" 1 1 1 0 
199 8 
"deliberate self 
harm - superficial 
cuts to lower left 
arm" 1 
"2014-05-
19 
00:00:00" 
"2014-05-
19 
00:00:00" 1 1 1 0 
263 3 "Chest pain" 1 
"2014-04-
25 
00:00:00" "" 1 2 1 2 
263 4 
"Musculoskeletal 
pain (not 
specified)" 1 
"2014-04-
26 
00:00:00" 
"2014-04-
27 
00:00:00" 1 2 0 0 
263 5 "Wrist pain" 1 
"2014-05-
02 
00:00:00" 
"2014-05-
03 
00:00:00" 1 2 0 0 
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263 6 
"Pain in upper limb 
" 1 
"2014-05-
03 
00:00:00" 
"2014-05-
04 
00:00:00" 1 2 0 0 
263 7 "Headache" 1 
"2014-05-
04 
00:00:00" 
"2014-05-
05 
00:00:00" 1 2 0 0 
263 8 "Wrist pain" 2 
"2014-05-
12 
00:00:00" 
"2014-05-
14 
00:00:00" 1 2 0 0 
263 9 "Headache" 1 
"2014-05-
17 
00:00:00" 
"2014-05-
18 
00:00:00" 1 2 0 0 
263 10 
"Restraint, 
handcuffed - wrist 
pain" 1 
"2014-05-
12 
00:00:00" 
"2014-05-
12 
00:00:00" 1 1 1 0 
135 6 "Headache" 1 
"2014-06-
10 
00:00:00" 
"2014-06-
10 
00:00:00" 1 2 0 0 
171 22 "Pain in elbow" 1 
"2014-05-
24 
00:00:00" 
"2014-05-
24 
00:00:00" 1 2 0 0 
171 23 
"Headache and 
earache" 1 
"2014-05-
30 
00:00:00" 
"2014-05-
30 
00:00:00" 1 2 0 0 
171 24 "Toothache" 1 
"2014-06-
14 
00:00:00" 
"2014-06-
14 
00:00:00" 1 2 0 0 
212 7 
"Chest pains in 
response to 
exercise" 1 
"2014-06-
09 
00:00:00" 
"2014-06-
09 
00:00:00" 1 2 0 0 
212 8 "Headache" 1 
"2014-05-
28 
00:00:00" 
"2014-05-
29 
00:00:00" 1 2 0 0 
177 4 "stomach pain" 1 
"2014-05-
30 
00:00:00" 
"2014-05-
30 
00:00:00" 1 2 0 0 
177 5 "abdominal pain" 1 
"2014-05-
31 
00:00:00" 
"2014-05-
31 
00:00:00" 1 2 0 0 
177 6 "headache" 1 
"2014-06-
14 
00:00:00" 
"2014-06-
14 
00:00:00" 1 2 0 0 
237 2 "Insomnia" 1 
"2014-05-
30 
00:00:00" 
"2014-05-
30 
00:00:00" 1 2 0 0 
237 3 "Headache" 1 
"2014-06-
09 
00:00:00" 
"2014-06-
10 
00:00:00" 1 2 0 0 
230 3 
"Fight, cuts to right 
side of face and 
neck" 1 
"2014-06-
01 
00:00:00" 
"2014-06-
01 
00:00:00" 1 1 1 0 
253 5 "Headache" 1 
"2014-06-
10 
00:00:00" 
"2014-06-
10 
00:00:00" 1 2 0 0 
253 6 "headache" 1 "2014-06- "2014-06- 1 2 0 0 
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13 
00:00:00" 
13 
00:00:00" 
253 7 
"hayfever 
symptoms" 1 
"2014-06-
14 
00:00:00" 
"2014-06-
14 
00:00:00" 1 2 0 0 
226 2 
"Pain in jaw from 
falling out of bed 5 
days ago, referred 
to GP, x-ray done" 1 
"2014-05-
31 
00:00:00" 
"2014-06-
11 
00:00:00" 1 1 0 0 
226 3 "Hayfever " 1 
"2014-06-
14 
00:00:00" 
"2014-06-
15 
00:00:00" 1 2 0 0 
62 14 
"Adjudication for 
various things" 1 
"2014-06-
05 
00:00:00" "" 1 1 0 0 
54 21 
"wrist injury, 
restrained when 
taken to 
segrgation" 1 
"2014-06-
06 
00:00:00" 
"2014-06-
06 
00:00:00" 1 1 0 0 
54 22 "Segregation" 1 
"2014-06-
06 
00:00:00" "" 1 1 0 0 
115 22 "headache" 1 
"2014-05-
27 
00:00:00" 
"2014-05-
27 
00:00:00" 1 2 0 0 
115 23 "headache" 1 
"2014-05-
31 
00:00:00" 
"2014-06-
01 
00:00:00" 1 2 0 0 
115 24 "headache" 1 
"2014-06-
03 
00:00:00" 
"2014-06-
03 
00:00:00" 1 2 0 0 
115 25 "headache" 1 
"2014-06-
05 
00:00:00" 
"2014-06-
05 
00:00:00" 1 2 0 0 
115 26 "headache" 1 
"2014-06-
15 
00:00:00" 
"2014-06-
15 
00:00:00" 1 2 0 0 
199 9 "headache" 1 
"2014-05-
25 
00:00:00" 
"2014-05-
25 
00:00:00" 1 2 0 0 
199 10 
"deliberate self 
harm - superficial 
cuts to lower left 
arm" 1 
"2014-05-
29 
00:00:00" 
"2014-05-
29 
00:00:00" 1 1 1 0 
199 11 "headache" 1 
"2014-05-
31 
00:00:00" 
"2014-05-
31 
00:00:00" 1 2 0 0 
199 12 
"deliberate self 
harm - superficial 
cuts to left wrist" 1 
"2014-06-
05 
00:00:00" 
"2014-06-
05 
00:00:00" 1 1 1 0 
199 13 "Hayfever" 1 
"2014-06-
15 
00:00:00" "" 1 2 0 0 
198 2 "toothache" 1 
"2014-05-
29 
"2014-05-
29 1 2 0 0 
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00:00:00" 00:00:00" 
263 11 "Sore lips" 1 
"2014-05-
24 
00:00:00" 
"2014-05-
24 
00:00:00" 1 2 0 0 
263 12 
"Difficulty 
breathing and pain 
in nostrils, referred 
to GP" 1 
"2014-06-
03 
00:00:00" "" 1 1 0 0 
263 13 
"Pain in wrist from 
restraint 3 weeks 
ago, seen by 
physio" 1 
"2014-06-
04 
00:00:00" 
"2014-06-
04 
00:00:00" 1 1 0 0 
263 14 "headache" 1 
"2014-06-
07 
00:00:00" 
"2014-06-
07 
00:00:00" 1 2 0 0 
263 15 "toothache" 1 
"2014-06-
09 
00:00:00" 
"2014-06-
09 
00:00:00" 1 2 0 0 
263 16 
"deliberate self 
harm superficial 
cuts to left 
forearm" 1 
"2014-06-
11 
00:00:00" 
"2014-06-
11 
00:00:00" 1 1 1 0 
263 17 "headache" 1 
"2014-06-
11 
00:00:00" 
"2014-06-
11 
00:00:00" 1 2 0 0 
263 18 
"Nosebleed and 
symptoms of 
sinusitis querry, 
referred to GP" 1 
"2014-06-
13 
00:00:00" 
"2014-06-
13 
00:00:00" 1 1 0 0 
263 19 
"ACCT document 
(for when 
individual poses 
risk to self or 
other) open" 1 
"2014-06-
15 
00:00:00" "" 1 1 0 0 
263 20 "headache" 1 
"2014-06-
15 
00:00:00" 
"2014-06-
15 
00:00:00" 1 2 0 0 
190 3 
"Possibly hearing 
voices - to be 
investigated 
ASAP" 1 
"2014-06-
30 
00:00:00" 
"2014-06-
30 
00:00:00" 2 1 1 2 
270 2 
"Severe appetite 
reduction" 1 
"2014-06-
03 
00:00:00" 
"2014-07-
03 
00:00:00" 1 1 0 0 
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